# EDGAR Filing Document

**Accession Number:** 0001355064
**File Stem:** 0001580642-23-001477
**Filing Date:** 2023-3
**Character Count:** 410538
**Document Hash:** 3ef7299f009c6a8119002928825567f9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001580642-23-001477.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001580642-23-001477

**CONFORMED SUBMISSION TYPE**: N-CSRS

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**EFFECTIVENESS DATE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MUTUAL FUND SERIES TRUST
- **CENTRAL INDEX KEY:** 0001355064
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** OH
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** N-CSRS
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-21872
- **FILM NUMBER:** 23727963

**BUSINESS ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474
- **BUSINESS PHONE:** 631 549 1859

**MAIL ADDRESS:**
- **STREET 1:** C/O GEMINI FUND SERVICES LLC
- **STREET 2:** 4221 NORTH 203RD STREET, SUITE 100
- **CITY:** ELKHORN
- **STATE:** NE
- **ZIP:** 68022-3474

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATALYST FUNDS
- **DATE OF NAME CHANGE:** 20060303

## Series and Classes Contracts Data

### Eventide Gilead Fund (Series ID: S000022598)

| Class ID   | Class Name                   | Ticker Symbol   |
|:---|:---|:---|
| C000065340 | Eventide Gilead Fund Class N | ETGLX           |
| C000080457 | Eventide Gilead Fund Class A | ETAGX           |
| C000080458 | Eventide Gilead Fund Class C | ETCGX           |
| C000080459 | Eventide Gilead Fund Class I | ETILX           |

### Eventide Healthcare & Life Sciences Fund (Series ID: S000039514)

| Class ID   | Class Name                                              | Ticker Symbol   |
|:---|:---|:---|
| C000121707 | Eventide Healthcare & Life Sciences Fund Class A Shares | ETAHX           |
| C000121708 | Eventide Healthcare & Life Sciences Fund Class C Shares | ETCHX           |
| C000121709 | Eventide Healthcare & Life Sciences Fund Class N Shares | ETNHX           |
| C000121710 | Eventide Healthcare & Life Sciences Fund Class I Shares | ETIHX           |

### Eventide Multi-Asset Income Fund (Series ID: S000049985)

| Class ID   | Class Name                               | Ticker Symbol   |
|:---|:---|:---|
| C000157835 | Eventide Multi-Asset Income Fund Class A | ETAMX           |
| C000157836 | Eventide Multi-Asset Income Fund Class C | ETCMX           |
| C000157837 | Eventide Multi-Asset Income Fund Class I | ETIMX           |
| C000157838 | Eventide Multi-Asset Income Fund Class N | ETNMX           |

### Eventide Dividend Opportunities Fund (Series ID: S000059102)

| Class ID   | Class Name                                          | Ticker Symbol   |
|:---|:---|:---|
| C000193764 | Eventide Dividend Opportunities Fund Class A Shares | ETADX           |
| C000193765 | Eventide Dividend Opportunities Fund Class C Shares | ETCDX           |
| C000193766 | Eventide Dividend Opportunities Fund Class I Shares | ETIDX           |
| C000193767 | Eventide Dividend Opportunities Fund Class N Shares | ETNDX           |

### Eventide Limited-Term Bond Fund (Series ID: S000062486)

| Class ID   | Class Name                              | Ticker Symbol   |
|:---|:---|:---|
| C000202730 | Class A Eventide Limited-Term Bond Fund | ETABX           |
| C000202731 | Class C Eventide Limited-Term Bond Fund | ETCBX           |
| C000202732 | Class I Eventide Limited-Term Bond Fund | ETIBX           |
| C000202733 | Class N Eventide Limited-Term Bond Fund | ETNBX           |

### Eventide Exponential Technologies Fund (Series ID: S000068813)

| Class ID   | Class Name                                           | Ticker Symbol   |
|:---|:---|:---|
| C000219891 | Eventide Exponential Technologies Fund Class N Share | ETNEX           |
| C000219892 | Eventide Exponential Technologies Fund Class A Share | ETAEX           |
| C000219893 | Eventide Exponential Technologies Fund Class C Share | ETCEX           |
| C000219894 | Eventide Exponential Technologies Fund Class I Share | ETIEX           |

### Eventide Core Bond Fund (Series ID: S000069085)

| Class ID   | Class Name                             | Ticker Symbol   |
|:---|:---|:---|
| C000220843 | Eventide Core Bond Fund Class N Shares | ETNRX           |
| C000220844 | Eventide Core Bond Fund Class A Shares | ETARX           |
| C000220845 | Eventide Core Bond Fund Class C Shares | ETCRX           |
| C000220846 | Eventide Core Bond Fund Class I Shares | ETIRX           |

### Eventide Large Cap Focus Fund (Series ID: S000076523)

| Class ID   | Class Name                            | Ticker Symbol   |
|:---|:---|:---|
| C000236479 | Eventide Large Cap Focus Fund Class N | ETLNX           |
| C000236480 | Eventide Large Cap Focus Fund Class A | ETLAX           |
| C000236481 | Eventide Large Cap Focus Fund Class C | ETLCX           |
| C000236482 | Eventide Large Cap Focus Fund Class I | ETLIX           |

**united states<br> securities and exchange commission<br> washington, d.c. 20549<br>form n-csr<br>certified shareholder report of registered management<br> investment companies**

Investment Company Act file number <u>811-21872</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Mutual Fund Series Trust</u> 

(Exact name of registrant as specified in charter)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>225 Pictoria Drive, Suite 450, Cincinnati, Ohio 45246</u> 

(Address of principal executive offices) (Zip code)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>CT CORPORATION SYSTEM</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>1300 EAST NINTH STREET, CLEVELAND, OH 44114</u> 

(Name and address of agent for service)

Registrant's telephone number, including area code: <u>631-470-2619</u> 

Date of fiscal year end: <u>6/30</u> 

Date of reporting period: <u>12/31/22</u> 

ITEM 1. REPORTS TO SHAREHOLDERS.

![(EVENTIDE LOGO)](ef001_v1.jpg)

---

| | |
|:---|:---|
| **Semi-Annual Report** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **Eventide Dividend Opportunities Fund** |
| **Eventide Exponential Technologies Fund** |
| **Eventide Gilead Fund** |
| **Eventide Healthcare & Life Sciences Fund** |
| **Eventide Large Cap Focus Fund** |
| **Eventide Limited-Term Bond Fund** |
| **Eventide Multi-Asset Income Fund** |
| **Eventide Asset Management, LLC** |
| One International Place, Suite 4210 |
| Boston, MA 02110 |
| 1-877-771-3836 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **1** |
| **E V E N T I D E** | **1** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**Shareholder Letter (Unaudited)**

**Market volatility spikes two kinds of fear: Fear of missing out and fear of loss.**

If someone asked me in January of 2022 to predict some of the key news and market headlines over the next twelve months, I would have been way off.

Russia invaded Ukraine. Confidence in cryptocurrencies crumbled from scandals and selloffs. The energy sector was the top-performing sector in the S&P 500. Among other extreme weather events, monsoons left a third of Pakistan under water. In June, inflation hit its highest rate since the early 1980s. China re-opened its borders after three years of a zero-tolerance Covid policy. And in U.S. politics, the "red wave" that many people thought would happen in the midterms was little more than a red ripple.

Alongside these events, there were macroeconomic factors putting pressure on markets–the result of government spending (fiscal policy), interest rates (monetary policy), and our position in the market cycle.

**Fear encourages poor investor behavior**

These headlines can spike fear for you as an investor.

Fear of missing out on opportunities that could make you rich and fear of losing money if you don't react quickly enough.

It is well known that fear encourages poor investor behavior. History shows that investor responses, though attempting to capitalize on market opportunities, often result in actual returns being lower than the broader market's returns, meaning they would have been better off riding the ups and downs of the market without making tactical moves.

So what do you do in times of market volatility?

Develop timeless convictions to counter fear.

**Timeless convictions counter fear**

It is a part of our regular rhythm at Eventide to repeat our timeless convictions out loud to each other. Some of them are even fixed on our walls and our coffee cups. Our convictions anchor us as we navigate the ups and downs of the market with courage rather than fear.

We remain committed to our strongest investment conviction, our investment philosophy, a philosophy that is rooted in our understanding of who people are, how they operate, and how they flourish. It states, *"We believe high-quality companies that excel at creating value for others and trade at a discount to intrinsic value offer superior long-term risk-adjusted returns."* It is within this conviction that we can make decisions to navigate volatile market conditions.

---

| | |
|:---|:---|
| **E V E N T I D E** | **2** |
| **E V E N T I D E** | **2** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**Conclusion**

To you, our shareholders, we are grateful for your trust. If someone were to ask me to predict some of the headline events that will take place in 2023, I would be just as off as I would have been last year. Thankfully, our investment approach isn't dependent on our ability to predict the unpredictable—We don't let fear of missing out or fear of loss guide our approach.

On your behalf and in your interest, our aim is to make strategically anchored, long-term decisions based on firmly held convictions. We believe this leads to portfolios that are better for our investors and better for the world.

Thank you for your trust,

Robin John

CEO, Founding Member

***This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at https://www.eventidefunds.com/prospectus or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.***

*7087-NLD 01/31/2023*

---

| | |
|:---|:---|
| **E V E N T I D E** | **3** |
| **E V E N T I D E** | **3** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmark:**

---

| | | | |
|:---|:---|:---|:---|
|  | *Six Month* |  | *Since* |
|  | *Return* | *1 Year Return* | *Inception <sup>2</sup>* |
| Class N | -2.76% | -13.65% | -7.04% |
| Class A without load | -2.63% | -13.61% | -7.04% |
| Class A with 5.75% load | -8.18% | -18.61% | -9.29% |
| Class C | -3.13% | -14.23% | -7.73% |
| Class I | -2.51% | -13.25% | -6.80% |
| Bloomberg U.S. Aggregate Bond Index <sup>3</sup> | -2.97% | -13.01% | -6.28% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Total returns would have been lower absent the manager's fee waiver. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 0.83%, 1.58%, 0.78% and 0.58% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Per the Fund's most recent prospectus, total annual Fund estimated expenses before waiver are 1.01%, 1.76%, 0.96% and 0.76% for Class A shares, Class C shares, Class N shares and Class I shares, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Eventide Core Bond Fund commenced operations on July 31, 2020.* 

*3.* *The Bloomberg U.S. Aggregate Bond Index is a broad-based flagship benchmark that measures the investment grade, US dollar -denominated, fixed-rate taxable bond market. The index includes Treasuries, government-related and corporate securities, MBS (agency fixed-rate pass-throughs), ABS and CMBS (agency and non-agency). Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Agency Fixed Rate | 18.0% |
| Electric Utilities | 17.0% |
| Banking | 9.0% |
| Government Sponsored | 6.9% |
| Auto Loan | 6.1% |
| Real Estate Investment Trusts | 5.1% |
| Institutional Financial Services | 3.5% |
| Insurance | 3.4% |
| Engineering & Construction | 3.0% |
| Machinery | 2.6% |
| Other / Cash & Cash Equivalents | 25.4% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **4** |
| **E V E N T I D E** | **4** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Six Month* |  |  | *Since* |
|  | *Return* | *1 Year Return* | *5 Year Return* | *Inception <sup>2</sup>* |
| Class N | 2.15% | -21.87% | 7.86% | 7.97% |
| Class A without load | 2.12% | -21.91% | 7.81% | 7.92% |
| Class A with 5.75% load | -3.76% | -26.41% | 6.54% | 6.71% |
| Class C | 1.70% | -22.55% | 7.00% | 7.12% |
| Class I | 2.24% | -21.75% | 8.08% | 8.18% |
| Russell Midcap Total Return Index <sup>3</sup> | 5.43% | -17.32% | 7.10% | 7.95% |
| Russell Midcap Value Index <sup>4</sup> | 5.01% | -12.03% | 5.72% | 6.52% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.20%, 1.95%, 1.15% and 0.95% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Eventide Dividend Opportunities Fund commenced operations on September 29, 2017.* 

*3.* *The Russell Midcap Total Return Index measures the performance of the mid-cap segment of the US equity universe. It is a subset of the Russell 1000 Index. It includes approximately 800 of the smallest securities based on a combination of their market cap and current index membership, representing approximately 31% of the total market capitalization of the Russell 1000 companies. It is constructed to provide a comprehensive and unbiased barometer for the mid-cap segment. The index is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap opportunity set. Investors cannot invest directly in an index.* 

*4.* *The Russell Midcap Value Index measures the performance of the mid-capitalization U.S. equities that exhibit value characteristics. It includes those Russell Midcap Index companies with relatively lower price-to-book ratios, lower I/B/E/S forecast medium term (2 year) growth and lower sales per share historical growth (5 years). Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Electric Utilities | 11.7% |
| Electrical Equipment | 11.5% |
| Medical Equipment & Devices | 8.8% |
| Oil & Gas Producers | 8.8% |
| Technology Services | 5.7% |
| Chemicals | 4.8% |
| Software | 4.5% |
| Institutional Financial Services | 4.1% |
| Semiconductors | 4.1% |
| Banking | 3.3% |
| Other / Cash & Cash Equivalents | 32.7% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings*

---

| | |
|:---|:---|
| **E V E N T I D E** | **5** |
| **E V E N T I D E** | **5** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | |
|:---|:---|:---|:---|
|  | *Six Month* |  | *Since* |
|  | *Return* | *1 Year Return* | *Inception <sup>2</sup>* |
| Class N | -9.62% | -45.08% | 0.05% |
| Class A without load | -9.70% | -45.08% | 0.05% |
| Class A with 5.75% load | -14.91% | -48.24% | -2.29% |
| Class C | -10.12% | -45.56% | -0.72% |
| Class I | -9.57% | -44.98% | 0.25% |
| S&P 500 Total Return Index <sup>3</sup> | 2.31% | -18.11% | 10.62% |
| S&P North American Technology Sector Industry Index <sup>4</sup> | -4.88% | -35.36% | 1.10% |
| Exponential Technologies Blended Index <sup>5</sup> | -4.01% | -35.04% | 1.44% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.68%, 2.43%, 1.63% and 1.43% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. Redemptions within 180 days of purchase are subject to a redemption fee of 1.00%. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Eventide Exponential Technologies Fund commenced operations on June 30, 2020.* 

*3.* *The S&P 500 Total Return Index, a registered trademark of McGraw-Hill Co., Inc., is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index.* 

*4.* *The S&P North American Technology Sector Industry Index provides investors with a benchmark that represents U.S. securities classified under the GICS<sup>®</sup> information technology sector as well as the internet & direct marketing retail, interactive home entertainment, and interactive media & services sub-industries. Investors cannot invest directly in an index.* 

*5.* *The Exponential Technologies Blended Index is comprised of 50% of the S&P North American Technology Software Index, 20% of the S&P Technology Hardware Select Industry Index, 20% of the Philadelphia Stock Exchange Semiconductor Index and 10% of the S&P 500 Communications Services Sector. The Eventide Exponential Technologies Blended Index rebalances its weightings on a monthly frequency. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Software | 48.1% |
| Semiconductors | 17.9% |
| Specialty Finance | 7.2% |
| Industrial Intermediate Prod | 4.9% |
| Technology Services | 4.4% |
| Infrastructure REIT | 3.1% |
| Renewable Energy | 3.1% |
| E-Commerce Discretionary | 2.7% |
| Advertising & Marketing | 1.8% |
| Consumer Services | 1.8% |
| Other / Cash & Cash Equivalents | 5.0% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **6** |
| **E V E N T I D E** | **6** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;*Six Month* |  |  |  | &nbsp;&nbsp;*Since* | &nbsp;&nbsp;*Since* | &nbsp;&nbsp;*Since* |
|  | &nbsp;&nbsp;*Return* | &nbsp;&nbsp;*1 Year Return* | &nbsp;&nbsp;*5 Year Return* | &nbsp;&nbsp;*10 Year Return* | &nbsp;&nbsp;*Inception <sup>2</sup>* | &nbsp;&nbsp;*Inception <sup>3</sup>* | &nbsp;&nbsp;*Inception <sup>4</sup>* |
| Class N | &nbsp;&nbsp;-1.43% | &nbsp;&nbsp;-34.05% | &nbsp;&nbsp;8.25% | &nbsp;&nbsp;13.39% | &nbsp;&nbsp;12.67% | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A |
| Class A without load | &nbsp;&nbsp;-1.44% | &nbsp;&nbsp;-34.08% | &nbsp;&nbsp;8.21% | &nbsp;&nbsp;13.35% | &nbsp;&nbsp;N/A | &nbsp;&nbsp;14.20% | &nbsp;&nbsp;N/A |
| Class A with 5.75% load | &nbsp;&nbsp;-7.10% | &nbsp;&nbsp;-37.87% | &nbsp;&nbsp;6.94% | &nbsp;&nbsp;12.68% | &nbsp;&nbsp;N/A | &nbsp;&nbsp;13.69% | &nbsp;&nbsp;N/A |
| Class C | &nbsp;&nbsp;-1.80% | &nbsp;&nbsp;-34.57% | &nbsp;&nbsp;7.39% | &nbsp;&nbsp;12.48% | &nbsp;&nbsp;N/A | &nbsp;&nbsp;13.33% | &nbsp;&nbsp;N/A |
| Class I | &nbsp;&nbsp;-1.33% | &nbsp;&nbsp;-33.92% | &nbsp;&nbsp;8.47% | &nbsp;&nbsp;13.62% | &nbsp;&nbsp;N/A | &nbsp;&nbsp;N/A | &nbsp;&nbsp;13.23% |
| S&P 500 Total Return Index <sup>5</sup> | &nbsp;&nbsp;2.31% | &nbsp;&nbsp;-18.11% | &nbsp;&nbsp;9.42% | &nbsp;&nbsp;12.56% | &nbsp;&nbsp;10.13% | &nbsp;&nbsp;12.61% | &nbsp;&nbsp;12.34% |
| Russell Midcap Growth Index <sup>6</sup> | &nbsp;&nbsp;6.20% | &nbsp;&nbsp;-26.72% | &nbsp;&nbsp;7.64% | &nbsp;&nbsp;11.41% | &nbsp;&nbsp;9.71% | &nbsp;&nbsp;12.44% | &nbsp;&nbsp;11.91% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. Per the Fund's most recent prospectus, total annual Fund expenses are 1.36%, 2.11%, 1.31%, and 1.11% for Class A shares, Class C shares, Class N shares and Class I shares, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Class N commenced operations on July 8, 2008.* 

 

*3.* *Class A and Class C commenced operations on October 28, 2009.* 

 

*4.* *Class I commenced operations on February 2, 2010.* 

 

*5.* *The S&P 500 Total Return Index, a registered trademark of McGraw-Hill Co., Inc., is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index.* 

 

*6.* *The Russell Midcap Growth Index measures the performance of the mid-cap growth segment of the U.S. equity universe. It includes those Russell Midcap Index companies with higher price-to-book ratios and higher forecasted growth values. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Software | 20.2% |
| Medical Equipment & Devices | 11.2% |
| Biotech & Pharma | 9.8% |
| Electric Equipment | 6.6% |
| Semiconductors | 5.9% |
| Electric Utilities | 4.9% |
| Transportation & Logistics | 3.8% |
| Technology Services | 3.4% |
| Commercial Support Services | 3.3% |
| Specialty Finance | 2.8% |
| Other / Cash & Cash Equivalents | 28.1% |
|  | 100.0% |

---

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **7** |
| **E V E N T I D E** | **7** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Six Month* |  |  |  | *Since* |
|  | *Return* | *1 Year Return* | *5 Year Return* | *10 Year Return* | *Inception <sup>2</sup>* |
| Class N | 22.91% | -19.77% | 7.59% | 15.51% | 15.52% |
| Class A without load | 22.84% | -19.83% | 7.53% | 15.43% | 15.44% |
| Class A with 5.75% load | 15.78% | -24.44% | 6.26% | 14.75% | 14.76% |
| Class C | 22.44% | -20.42% | 6.73% | 14.58% | 14.59% |
| Class I | 23.03% | -19.62% | 7.80% | 15.73% | 15.74% |
| S&P 500 Total Return Index <sup>3</sup> | 2.31% | -18.11% | 9.42% | 12.56% | 12.61% |
| S&P Biotechnology Select Industry Index <sup>4</sup> | 12.04% | -25.62% | -0.27% | 11.14% | 11.20% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. Per the Fund's most recent prospectus, total annual Fund expenses, including acquired fund fees, are 1.56%, 2.31%, 1.51% and 1.31% for Class A shares, Class C shares, Class N shares and Class I shares, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

 

*2.* *Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012.* 

 

*3.* *The S&P 500 Total Return Index, a registered trademark of McGraw-Hill Co., Inc., is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index.* 

 

*4.* *The S&P Biotechnology Select Industry Index is designed to measure the performance of narrow GICS<sup>®</sup> sub-industries and is comprised of stock in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | % of Net Assets |
| Biotech & Pharma | 69.9% |
| Medical Equipment & Devices | 13.8% |
| Short-Term Investments | 4.9% |
| Software | 4.4% |
| Other / Cash & Cash Equivalents | 7.0% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **8** |
| **E V E N T I D E** | **8** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmark:**

---

| | | |
|:---|:---|:---|
|  | *Six Month* | *Since* |
|  | *Return* | *Inception <sup>2</sup>* |
| Class N | -2.69% | -2.69% |
| Class A without load | -2.68% | -2.68% |
| Class A with 5.75% load | -8.27% | -8.27% |
| Class C | -3.00% | -3.00% |
| Class I | -2.65% | -2.65% |
| S&P 500 Total Return Index <sup>3</sup> | 2.31% | 2.31% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Total returns would have been lower absent the manager's fee waiver. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.19%, 1.94%, 1.14% and 0.94% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Per the Fund's most recent prospectus, total annual Fund estimated expenses before waiver are 1.46%, 2.21%, 1.41% and 1.21% for Class A shares, Class C shares, Class N shares and Class I shares, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Eventide Large Cap Focus Fund commenced operations on June 30, 2022.* 

*3.* *The S&P 500 Total Return Index, a registered trademark of McGraw-Hill Co., Inc., is a market capitalization-weighted index of 500 widely held common stocks. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Software | 24.1% |
| Medical Equipment & Devices | 10.9% |
| Biotech & Pharma | 8.9% |
| Semiconductors | 8.7% |
| Commercial Support Services | 5.6% |
| Retail - Discretionary | 5.5% |
| Electrical Equipment | 4.7% |
| Short-Term Investments | 4.4% |
| Institutional Financial Services | 3.8% |
| Technology Services | 3.3% |
| Other / Cash & Cash Equivalents | 20.1% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **9** |
| **E V E N T I D E** | **9** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Six Month* |  |  |  | *Since* | *Since* |
|  | *Return* | *1 Year Return* | *5 Year Return* | *10 Year Return* | *Inception <sup>2</sup>* | *Inception <sup>3</sup>* |
| Class N | -0.34% | -5.80% | N/A | N/A | N/A | 0.62% |
| Class A without load | -0.46% | -5.84% | 0.21% | 1.06% | 1.82% | N/A |
| Class A with 5.75% load | -6.14% | -11.23% | -0.96% | 0.47% | 1.34% | N/A |
| Class C | -0.72% | -6.56% | N/A | N/A | N/A | -0.17% |
| Class I | -0.23% | -5.57% | 0.49% | 0.90% | 1.51% | N/A |
| Bloomberg 1-5 Year Government/Credit Index <sup>4</sup> | -0.99% | -5.49% | 0.85% | 0.98% | 1.26% | 0.88% |
| Bloomberg U.S. Intermediate Aggregate Bond Index <sup>5</sup> | -2.18% | -9.50% | 0.31% | 1.00% | 1.60% | 0.38% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Total returns would have been lower absent the manager's fee waiver. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 0.80%, 1.55%, 0.75% and 0.55% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Per the Fund's most recent prospectus, total annual Fund expenses before waiver are 0.89%, 1.64%, 0.84% and 0.64% for Class A shares, Class C shares, Class N shares and Class I shares, respectively. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Class A and Class I commenced operations on July 28, 2010.* 

*3.* *Class N and Class C commenced operations on December 14, 2018.* 

*4.* *The Bloomberg 1-5 Year Government/Credit Index measures the performance of U.S. dollar-denominated U.S. Treasury bonds, government related bonds (i.e., U.S. and non-U.S. agencies, sovereign, quasi-sovereign, supranational and local authority debt) and investment grade U.S. corporate bonds that have a remaining maturity of greater than or equal to one year and less than five years. Investors cannot invest directly in an index.* 

*5.* *The Bloomberg U.S. Intermediate Aggregate Bond Index is a market capitalization-weighted index, meaning the securities in the index are weighted according to the market size of each bond type. Most U.S. traded investment grade bonds are represented. Municipal bonds, and Treasury Inflation-Protected Securities are excluded, due to tax treatment issues. The index includes Treasury securities, government agency bonds, mortgage-backed bonds, corporate bonds, and a small amount of foreign bonds traded in U.S. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Electric Utilities | 14.9% |
| Government Sponsored | 11.9% |
| Government Owned, No Guarantee | 10.8% |
| Banking | 10.4% |
| Real Estate Investment Trusts | 7.5% |
| Auto Loan | 5.7% |
| Insurance | 4.4% |
| Engineering & Construction | 3.4% |
| Retail - Discretionary | 3.4% |
| Institutional Financial Services | 2.2% |
| Other / Cash & Cash Equivalents | 25.4% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **10** |
| **E V E N T I D E** | **10** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **PORTFOLIO REVIEW (Unaudited)** |
| **December 31, 2022** |

---

**Average Annual Total Return through December 31, 2022<sup>1</sup>, as compared to its benchmarks:**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Six Month* |  |  | *Since* |
|  | *Return* | *1 Year Return* | *5 Year Return* | *Inception <sup>2</sup>* |
| Class N | 0.38% | -15.45% | 4.93% | 5.79% |
| Class A without load | 0.35% | -15.53% | 4.91% | 5.76% |
| Class A with 5.75% load | -5.41% | -20.40% | 3.68% | 4.93% |
| Class C | -0.02% | -16.13% | 4.08% | 4.95% |
| Class I | 0.48% | -15.28% | 5.13% | 5.99% |
| Russell Midcap Total Return Index <sup>3</sup> | 5.43% | -17.32% | 7.10% | 8.12% |
| Russell Midcap Value Index <sup>4</sup> | 5.01% | -12.03% | 5.72% | 7.29% |
| Bloomberg U.S. Intermediate Aggregate Bond Index <sup>5</sup> | -2.18% | -9.50% | 0.31% | 0.83% |
| Multi-Asset Income Blended Index <sup>6</sup> | 1.83% | -13.07% | 4.19% | 4.83% |

---

*1.* *The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Investment return and principal value will fluctuate, so that shares, when redeemed, may be worth more or less than their original cost. The returns shown do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or on the redemptions of Fund shares. Past performance is no guarantee of future results. Performance figures for periods greater than 1 year are annualized. The Fund's manager has contractually agreed to waive fees and/or reimburse expenses of the Fund to the extent necessary to limit operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expenses on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at 1.07%, 1.82%, 1.02% and 0.82% for Class A shares, Class C shares, Class N shares and Class I shares, respectively, through October 31, 2023. Class A shares are subject to a maximum sales charge of 5.75% imposed on purchases and have a maximum deferred sales charge of 1.00% on purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months. Class C shares are subject to a maximum deferred sales charge of 1.00% on shares sold within 12 months. A $15 fee may be charged for redemptions made by wire. For performance information current to the most recent month-end, please call toll-free 1-877-771-3836.* 

*2.* *Eventide Multi-Asset Income Fund commenced operations on July 15, 2015.* 

*3.* *The Russell Midcap Total Return Index measures the performance of the mid-cap segment of the US equity universe. It is a subset of the Russell 1000 Index. It includes approximately 800 of the smallest securities based on a combination of their market cap and current index membership, representing approximately 31% of the total market capitalization of the Russell 1000 companies. It is constructed to provide a comprehensive and unbiased barometer for the mid-cap segment. The index is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true mid-cap opportunity set. Investors cannot invest directly in an index.* 

*4.* *The Russell Midcap Value Index measures the performance of the mid-capitalization U.S. equities that exhibit value characteristics. It includes those Russell Midcap Index companies with relatively lower price-to-book ratios, lower I/B/E/S forecast medium term (2 year) growth and lower sales per share historical growth (5 years). Investors cannot invest directly in an index.* 

*5.* *The Bloomberg U.S. Intermediate Aggregate Bond Index is a market capitalization-weighted index, meaning the securities in the index are weighted according to the market size of each bond type. Most U.S. traded investment grade bonds are represented. Municipal bonds, and Treasury Inflation-Protected Securities are excluded, due to tax treatment issues. The index includes Treasury securities, government agency bonds, mortgage-backed bonds, corporate bonds, and a small amount of foreign bonds traded in U.S. Investors cannot invest directly in an index.* 

*6.* *The Multi-Asset Income Blended Index is comprised of 50% of the Russell Midcap Total Return Index and 50% of the Bloomberg U.S. Intermediate Aggregate Bond Index. The Eventide Multi-Asset Income Blended Index rebalances its weightings on a monthly frequency. Investors cannot invest directly in an index.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **11** |
| **E V E N T I D E** | **11** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **PORTFOLIO REVIEW (Unaudited)(Continued)** |
| **December 31, 2022** |

---

---

| | |
|:---|:---|
| **Holdings by Industry or Asset Class** | *% of Net Assets* |
| Electric Utilities | 13.1% |
| Agency Fixed Rate | 9.7% |
| Banking | 6.2% |
| Electric Equipment | 6.2% |
| Oil & Gas Producers | 5.4% |
| Government Sponsored | 5.3% |
| Medical Equipment & Devices | 4.1% |
| Government Owned, No Guarantee | 3.6% |
| Real Estate Investment Trusts | 3.6% |
| Semiconductors | 3.4% |
| Other / Cash & Cash Equivalents | 39.4% |
|  | 100.0% |

---

------

*Please refer to the Schedule of Investments in this semi-annual report for a detailed listing of the Fund's holdings.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **12** |
| **E V E N T I D E** | **12** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **ASSET BACKED SECURITIES — 8.4%** |  |  |  |  |
|  | **AUTO LOAN — 6.1%** |  |  |  |  |
| 1375000 | CarMax Auto Owner Trust Series 2020-4 C | CarMax Auto Owner Trust Series 2020-4 C | 1.3000 | 08/17/26 | $1255588 |
| 1000000 | CarMax Auto Owner Trust Series 2021-2 C | CarMax Auto Owner Trust Series 2021-2 C | 1.3400 | 02/16/27 | 905116 |
| 1150000 | World Omni Auto Receivables Trust Series 2019-B C | World Omni Auto Receivables Trust Series 2019-B C | 3.0300 | 01/15/26 | 1137811 |
|  |  |  |  |  | 3298515 |
|  | **OTHER ABS — 2.3%** |  |  |  |  |
| 1350000 | PFS Financing Corporation Series 2020-G A<sup>1</sup> | PFS Financing Corporation Series 2020-G A<sup>1</sup> | 0.9700 | 02/15/26 | 1274528 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $4,916,914)** | **TOTAL ASSET BACKED SECURITIES (Cost $4,916,914)** |  |  | 4573043 |
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 51.5%** |  |  |  |  |
|  | **AUTOMOTIVE — 0.9%** |  |  |  |  |
| 600000 | Dana, Inc. |  | 4.2500 | 09/01/30 | 484254 |
|  | **BANKING — 9.0%** |  |  |  |  |
| 1375000 | Bank of America Corporation<sup>2</sup> | US0003M + 0.870% | 2.4560 | 10/22/25 | 1300742 |
| 1375000 | JPMorgan Chase & Company<sup>2</sup> | SOFRRATE + 0.600% | 0.6530 | 09/16/24 | 1326609 |
| 1200000 | National Bank of Canada<sup>2</sup> | H15T1Y + 0.400% | 0.5500 | 11/15/24 | 1149201 |
| 1000000 | Royal Bank of Canada |  | 1.1500 | 07/14/26 | 882923 |
| 250000 | Toronto-Dominion Bank (The) |  | 1.2500 | 12/13/24 | 232923 |
|  |  |  |  |  | 4892398 |
|  | **BIOTECH & PHARMA — 1.4%** |  |  |  |  |
| 750000 | Zoetis, Inc. |  | 5.4000 | 11/14/25 | 766467 |
|  | **ELEC & GAS MARKETING & TRADING — 1.6%** |  |  |  |  |
| 700000 | Consolidated Edison Company of New York, Inc. |  | 3.9500 | 04/01/50 | 561777 |
| 350000 | Southern Power Company |  | 0.9000 | 01/15/26 | 308821 |
|  |  |  |  |  | 870598 |
|  | **ELECTRIC UTILITIES — 17.0%** |  |  |  |  |
| 375000 | AES Corporation (The) |  | 1.3750 | 01/15/26 | 333768 |
| 500000 | Ameren Illinois Company |  | 5.9000 | 12/01/52 | 550269 |
| 250000 | Avangrid, Inc. |  | 3.1500 | 12/01/24 | 239246 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **13** |
| **E V E N T I D E** | **13** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 51.5% (Continued)** |  |  |  |  |
|  | **ELECTRIC UTILITIES — 17.0% (Continued)** |  |  |  |  |
| 500000 | CenterPoint Energy, Inc.<sup>2</sup> | SOFRRATE + 0.650% | 4.6090 | 05/13/24 | $494276 |
| 1225000 | DTE Electric Company |  | 3.9500 | 03/01/49 | 1018769 |
| 250000 | Duke Energy Florida, LLC |  | 2.5000 | 12/01/29 | 215192 |
| 650000 | Interstate Power and Light Company |  | 3.5000 | 09/30/49 | 469871 |
| 1175000 | MidAmerican Energy Company |  | 4.2500 | 07/15/49 | 1010461 |
| 1150000 | National Rural Utilities Cooperative Finance Corporation |  | 1.3500 | 03/15/31 | 855357 |
| 810000 | NextEra Energy Capital Holdings, Inc.<sup>2</sup> | SOFRRATE + 0.540% | 4.5940 | 03/01/23 | 809662 |
| 500000 | NextEra Energy Capital Holdings, Inc.<sup>2</sup> | US0003M + 2.409% | 4.8000 | 12/01/77 | 409818 |
| 1425000 | Northern States Power Company |  | 2.9000 | 03/01/50 | 990637 |
| 1450000 | Public Service Company of Oklahoma |  | 3.1500 | 08/15/51 | 976007 |
| 1500000 | Wisconsin Public Service Corporation |  | 2.8500 | 12/01/51 | 974457 |
|  |  |  |  |  | 9347790 |
|  | **ENGINEERING & CONSTRUCTION — 3.0%** |  |  |  |  |
| 600000 | Installed Building Products, Inc.<sup>1</sup> |  | 5.7500 | 02/01/28 | 540435 |
| 700000 | MasTec, Inc.<sup>1</sup> |  | 4.5000 | 08/15/28 | 629376 |
| 575000 | Quanta Services, Inc. Class B |  | 2.9000 | 10/01/30 | 475548 |
|  |  |  |  |  | 1645359 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 3.5%** |  |  |  |  |
| 1425000 | Morgan Stanley<sup>2</sup> | SOFRRATE + 0.745% | 0.8640 | 10/21/25 | 1309340 |
| 875000 | Nasdaq, Inc. |  | 3.2500 | 04/28/50 | 597055 |
|  |  |  |  |  | 1906395 |
|  | **INSURANCE — 3.4%** |  |  |  |  |
| 1000000 | Aflac, Inc. |  | 1.1250 | 03/15/26 | 888230 |
| 1125000 | Pacific Life Global Funding II<sup>1</sup> |  | 1.3750 | 04/14/26 | 994490 |
|  |  |  |  |  | 1882720 |
|  | **MACHINERY — 2.6%** |  |  |  |  |
| 650000 | Mueller Water Products, Inc.<sup>1</sup> |  | 4.0000 | 06/15/29 | 572016 |
| 1000000 | Xylem, Inc./NY |  | 1.9500 | 01/30/28 | 861804 |
|  |  |  |  |  | 1433820 |
|  | **OIL & GAS PRODUCERS — 0.4%** |  |  |  |  |
| 250000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 225510 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **14** |
| **E V E N T I D E** | **14** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 51.5% (Continued)** |  |  |  |  |
|  | **REAL ESTATE INVESTMENT TRUSTS — 5.1%** |  |  |  |  |
| 500000 | AvalonBay Communities, Inc. |  | 2.0500 | 01/15/32 | $395254 |
| 700000 | HAT Holdings I, LLC/HAT Holdings II, LLC<sup>1</sup> |  | 3.3750 | 06/15/26 | 609133 |
| 500000 | Prologis, L.P. |  | 1.2500 | 10/15/30 | 381419 |
| 1180000 | Public Storage<sup>2</sup> | SOFRRATE + 0.470% | 4.2380 | 04/23/24 | 1171885 |
| 250000 | Welltower, Inc. |  | 2.7000 | 02/15/27 | 225743 |
|  |  |  |  |  | 2783434 |
|  | **SEMICONDUCTORS — 1.5%** |  |  |  |  |
| 1000000 | NXP BV/NXP Funding, LLC/NXP USA, Inc. |  | 2.5000 | 05/11/31 | 801598 |
|  | **TECHNOLOGY SERVICES — 0.4%** |  |  |  |  |
| 250000 | Verisk Analytics, Inc. |  | 5.5000 | 06/15/45 | 237478 |
|  | **WHOLESALE - CONSUMER STAPLES — 1.7%** |  |  |  |  |
| 1125000 | Sysco Corporation |  | 2.4000 | 02/15/30 | 940287 |
|  | **TOTAL CORPORATE BONDS (Cost $33,646,688)** |  |  |  | 28218108 |
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 10.2%** |  |  |  |  |
|  | **COMBINED UTILITIES — 1.9%** |  |  |  |  |
| 1000000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | 01/01/27 | 1031120 |
|  | **MISCELLANEOUS TAX — 1.6%** |  |  |  |  |
| 900000 | Commonwealth of Massachusetts |  | 3.6390 | 07/15/24 | 887485 |
|  | **MULTI-FAMILY HOUSING — 1.5%** |  |  |  |  |
| 250000 | Maine State Housing Authority |  | 0.4000 | 11/15/24 | 237937 |
| 500000 | New York City Housing Development Corporation |  | 0.6500 | 11/01/25 | 464509 |
| 100000 | New York State Housing Finance Agency |  | 0.7000 | 11/01/25 | 92397 |
|  |  |  |  |  | 794843 |
|  | **SINGLE-FAMILY HOUSING — 1.5%** |  |  |  |  |
| 431264 | Minnesota Housing Finance Agency |  | 1.5800 | 02/01/51 | 365373 |
| 480000 | Texas Department of Housing & Community Affairs |  | 0.5000 | 07/01/24 | 460284 |
|  |  |  |  |  | 825657 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **15** |
| **E V E N T I D E** | **15** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 10.2% (Continued)** |  |  |  |
|  | **STATE — 1.8%** |  |  |  |
| 1250000 | State of Oregon | 2.3370 | 11/01/33 | $980216 |
|  | **WATER AND SEWER — 1.9%** |  |  |  |
| 1500000 | City of Aurora, CO Water Revenue | 2.6260 | 08/01/41 | 1065747 |
|  | **TOTAL MUNICIPAL BONDS (Cost $6,595,477)** |  |  | 5585068 |
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 25.9%** |  |  |  |
|  | **AGENCY FIXED RATE — 18.0%** |  |  |  |
| 944178 | Fannie Mae Pool BO9355 | 3.0000 | 03/01/50 | 835967 |
| 917261 | Fannie Mae Pool BP5878 | 2.5000 | 06/01/50 | 784368 |
| 798406 | Fannie Mae Pool FM4720 | 3.0000 | 10/01/50 | 709897 |
| 748119 | Fannie Mae Pool MA4307 | 3.0000 | 04/01/51 | 659452 |
| 1211976 | Fannie Mae Pool MA4625 | 3.5000 | 06/01/52 | 1104191 |
| 970910 | Fannie Mae Pool MA4655 | 4.0000 | 07/01/52 | 913124 |
| 978305 | Fannie Mae Pool MA4700 | 4.0000 | 08/01/52 | 919775 |
| 1058457 | Freddie Mac Pool SD8090 | 2.0000 | 09/01/50 | 868505 |
| 694745 | Freddie Mac Pool SD8128 | 2.0000 | 02/01/51 | 569795 |
| 684326 | Freddie Mac Pool SD8129 | 2.5000 | 02/01/51 | 584386 |
| 1098794 | Freddie Mac Pool RA5696 | 2.5000 | 08/01/51 | 935607 |
| 1057848 | Freddie Mac Pool SD8214 | 3.5000 | 05/01/52 | 964534 |
|  |  |  |  | 9849601 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 1.0%** |  |  |  |
| 500000 | Federal National Mortgage Association | 5.6250 | 07/15/37 | 561759 |
|  | **GOVERNMENT SPONSORED — 6.9%** |  |  |  |
| 1150000 | Federal Farm Credit Banks Funding Corporation | 5.0800 | 12/01/23 | 1150606 |
| 1250000 | Federal Farm Credit Banks Funding Corporation | 1.7300 | 09/22/31 | 1000910 |
| 1000000 | Federal Home Loan Mortgage Corporation | 5.2000 | 05/17/24 | 1000395 |
| 600000 | Federal Home Loan Mortgage Corporation | 5.2500 | 12/09/24 | 600471 |
|  |  |  |  | 3752382 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $15,869,485)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $15,869,485)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $15,869,485)** | 14163742 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **16** |
| **E V E N T I D E** | **16** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | |
|:---|:---|
|  | *Fair Value* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENTS - 96.0% (Cost $61,028,564)** | $52539961 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**OTHER ASSETS IN EXCESS OF LIABILITIES - 4.0%** | 2167624 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**NET ASSETS - 100.0%** | $54707585 |

---

LLC - Limited Liability Company

L.P. - Limited Partnership

H15T1Y US Treasury Yield Curve Rate T Note Constant Maturity 1 Year

SOFRRATE United States SOFR Secured Overnight Financing Rate

US0003M ICE LIBOR USD 3 Month

1. *Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of December 31, 2022 the total market value of 144A securities is $4,619,978 or 8.4% of net assets.* 

2. *Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **17** |
| **E V E N T I D E** | **17** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 90.2%** |  |
|  | **BANKING - 3.3%** |  |
| 95600 | First Republic Bank | $11652684 |
| 133912 | Synovus Financial Corporation | 5028396 |
|  |  | 16681080 |
|  | **BIOTECH & PHARMA - 2.4%** |  |
| 309703 | Royalty Pharma plc, Class A | 12239463 |
|  | **CHEMICALS - 4.8%** |  |
| 659100 | Element Solutions, Inc. | 11989029 |
| 52687 | Sherwin-Williams Company (The) | 12504206 |
|  |  | 24493235 |
|  | **DIVERSIFIED INDUSTRIALS - 2.1%** |  |
| 239200 | Pentair PLC | 10759216 |
|  | **ELECTRIC UTILITIES - 9.3%** |  |
| 264353 | Clearway Energy, Inc. | 8424930 |
| 195500 | CMS Energy Corporation | 12381015 |
| 212742 | NextEra Energy Partners, L.P. | 14911087 |
| 129100 | WEC Energy Group, Inc. | 12104416 |
|  |  | 47821448 |
|  | **ELECTRICAL EQUIPMENT - 11.5%** |  |
| 580600 | nVent Electric plc | 22335682 |
| 36061 | Roper Technologies, Inc. | 15581597 |
| 120268 | Trane Technologies PLC | 20215848 |
|  |  | 58133127 |
|  | **HEALTH CARE FACILITIES & SERVICES - 1.6%** |  |
| 138000 | Encompass Health Corporation | 8253780 |
|  | **HOME CONSTRUCTION - 1.1%** |  |
| 66013 | DR Horton, Inc. | 5884399 |
|  | **INDUSTRIAL REIT - 2.4%** |  |
| 50808 | EastGroup Properties, Inc. | 7522632 |
| 45093 | Prologis, Inc. | 5083334 |
|  |  | 12605966 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **18** |
| **E V E N T I D E** | **18** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 90.2% (Continued)** |  |
|  | **INFRASTRUCTURE REIT - 2.0%** |  |
| 73779 | Crown Castle, Inc. | $10007384 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 4.1%** |  |
| 343365 | Nasdaq, Inc. | 21065443 |
|  | **INSURANCE - 2.5%** |  |
| 67636 | Arthur J Gallagher & Company | 12752091 |
|  | **MACHINERY - 2.2%** |  |
| 50357 | IDEX Corporation | 11498014 |
|  | **MEDICAL EQUIPMENT & DEVICES - 8.8%** |  |
| 144200 | Baxter International, Inc. | 7349874 |
| 146006 | Bruker Corporation | 9979510 |
| 5637 | Mettler-Toledo International, Inc.<sup>1</sup> | 8148002 |
| 105400 | STERIS plc | 19466325 |
|  |  | 44943711 |
|  | **OFFICE REIT - 0.9%** |  |
| 32335 | Alexandria Real Estate Equities, Inc. | 4710239 |
|  | **OIL & GAS PRODUCERS - 8.8%** |  |
| 70400 | Cheniere Energy, Inc. | 10557184 |
| 70226 | Devon Energy Corporation | 4319601 |
| 148994 | EQT Corporation | 5040467 |
| 103098 | Targa Resources Corporation | 7577703 |
| 536047 | Williams Companies, Inc. (The) | 17635947 |
|  |  | 45130902 |
|  | **RESIDENTIAL REIT - 1.1%** |  |
| 90110 | Equity LifeStyle Properties, Inc. | 5821106 |
|  | **SEMICONDUCTORS - 4.1%** |  |
| 138830 | Entegris, Inc. | 9105860 |
| 30961 | KLA Corporation | 11673226 |
|  |  | 20779086 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **19** |
| **E V E N T I D E** | **19** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Shares* |  |  |  | *Fair Value* |
|  | **COMMON STOCKS — 90.2% (Continued)** |  |  |  |
|  | **SOFTWARE - 4.5%** |  |  |  |
| 76771 | Palo Alto Networks, Inc.<sup>1</sup> |  |  | $10712625 |
| 38748 | Synopsys, Inc.<sup>1</sup> |  |  | 12371849 |
|  |  |  |  | 23084474 |
|  | **SPECIALTY FINANCE - 0.9%** |  |  |  |
| 61600 | Walker & Dunlop, Inc. |  |  | 4834368 |
|  | **SPECIALTY REITS - 0.8%** |  |  |  |
| 134851 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. |  |  | 3907982 |
|  | **TECHNOLOGY SERVICES - 5.8%** |  |  |  |
| 117167 | CDW Corporation/DE |  |  | 20923683 |
| 47193 | Verisk Analytics, Inc. |  |  | 8325789 |
|  |  |  |  | 29249472 |
|  | **TRANSPORTATION & LOGISTICS - 2.7%** |  |  |  |
| 49200 | Old Dominion Freight Line, Inc. |  |  | 13961976 |
|  | **WHOLESALE - CONSUMER STAPLES - 1.9%** |  |  |  |
| 130400 | Sysco Corporation |  |  | 9969080 |
|  | **WHOLESALE - DISCRETIONARY - 0.6%** |  |  |  |
| 10100 | Pool Corporation |  |  | 3053533 |
|  | **TOTAL COMMON STOCKS (Cost $484,354,568)** |  |  | 461640575 |
| *Shares* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **PREFERRED STOCKS — 3.7%** |  |  |  |
|  | **AUTOMOTIVE — 1.3%** |  |  |  |
| 62500 | Aptiv plc | 5.5000 | 06/15/23 | 6726170 |
|  | **ELECTRIC UTILITIES — 2.4%** |  |  |  |
| 119600 | AES Corporation (The) | 6.8750 | 02/15/24 | 12200396 |
|  | **TOTAL PREFERRED STOCKS (Cost $21,140,597)** |  |  | 18926566 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **20** |
| **E V E N T I D E** | **20** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 0.8%** |  |  |  |
|  | **ASSET MANAGEMENT — 0.8%** |  |  |  |
| 2000000 | Calvert Impact Capital, Inc.<sup>2</sup> | 1.0000 | 11/15/23 | $2000300 |
| 2000000 | Vision Fund International<sup>2,3,4</sup> | 2.6110 | 11/30/23 | 2000000 |
|  |  |  |  | 4000300 |
|  | **TOTAL CORPORATE BONDS (Cost $4,000,000)** |  |  | 4000300 |
| *Shares* |  |  |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 0.3%** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.3%** |  |  |  |
| 103710 | Fidelity Government Portfolio, Class I, 4.06%<sup>5</sup> |  |  | 103710 |
| 1304787 | First American Government Obligations Fund, Class U, 4.10%<sup>5</sup> |  |  | 1304787 |
|  | **TOTAL MONEY MARKET FUNDS (Cost $1,408,497)** |  |  | 1408497 |
|  | **TOTAL SHORT-TERM INVESTMENTS (Cost $1,408,497)** |  |  | 1408497 |
|  | **TOTAL INVESTMENTS - 95.0% (Cost $510,903,662)** |  |  | $485975938 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 5.0%** |  |  | 25846350 |
|  | **NET ASSETS - 100.0%** |  |  | $511822288 |

---

L.P. - Limited Partnership

PLC - Public Limited Company

REIT - Real Estate Investment Trust

*1.* *Non-income producing security.* 

 

*2.* *Illiquid security. The total fair value of these securities as of December 31, 2022 was $4,000,300, representing 0.8% of net assets.* 

 

*3.* *The value of this security has been determined in good faith under policies of the Board of Trustees.* 

 

*4.* *Restricted security. See Note 6 for additional details.* 

 

*5.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **21** |
| **E V E N T I D E** | **21** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 97.3%** |  |
|  | **ADVERTISING & MARKETING – 1.8%** |  |
| 35000 | Trade Desk, Inc. (The), Class A<sup>1</sup> | $1569050 |
|  | **CONSUMER SERVICES - 1.8%** |  |
| 130000 | Coursera, Inc.<sup>1</sup> | 1537900 |
|  | **E-COMMERCE DISCRETIONARY - 2.7%** |  |
| 109503 | Global-e Online Ltd.<sup>1</sup> | 2260142 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 4.9%** |  |
| 127839 | Xometry, Inc.<sup>1</sup> | 4120251 |
|  | **INFRASTRUCTURE REIT - 3.1%** |  |
| 19500 | Crown Castle, Inc. | 2644980 |
|  | **RENEWABLE ENERGY - 5.4%** |  |
| 6782 | Enphase Energy, Inc.<sup>1</sup> | 1796959 |
| 112734 | Shoals Technologies Group, Inc.<sup>1</sup> | 2781148 |
|  |  | 4578107 |
|  | **SEMICONDUCTORS - 17.9%** |  |
| 38773 | Entegris, Inc. | 2543121 |
| 7998 | KLA Corporation | 3015486 |
| 6800 | Lam Research Corporation | 2858040 |
| 51586 | Lattice Semiconductor Corporation<sup>1</sup> | 3346900 |
| 9649 | Monolithic Power Systems, Inc. | 3411982 |
|  |  | 15175529 |
|  | **SOFTWARE – 48.1%** |  |
| 614173 | Arteris, Inc.<sup>1</sup> | 2640944 |
| 31317 | Bill.com Holdings, Inc.<sup>1</sup> | 3412300 |
| 1934 | Constellation Software, Inc. | 3013307 |
| 24000 | Crowdstrike Holdings, Inc., Class A<sup>1</sup> | 2526960 |
| 38016 | Datadog, Inc.<sup>1</sup> | 2794176 |
| 131435 | DoubleVerify Holdings, Inc.<sup>1</sup> | 2886313 |
| 164266 | Doximity, Inc.<sup>1</sup> | 5512766 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **22** |
| **E V E N T I D E** | **22** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Shares* |  |  |  | *Fair Value* |
|  | **COMMON STOCKS — 97.3% (Continued)** |  |  |  |
|  | **SOFTWARE – 48.1% (Continued)** |  |  |  |
| 35000 | Five9, Inc.<sup>1</sup> |  |  | $2375100 |
| 6000 | HubSpot, Inc.<sup>1</sup> |  |  | 1734780 |
| 31503 | Palo Alto Networks, Inc.<sup>1</sup> |  |  | 4395929 |
| 37090 | Sprout Social, Inc., Class A<sup>1</sup> |  |  | 2094101 |
| 14857 | Synopsys, Inc.<sup>1</sup> |  |  | 4743692 |
| 89000 | ZoomInfo Technologies, Inc., Class A<sup>1</sup> |  |  | 2679790 |
|  |  |  |  | 40810158 |
|  | **SPECIALTY FINANCE - 7.2%** |  |  |  |
| 247907 | Flywire Corporation<sup>1</sup> |  |  | 6066284 |
|  | **TECHNOLOGY SERVICES - 4.4%** |  |  |  |
| 237650 | Dlocal Ltd./Uruguay<sup>1</sup> |  |  | 3700211 |
|  | **TOTAL COMMON STOCKS (Cost $92,196,654)** |  |  | 82462612 |
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 1.1%** |  |  |  |
|  | **ASSET MANAGEMENT — 1.1%** |  |  |  |
| 900000 | Calvert Impact Capital, Inc.<sup>2</sup> | 1.0000 | 11/15/23 | 900135 |
|  | **TOTAL CORPORATE BONDS (Cost $900,000)** |  |  | 900135 |
| *Shares* |  |  |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>3</sup>** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.0% <sup>3</sup>** |  |  |  |
| 11627 | Fidelity Government Portfolio, Class I, 4.06% (Cost $11,627)<sup>4</sup> |  |  | 11627 |
|  | **TOTAL INVESTMENTS - 98.4% (Cost $93,108,281)** |  |  | $83374374 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 1.6%** |  |  | 1360710 |
|  | **NET ASSETS - 100.0%** |  |  | $84735084 |

---

LTD - Limited Company

REIT - Real Estate Investment Trust

*1.* *Non-income producing security.* 

 

*2.* *Illiquid security. The total fair value of these securities as of December 31, 2022 was $900,135, representing 1.1% of net assets.* 

 

*3.* *Percentage rounds to less than 0.1%.* 

 

*4.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **23** |
| **E V E N T I D E** | **23** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 92.4%** |  |
|  | **ADVERTISING & MARKETING – 1.9%** |  |
| 1429957 | Trade Desk, Inc. (The), Class A<sup>1</sup> | $64104972 |
|  | **AUTOMOTIVE - 2.1%** |  |
| 719700 | Aptiv plc<sup>1</sup> | 67025661 |
|  | **BIOTECH & PHARMA - 9.7%** |  |
| 191382 | Argenx S.E. - ADR<sup>1</sup> | 72501243 |
| 473923 | Ascendis Pharma A/S - ADR<sup>1</sup> | 57880216 |
| 1344376 | Collegium Pharmaceutical, Inc.<sup>1</sup> | 31189523 |
| 930000 | Guardant Health, Inc.<sup>1</sup> | 25296000 |
| 634200 | Horizon Therapeutics plc<sup>1</sup> | 72171959 |
| 1051275 | Praxis Precision Medicines, Inc.<sup>1</sup> | 2502035 |
| 200000 | Prometheus Biosciences, Inc.<sup>1</sup> | 22000000 |
| 412913 | Royalty Pharma plc, Class A | 16318322 |
| 130876 | Seagen, Inc.<sup>1</sup> | 16818875 |
|  |  | 316678173 |
|  | **COMMERCIAL SUPPORT SERVICES - 3.3%** |  |
| 804000 | Waste Connections, Inc. | 106578240 |
|  | **CONSUMER SERVICES - 1.2%** |  |
| 3239179 | Coursera, Inc.<sup>1</sup> | 38319488 |
|  | **E-COMMERCE DISCRETIONARY - 1.7%** |  |
| 2682658 | Global-e Online Ltd.<sup>1</sup> | 55370061 |
|  | **ELECTRIC UTILITIES - 4.9%** |  |
| 775019 | Brookfield Renewable Corporation | 21344023 |
| 1236000 | Brookfield Renewable Partners, L.P. | 31320240 |
| 740862 | Clearway Energy, Inc. | 23611272 |
| 1151500 | NextEra Energy Partners, L.P. | 80708635 |
|  |  | 156984170 |
|  | **ELECTRICAL EQUIPMENT - 6.6%** |  |
| 125900 | Novanta, Inc.<sup>1</sup> | 17106033 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **24** |
| **E V E N T I D E** | **24** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 92.4% (Continued)** |  |
|  | **ELECTRICAL EQUIPMENT - 6.6% (Continued)** |  |
| 229000 | Roper Technologies, Inc. | $98948610 |
| 613600 | Trane Technologies PLC | 103140024 |
|  |  | 219194667 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS - 1.1%** |  |
| 882000 | Trex Company, Inc.<sup>1</sup> | 37335060 |
|  | **HOME CONSTRUCTION - 1.7%** |  |
| 622000 | DR Horton, Inc. | 55445080 |
|  | **INDUSTRIAL INTERMEDIATE PROD - 2.0%** |  |
| 1975393 | Xometry, Inc.<sup>1</sup> | 63666916 |
|  | **INFRASTRUCTURE REIT - 0.9%** |  |
| 235000 | Crown Castle, Inc. | 31875400 |
|  | **MEDICAL EQUIPMENT & DEVICES - 10.1%** |  |
| 1020700 | Exact Sciences Corporation<sup>1</sup> | 50534857 |
| 240000 | IDEXX Laboratories, Inc.<sup>1</sup> | 97910400 |
| 75000 | Intuitive Surgical, Inc.<sup>1</sup> | 19901250 |
| 112000 | Mettler-Toledo International, Inc.<sup>1</sup> | 161890400 |
|  |  | 330236907 |
|  | **OIL & GAS PRODUCERS - 1.4%** |  |
| 301000 | Cheniere Energy, Inc. | 45137960 |
|  | **RENEWABLE ENERGY - 2.4%** |  |
| 163000 | Enphase Energy, Inc.<sup>1</sup> | 43188480 |
| 1408098 | Shoals Technologies Group, Inc.<sup>1</sup> | 34737778 |
|  |  | 77926258 |
|  | **RETAIL - DISCRETIONARY - 2.5%** |  |
| 421500 | Lowe's Companies, Inc. | 83979660 |
|  | **SEMICONDUCTORS - 5.9%** |  |
| 69000 | ASML Holding N.V. - ADR | 37701600 |
| 487768 | Entegris, Inc. | 31992703 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **25** |
| **E V E N T I D E** | **25** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 92.4% (Continued)** |  |
|  | **SEMICONDUCTORS - 5.9% (Continued)** |  |
| 108100 | Lam Research Corporation | $45434430 |
| 568544 | Lattice Semiconductor Corporation<sup>1</sup> | 36887135 |
| 107998 | Monolithic Power Systems, Inc. | 38189173 |
|  |  | 190205041 |
|  | **SOFTWARE - 20.2%** |  |
| 233993 | Bill.com Holdings, Inc.<sup>1</sup> | 25495877 |
| 583100 | Crowdstrike Holdings, Inc., Class A<sup>1</sup> | 61394599 |
| 466619 | Datadog, Inc.<sup>1</sup> | 34296497 |
| 3087460 | DoubleVerify Holdings, Inc.<sup>1</sup> | 67800622 |
| 3065773 | Doximity, Inc.<sup>1</sup> | 102887342 |
| 1021755 | Evolent Health, Inc., Class A<sup>1</sup> | 28690881 |
| 1007851 | Five9, Inc.<sup>1</sup> | 68392769 |
| 172331 | HubSpot, Inc.<sup>1</sup> | 49826062 |
| 569511 | Palo Alto Networks, Inc.<sup>1</sup> | 79469565 |
| 830457 | Sprout Social, Inc., Class A<sup>1</sup> | 46887602 |
| 3118158 | ZoomInfo Technologies, Inc., Class A<sup>1</sup> | 93887738 |
|  |  | 659029554 |
|  | **SPECIALTY FINANCE - 2.8%** |  |
| 3777381 | Flywire Corporation<sup>1</sup> | 92432513 |
|  | **SPECIALTY REITS - 0.6%** |  |
| 635000 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. | 18402300 |
|  | **TECHNOLOGY SERVICES - 3.4%** |  |
| 5758276 | Dlocal Ltd./Uruguay<sup>1</sup> | 89656357 |
| 125000 | Verisk Analytics, Inc. | 22052500 |
|  |  | 111708857 |
|  | **TRANSPORTATION & LOGISTICS - 3.8%** |  |
| 220000 | GXO Logistics, Inc.<sup>1</sup> | 9391800 |
| 378000 | Old Dominion Freight Line, Inc. | 107268840 |
| 115000 | RXO, Inc.<sup>1</sup> | 1978000 |
| 115000 | XPO Logistics, Inc.<sup>1</sup> | 3828350 |
|  |  | 122466990 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **26** |
| **E V E N T I D E** | **26** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Shares* |  |  |  | *Fair Value* |
|  | **COMMON STOCKS — 92.4% (Continued)** |  |  |  |
|  | **WHOLESALE - DISCRETIONARY - 2.2%** |  |  |  |
| 237000 | Pool Corporation |  |  | $71652210 |
|  | **TOTAL COMMON STOCKS (Cost $2,467,043,035)** |  |  | 3015756138 |
| *Shares* |  |  |  | *Fair Value* |
|  | **CONTINGENT VALUE RIGHTS — 0.1%** |  |  |  |
|  | **BIOTECH & PHARMA - 0.1%** |  |  |  |
| 3982940 | Peloton Therapeutics, Inc. - CVR<sup>1,2,3,4,5</sup> |  |  | 2906351 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** |  |  | 2906351 |
| *Shares* |  |  |  | *Fair Value* |
|  | **PRIVATE INVESTMENTS — 1.0%** |  |  |  |
|  | **MEDICAL EQUIPMENT & DEVICES — 1.0%** |  |  |  |
| 139527 | Beta Bionic Series B<sup>1,2,3,4,5,6</sup> |  |  | 18435172 |
| 48872 | Beta Bionics Series B2<sup>1,2,3,4,5,6</sup> |  |  | 6457272 |
| 71900 | Beta Bionics Series C<sup>1,2,3,4,5,6</sup> |  |  | 7599916 |
|  |  |  |  | 32492360 |
|  | **TOTAL PRIVATE INVESTMENTS (Cost $37,399,898)** |  |  | 32492360 |
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 1.6%** |  |  |  |
|  | **ASSET MANAGEMENT — 1.6%** |  |  |  |
| 12000000 | Calvert Impact Capital, Inc.<sup>2</sup> | 1.0000 | 11/15/23 | 12001800 |
| 12000000 | Calvert Impact Capital, Inc.<sup>2</sup> | 1.5000 | 11/15/24 | 12000000 |
| 7000000 | Vision Fund International<sup>2,3,5</sup> | 2.6110 | 11/30/23 | 7000000 |
| 5000000 | Vision Fund International<sup>2,3,5</sup> | 4.7400 | 06/16/25 | 5000000 |
| 5000000 | Vision Fund International<sup>2,3,5</sup> | 5.9030 | 09/19/25 | 5000000 |
| 5000000 | Vision Fund International<sup>2,3,5</sup> | 3.1500 | 12/15/25 | 5000000 |
| 5000000 | Vision Fund International<sup>2,3,5</sup> | 3.2230 | 12/15/26 | 5000000 |
|  |  |  |  | 51001800 |
|  | **TOTAL CORPORATE BONDS (Cost $51,000,000)** |  |  | 51001800 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **27** |
| **E V E N T I D E** | **27** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **WARRANT — 0.1%** |  |
|  | **MEDICAL EQUIPMENT & DEVICES - 0.1%** |  |
| 17975 | Beta Bionics Series C Warrant<sup>1,2,3,4,5,6</sup> | $1899799 |
|  | **TOTAL WARRANT (Cost $–)** | 1899799 |
| *Shares* |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 1.0%** |  |
|  | **MONEY MARKET FUNDS - 1.0%** |  |
| 33374557 | Fidelity Government Portfolio, Class I, 4.06% (Cost $33,374,557)<sup>7</sup> | 33374557 |
|  | **TOTAL INVESTMENTS - 96.2% (Cost $2,588,817,490)** | $3137431005 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.8%** | 124925796 |
|  | **NET ASSETS - 100.0%** | $3262356801 |

---

ADR - American Depositary Receipt

A/S - Anonim Sirketi

CVR - Contingent Value Rights

L.P. - Limited Partnership

LTD - Limited Company

PLC - Public Limited Company

REIT - Real Estate Investment Trust

*1.* *Non-income producing security.* 

 

*2.* *Illiquid security. The total fair value of these securities as of December 31, 2022 was $88,300,310, representing 2.7% of net assets.* 

 

*3.* *The value of this security has been determined in good faith under policies of the Board of Trustees.* 

 

*4.* *Private investment.* 

 

*5.* *Restricted security. See Note 6 for additional details.* 

 

*6.* *Affiliated Company – Eventide Gilead Fund holds in excess of 5% of outstanding voting securities of this security.* 

 

*7.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **28** |
| **E V E N T I D E** | **28** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 81.9%** |  |
|  | **BIOTECH & PHARMA - 65.1%** |  |
| 1879959 | ADC Therapeutics S.A.<sup>1</sup> | $7219043 |
| 902000 | ALX Oncology Holdings, Inc.<sup>1</sup> | 10165540 |
| 250000 | Amylyx Pharmaceuticals, Inc.<sup>1</sup> | 9237500 |
| 3626508 | Annexon, Inc.<sup>1,2</sup> | 18749046 |
| 339355 | Apellis Pharmaceuticals, Inc.<sup>1</sup> | 17548047 |
| 240000 | Arcus Biosciences, Inc.<sup>1</sup> | 4963200 |
| 137000 | Argenx S.E. - ADR<sup>1</sup> | 51899711 |
| 308786 | Ascendis Pharma A/S - ADR<sup>1</sup> | 37712034 |
| 2251368 | Aura Biosciences, Inc.<sup>1,2</sup> | 23639364 |
| 267025 | Beam Therapeutics, Inc.<sup>1</sup> | 10443348 |
| 853800 | Bicycle Therapeutics plc - ADR<sup>1</sup> | 25272480 |
| 230000 | BioMarin Pharmaceutical, Inc.<sup>1</sup> | 23802700 |
| 438500 | Blueprint Medicines Corporation<sup>1</sup> | 19210685 |
| 1463050 | Celldex Therapeutics, Inc.<sup>1</sup> | 65208139 |
| 368811 | Chinook Therapeutics, Inc.<sup>1</sup> | 9662848 |
| 2589778 | Cogent Biosciences, Inc.<sup>1</sup> | 29937834 |
| 1285217 | Collegium Pharmaceutical, Inc.<sup>1</sup> | 29817035 |
| 935091 | Compass Therapeutics, Inc.<sup>1</sup> | 4703508 |
| 556000 | Cytokinetics, Inc.<sup>1</sup> | 25475920 |
| 4692461 | Freeline Therapeutics Holdings plc Series C - ADR<sup>1,2</sup> | 2336376 |
| 751000 | Guardant Health, Inc.<sup>1</sup> | 20427200 |
| 337000 | Horizon Therapeutics plc<sup>1</sup> | 38350600 |
| 3693720 | Immunovant, Inc.<sup>1</sup> | 65563530 |
| 698413 | Insmed, Inc.<sup>1</sup> | 13954292 |
| 319000 | Intellia Therapeutics, Inc.<sup>1</sup> | 11129910 |
| 800000 | Intercept Pharmaceuticals, Inc.<sup>1</sup> | 9896000 |
| 110000 | Ionis Pharmaceuticals, Inc.<sup>1</sup> | 4154700 |
| 276200 | KalVista Pharmaceuticals, Inc.<sup>1</sup> | 1867112 |
| 519700 | Karuna Therapeutics, Inc.<sup>1</sup> | 102121049 |
| 3150000 | Marinus Pharmaceuticals, Inc.<sup>1,2</sup> | 12537000 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **29** |
| **E V E N T I D E** | **29** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 81.9% (Continued)** |  |
|  | **BIOTECH & PHARMA - 65.1% (Continued)** |  |
| 203600 | Mirati Therapeutics, Inc.<sup>1</sup> | $9225116 |
| 2057000 | Mirum Pharmaceuticals, Inc.<sup>1,2</sup> | 40111500 |
| 135000 | Neurocrine Biosciences, Inc.<sup>1</sup> | 16124400 |
| 2466787 | Praxis Precision Medicines, Inc.<sup>1,2</sup> | 5870953 |
| 832938 | Prometheus Biosciences, Inc.<sup>1</sup> | 91623179 |
| 438732 | Prothena Corp plc<sup>1</sup> | 26433603 |
| 470654 | Rocket Pharmaceuticals, Inc.<sup>1</sup> | 9210699 |
| 1690300 | Roivant Sciences Ltd.<sup>1</sup> | 13505497 |
| 111669 | Seagen, Inc.<sup>1</sup> | 14350583 |
| 1561092 | Talaris Therapeutics, Inc.<sup>1</sup> | 1592314 |
| 359000 | Ultragenyx Pharmaceutical, Inc.<sup>1</sup> | 16632470 |
| 3405644 | VectivBio Holding A.G.<sup>1,2</sup> | 29322595 |
| 641200 | Xenon Pharmaceuticals, Inc.<sup>1</sup> | 25282516 |
| 2156515 | Zentalis Pharmaceuticals, Inc.<sup>1</sup> | 43432212 |
|  |  | 1049723388 |
|  | **MEDICAL EQUIPMENT & DEVICES - 12.4%** |  |
| 2230665 | 908 Devices, Inc.<sup>1,2</sup> | 16997667 |
| 846665 | Exact Sciences Corporation<sup>1</sup> | 41918384 |
| 17300 | IDEXX Laboratories, Inc.<sup>1</sup> | 7057708 |
| 349711 | Inari Medical, Inc.<sup>1</sup> | 22227631 |
| 108220 | Inspire Medical Systems, Inc.<sup>1</sup> | 27258454 |
| 239135 | iRhythm Technologies, Inc.<sup>1</sup> | 22399776 |
| 10500 | Mettler-Toledo International, Inc.<sup>1</sup> | 15177225 |
| 119000 | Repligen Corporation<sup>1</sup> | 20147890 |
| 39700 | Shockwave Medical, Inc.<sup>1</sup> | 8162717 |
| 732000 | Veracyte, Inc.<sup>1</sup> | 17370360 |
|  |  | 198717812 |
|  | **SOFTWARE - 4.4%** |  |
| 697862 | Doximity, Inc.<sup>1</sup> | 23420249 |
| 881000 | Evolent Health, Inc., Class A<sup>1</sup> | 24738480 |
| 1000000 | Privia Health Group, Inc.<sup>1</sup> | 22710000 |
|  |  | 70868729 |
|  | **TOTAL COMMON STOCKS (Cost $1,257,484,168)** | 1319309929 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **30** |
| **E V E N T I D E** | **30** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **CONTINGENT VALUE RIGHTS — 0.1%** |  |
|  | **BIOTECH & PHARMA - 0.1%** |  |
| 1528871 | Peloton Therapeutics, Inc. - CVR<sup>1,3,4,5,6</sup> | $1115617 |
|  | **TOTAL CONTINGENT VALUE RIGHTS (Cost $–)** | 1115617 |
| *Shares* |  |  |
|  | **PRIVATE INVESTMENTS — 6.0%** |  |
|  | **BIOTECH & PHARMA — 4.7%** |  |
| 4643043 | Arch Oncology, Inc. Series C1<sup>1,3,4,5,6</sup> | 565523 |
| 295276 | BioSplice Therapeutics<sup>1,3,4,5,6</sup> | 5435470 |
| 5000000 | Casma Therapeutics, Inc. Series B1<sup>1,2,3,4,5,6</sup> | 2185000 |
| 5000000 | Casma Therapeutics, Inc. Series B2<sup>1,2,3,4,5,6</sup> | 2185000 |
| 1820413 | Casma Therapeutics, Inc. Series C1<sup>1,2,3,4,5,6</sup> | 795520 |
| 1097561 | Flare Therapeutics, Inc. Series A<sup>1,3,4,5,6</sup> | 1042683 |
| 902439 | Flare Therapeutics, Inc. Series A2<sup>1,3,4,5,6</sup> | 857317 |
| 1228304 | Freeline Therapeutics Ltd. Series C<sup>1,2,3,6</sup> | 580994 |
| 928098 | Freenome Holdings, Inc. Series D<sup>1,3,4,5,6</sup> | 5760519 |
| 5000000 | Goldfinch Biopharma, Inc. Series A<sup>1,2,3,4,5,6</sup> |  |
| 8474576 | Goldfinch Biopharma, Inc. Series B<sup>1,2,3,4,5,6</sup> |  |
| 4237288 | Goldfinch Biopharma, Inc. Series B2<sup>1,2,3,4,5,6</sup> |  |
| 763319 | Kojin Therapeutics, Inc. Series A-1<sup>1,3,4,5,6</sup> | 1424998 |
| 763319 | Kojin Therapeutics, Inc. Series A-2<sup>1,3,4,5,6</sup> | 1424998 |
| 3831418 | Korro Bio, Inc. Series B1<sup>1,3,4,5,6</sup> | 9500001 |
| 8718446 | LEXEO Therapeutics Series B<sup>1,2,3,4,5,6</sup> | 14250300 |
| 686724 | Metagenomi Technologies, LLC Series B <sup>1,3,4,5,6</sup> | 9177586 |
| 98875 | Metagenomi Technologies, LLC Series B-1 <sup>1,3,4,5,6</sup> | 1321395 |
| 1017770 | Prometheus Laboratories, Inc.<sup>1,2,3,4,5,6</sup> | 667148 |
| 1489958 | Shoreline Biosciences Series B<sup>1,3,4,5,6</sup> | 14249958 |
| 3660670 | Turnstone Biologics, Inc. Series D<sup>1,3,4,5,6</sup> | 3923506 |
|  |  | 75347916 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **31** |
| **E V E N T I D E** | **31** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **PRIVATE INVESTMENTS — 6.0% (Continued)** |  |
|  | **MEDICAL EQUIPMENT & DEVICES — 1.3%** |  |
| 69763 | Beta Bionic Series B<sup>1,3,4,5,6</sup> | $9217520 |
| 59439 | Beta Bionics Series B2<sup>1,3,4,5,6</sup> | 7853449 |
| 35950 | Beta Bionics Series C<sup>1,3,4,5,6</sup> | 3799958 |
|  |  | 20870927 |
|  | **TOTAL PRIVATE INVESTMENTS (Cost $161,132,936)** | 96218843 |
| *Shares* |  | *Fair Value* |
|  | **WARRANT — 0.1%** |  |
|  | **MEDICAL EQUIPMENT & DEVICES - 0.1%** |  |
| 8987 | Beta Bionics Series C Warrant<sup>1,3,4,5,6</sup> | 949847 |
|  | **TOTAL WARRANT (Cost $–)** | 949847 |
| *Shares* |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 4.9%** |  |
|  | **MONEY MARKET FUNDS - 4.9%** |  |
| 3152856 | Fidelity Government Portfolio, Class I, 4.06%<sup>7</sup> | 3152856 |
| 74860321 | First American Government Obligations Fund, Class U, 4.10%<sup>7</sup> | 74860321 |
|  | **TOTAL MONEY MARKET FUNDS (Cost $78,013,177)** | 78013177 |
|  | **TOTAL SHORT-TERM INVESTMENTS (Cost $78,013,177)** | 78013177 |
|  | **TOTAL INVESTMENTS - 93.0% (Cost $1,496,630,281)** | $1495607413 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 7.0%** | 111772872 |
|  | **NET ASSETS - 100.0%** | $1607380285 |

---

ADR - American Depositary Receipt

A/S - Anonim Sirketi

CVR - Contingent Value Rights

LLC - Limited Liability Company

LTD - Limited Company

PLC - Public Limited Company

S.A. - Société Anonyme

*1.* *Non-income producing security.* 

 

*2.* *Affiliated Company – Eventide Healthcare & Life Sciences Fund holds in excess of 5% of outstanding voting securities of this security.* 

 

*3.* *Illiquid security. The total fair value of these securities as of December 31, 2022 was $98,284,308, representing 6.1% of net assets.* 

 

*4.* *The value of this security has been determined in good faith under policies of the Board of Trustees.* 

 

*5.* *Private investment.* 

 

*6.* *Restricted security. See Note 6 for additional details.* 

 

*7.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **32** |
| **E V E N T I D E** | **32** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 91.1%** |  |
|  | **AUTOMOTIVE - 1.0%** |  |
| 679 | Aptiv plc<sup>1</sup> | $63235 |
|  | **BANKING - 2.1%** |  |
| 1071 | First Republic Bank | 130544 |
|  | **BIOTECH & PHARMA - 8.9%** |  |
| 485 | Argenx S.E. - ADR<sup>1</sup> | 183733 |
| 3535 | Royalty Pharma plc, Class A | 139703 |
| 1627 | Zoetis, Inc. | 238437 |
|  |  | 561873 |
|  | **CHEMICALS - 2.9%** |  |
| 760 | Sherwin-Williams Company (The) | 180371 |
|  | **COMMERCIAL SUPPORT SERVICES - 5.6%** |  |
| 2683 | Waste Connections, Inc. | 355659 |
|  | **ELECTRIC UTILITIES - 2.9%** |  |
| 2207 | NextEra Energy, Inc. | 184505 |
|  | **ELECTRICAL EQUIPMENT - 4.7%** |  |
| 435 | Roper Technologies, Inc. | 187959 |
| 624 | Trane Technologies PLC | 104888 |
|  |  | 292847 |
|  | **INFRASTRUCTURE REIT - 1.5%** |  |
| 674 | Crown Castle, Inc. | 91421 |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 3.8%** |  |
| 3938 | Nasdaq, Inc. | 241596 |
|  | **MEDICAL EQUIPMENT & DEVICES - 10.9%** |  |
| 2607 | Edwards Lifesciences Corporation<sup>1</sup> | 194508 |
| 449 | IDEXX Laboratories, Inc.<sup>1</sup> | 183174 |
| 128 | Mettler-Toledo International, Inc.<sup>1</sup> | 185018 |
| 660 | STERIS plc | 121895 |
|  |  | 684595 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **33** |
| **E V E N T I D E** | **33** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 91.1% (Continued)** |  |
|  | **OIL & GAS PRODUCERS - 1.7%** |  |
| 3345 | Williams Companies, Inc. (The) | $110051 |
|  | **RENEWABLE ENERGY - 1.3%** |  |
| 299 | Enphase Energy, Inc.<sup>1</sup> | 79223 |
|  | **RETAIL - DISCRETIONARY - 5.5%** |  |
| 935 | Lowe's Companies, Inc. | 186289 |
| 188 | O'Reilly Automotive, Inc.<sup>1</sup> | 158678 |
|  |  | 344967 |
|  | **SEMICONDUCTORS - 8.7%** |  |
| 104 | ASML Holding N.V. - ADR | 56826 |
| 319 | KLA Corporation | 120273 |
| 277 | Lam Research Corporation | 116423 |
| 562 | NVIDIA Corporation | 82131 |
| 369 | NXP Semiconductors N.V. | 58313 |
| 1544 | Taiwan Semiconductor Manufacturing Company Ltd. - ADR | 115012 |
|  |  | 548978 |
|  | **SOFTWARE - 24.1%** |  |
| 206 | Constellation Software, Inc. | 320961 |
| 1106 | Crowdstrike Holdings, Inc., Class A<sup>1</sup> | 116451 |
| 1291 | Datadog, Inc.<sup>1</sup> | 94889 |
| 1701 | Palo Alto Networks, Inc.<sup>1</sup> | 237358 |
| 476 | ServiceNow, Inc.<sup>1</sup> | 184817 |
| 766 | Synopsys, Inc.<sup>1</sup> | 244576 |
| 1847 | Workday, Inc., Class A<sup>1</sup> | 309059 |
|  |  | 1508111 |
|  | **TECHNOLOGY SERVICES - 3.3%** |  |
| 14872 | Adyen N.V. - ADR<sup>1</sup> | 205233 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **34** |
| **E V E N T I D E** | **34** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 91.1% (Continued)** |  |
|  | **TRANSPORTATION & LOGISTICS - 2.2%** |  |
| 492 | Old Dominion Freight Line, Inc. | $139620 |
|  | **TOTAL COMMON STOCKS (Cost $5,905,885)** | 5722829 |
| *Shares* |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 4.4%** |  |
|  | **MONEY MARKET FUNDS - 4.4%** |  |
| 277572 | First American Government Obligations Fund, Class U, 4.10% (Cost $277,572)<sup>2</sup> | 277572 |
|  | **TOTAL INVESTMENTS - 95.5% (Cost $6,183,457)** | $6000401 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 4.5%** | 284185 |
|  | **NET ASSETS - 100.0%** | $6284586 |

---

ADR - American Depositary Receipt

LTD - Limited Company

PLC - Public Limited Company

REIT - Real Estate Investment Trust

*1.* *Non-income producing security.* 

 

*2.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **35** |
| **E V E N T I D E** | **35** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **ASSET BACKED SECURITIES — 7.7%** |  |  |  |  |
|  | **AUTO LOAN — 5.7%** |  |  |  |  |
| 3100000 | CarMax Auto Owner Trust Series 2020-4 C | CarMax Auto Owner Trust Series 2020-4 C | 1.3000 | 08/17/26 | $2830780 |
| 1000000 | CarMax Auto Owner Trust Series 2021-2 C | CarMax Auto Owner Trust Series 2021-2 C | 1.3400 | 02/16/27 | 905116 |
| 1500000 | CarMax Auto Owner Trust Series 2021-2 D | CarMax Auto Owner Trust Series 2021-2 D | 1.5500 | 10/15/27 | 1344879 |
| 3000000 | World Omni Auto Receivables Trust Series 2019-B C | World Omni Auto Receivables Trust Series 2019-B C | 3.0300 | 01/15/26 | 2968202 |
|  |  |  |  |  | 8048977 |
|  | **OTHER ABS — 2.0%** |  |  |  |  |
| 2950000 | PFS Financing Corporation Series 2020-G A<sup>1</sup> | PFS Financing Corporation Series 2020-G A<sup>1</sup> | 0.9700 | 02/15/26 | 2785080 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $11,654,599)** | **TOTAL ASSET BACKED SECURITIES (Cost $11,654,599)** |  |  | 10834057 |
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **COLLATERALIZED MORTGAGE OBLIGATIONS** — **0.0%<sup>2</sup>** | **COLLATERALIZED MORTGAGE OBLIGATIONS** — **0.0%<sup>2</sup>** |  |  |  |
| 63580 | Fannie Mae REMICS Series 2012-112 DA | Fannie Mae REMICS Series 2012-112 DA | 3.0000 | 10/25/42 | 57660 |
|  | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $63,580)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $63,580)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $63,580)** |  | 57660 |
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 57.1%** |  |  |  |  |
|  | **AUTOMOTIVE — 1.0%** |  |  |  |  |
| 1500000 | Honda Motor Company Ltd. |  | 2.2710 | 03/10/25 | 1421678 |
|  | **BANKING — 10.4%** |  |  |  |  |
| 3250000 | Bank of America Corporation<sup>3</sup> | US0003M + 0.870% | 2.4560 | 10/22/25 | 3074481 |
| 3150000 | JPMorgan Chase & Company<sup>3</sup> | SOFRRATE + 0.600% | 0.6530 | 09/16/24 | 3039143 |
| 3000000 | National Bank of Canada<sup>3</sup> | H15T1Y + 0.400% | 0.5500 | 11/15/24 | 2873002 |
| 3325000 | Royal Bank of Canada |  | 1.1500 | 07/14/26 | 2935718 |
| 2900000 | Toronto-Dominion Bank (The) |  | 1.2500 | 12/13/24 | 2701903 |
|  |  |  |  |  | 14624247 |
|  | **ELEC & GAS MARKETING & TRADING — 0.9%** | **ELEC & GAS MARKETING & TRADING — 0.9%** |  |  |  |
| 1500000 | Southern Power Company |  | 0.9000 | 01/15/26 | 1323517 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **36** |
| **E V E N T I D E** | **36** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 57.1% (Continued)** |  |  |  |  |
|  | **ELECTRIC UTILITIES — 14.9%** |  |  |  |  |
| 1050000 | AES Corporation (The) |  | 1.3750 | 01/15/26 | $934549 |
| 2700000 | Avangrid, Inc. |  | 3.1500 | 12/01/24 | 2583859 |
| 2720000 | CenterPoint Energy, Inc.<sup>3</sup> | SOFRRATE + 0.650% | 4.6090 | 05/13/24 | 2688862 |
| 2250000 | CMS Energy Corporation |  | 3.8750 | 03/01/24 | 2202639 |
| 1275000 | Georgia Power Company |  | 3.2500 | 04/01/26 | 1205598 |
| 3000000 | MidAmerican Energy Company |  | 3.1000 | 05/01/27 | 2813430 |
| 2200000 | National Rural Utilities Cooperative Finance |  | 3.4000 | 11/15/23 | 2170719 |
| 1031000 | NextEra Energy Capital Holdings, Inc. |  | 0.6500 | 03/01/23 | 1024007 |
| 800000 | NextEra Energy Capital Holdings, Inc.<sup>3</sup> | SOFRRATE + 0.540% | 4.5940 | 03/01/23 | 799666 |
| 2000000 | OGE Energy Corporation |  | 0.7030 | 05/26/23 | 1964866 |
| 2650000 | WEC Energy Group, Inc. |  | 0.5500 | 09/15/23 | 2569927 |
|  |  |  |  |  | 20958122 |
|  | **ELECTRICAL EQUIPMENT — 2.0%** |  |  |  |  |
| 2850000 | Roper Technologies, Inc. |  | 3.6500 | 09/15/23 | 2820293 |
|  | **ENGINEERING & CONSTRUCTION — 3.4%** |  |  |  |  |
| 1000000 | Installed Building Products, Inc.<sup>1</sup> |  | 5.7500 | 02/01/28 | 900726 |
| 1375000 | MasTec, Inc.<sup>1</sup> |  | 4.5000 | 08/15/28 | 1236273 |
| 2825000 | Quanta Services, Inc. |  | 0.9500 | 10/01/24 | 2604654 |
|  |  |  |  |  | 4741653 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 0.6%** | **FORESTRY, PAPER & WOOD PRODUCTS — 0.6%** | **FORESTRY, PAPER & WOOD PRODUCTS — 0.6%** |  |  |
| 1000000 | Louisiana-Pacific Corporation<sup>1</sup> |  | 3.6250 | 03/15/29 | 868041 |
|  | **HOME & OFFICE PRODUCTS — 0.7%** |  |  |  |  |
| 1250000 | Tempur Sealy International, Inc.<sup>1</sup> |  | 4.0000 | 04/15/29 | 1052006 |
|  | **HOME CONSTRUCTION — 0.7%** |  |  |  |  |
| 1000000 | Patrick Industries, Inc.<sup>1</sup> |  | 7.5000 | 10/15/27 | 974539 |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.7%** |  |  |  |  |
| 1000000 | United Rentals North America, Inc. |  | 3.8750 | 11/15/27 | 927120 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **37** |
| **E V E N T I D E** | **37** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 57.1% (Continued)** |  |  |  |  |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 2.2%** |  |  |  |  |
| 3350000 | Morgan Stanley<sup>3</sup> | SOFRRATE + 0.745% | 0.8640 | 10/21/25 | $3078098 |
|  | **INSURANCE — 4.4%** |  |  |  |  |
| 3000000 | Aflac, Inc. |  | 1.1250 | 03/15/26 | 2664690 |
| 2300000 | Brown & Brown, Inc. |  | 4.2000 | 09/15/24 | 2259604 |
| 1425000 | Pacific Life Global Funding II<sup>1</sup> |  | 1.3750 | 04/14/26 | 1259687 |
|  |  |  |  |  | 6183981 |
|  | **MACHINERY — 1.5%** |  |  |  |  |
| 1500000 | Mueller Water Products, Inc.<sup>1</sup> |  | 4.0000 | 06/15/29 | 1320037 |
| 1000000 | Xylem, Inc./NY |  | 1.9500 | 01/30/28 | 861804 |
|  |  |  |  |  | 2181841 |
|  | **OIL & GAS PRODUCERS — 0.8%** |  |  |  |  |
| 1250000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 1127548 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 7.5%** |  |  |  |  |
| 2500000 | Alexandria Real Estate Equities, Inc. |  | 3.8000 | 04/15/26 | 2424531 |
| 1750000 | American Tower Corporation |  | 3.3750 | 05/15/24 | 1704480 |
| 1400000 | HAT Holdings I, LLC/HAT Holdings II, LLC<sup>1</sup> |  | 3.3750 | 06/15/26 | 1218266 |
| 2700000 | Public Storage<sup>3</sup> | SOFRRATE + 0.470% | 4.2380 | 04/23/24 | 2681431 |
| 2800000 | Welltower, Inc. |  | 2.7000 | 02/15/27 | 2528326 |
|  |  |  |  |  | 10557034 |
|  | **RETAIL - DISCRETIONARY — 3.4%** |  |  |  |  |
| 700000 | Asbury Automotive Group, Inc. |  | 4.5000 | 03/01/28 | 617166 |
| 1200000 | AutoZone, Inc. |  | 2.8750 | 01/15/23 | 1199258 |
| 2459000 | O'Reilly Automotive, Inc. |  | 3.8500 | 06/15/23 | 2446139 |
| 500000 | Penske Automotive Group, Inc. |  | 3.5000 | 09/01/25 | 464817 |
|  |  |  |  |  | 4727380 |
|  | **SEMICONDUCTORS — 0.3%** |  |  |  |  |
| 500000 | Synaptics, Inc.<sup>1</sup> |  | 4.0000 | 06/15/29 | 421997 |
|  | **SOFTWARE — 0.7%** |  |  |  |  |
| 1000000 | Workday, Inc. |  | 3.5000 | 04/01/27 | 937642 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **38** |
| **E V E N T I D E** | **38** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 57.1% (Continued)** |  |  |  |  |
|  | **TECHNOLOGY SERVICES — 0.3%** |  |  |  |  |
| 500000 | Verisk Analytics, Inc. |  | 4.0000 | 06/15/25 | $486836 |
|  | **WHOLESALE - CONSUMER STAPLES — 0.7%** |  |  |  |  |
| 1000000 | Sysco Corporation |  | 3.7500 | 10/01/25 | 969534 |
|  | **TOTAL CORPORATE BONDS (Cost $86,555,816)** |  |  |  | 80383107 |
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 7.0%** |  |  |  |  |
|  | **COMBINED UTILITIES — 1.1%** |  |  |  |  |
| 1525000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | 01/01/27 | 1572457 |
|  | **COUNTY — 0.7%** |  |  |  |  |
| 1115000 | City & County of Honolulu, HI |  | 2.5180 | 10/01/26 | 1040887 |
|  | **MISCELLANEOUS TAX — 1.4%** |  |  |  |  |
| 2050000 | Commonwealth of Massachusetts |  | 3.6390 | 07/15/24 | 2021493 |
|  | **MULTI-FAMILY HOUSING — 0.7%** |  |  |  |  |
| 250000 | Maine State Housing Authority |  | 0.3000 | 11/15/23 | 243954 |
| 500000 | New York City Housing Development Corporation |  | 1.9300 | 02/01/25 | 468215 |
| 100000 | New York State Housing Finance Agency |  | 0.5000 | 05/01/24 | 96181 |
| 250000 | New York State Housing Finance Agency |  | 2.2000 | 11/01/24 | 237761 |
|  |  |  |  |  | 1046111 |
|  | **SINGLE-FAMILY HOUSING — 0.9%** |  |  |  |  |
| 65000 | Maryland Community Development Administration |  | 3.2420 | 09/01/48 | 62863 |
| 60000 | Massachusetts Housing Finance Agency |  | 4.0000 | 06/01/39 | 59703 |
| 495000 | Texas Department of Housing & Community Affairs |  | 0.3000 | 01/01/23 | 495000 |
| 600000 | Texas Department of Housing & Community Affairs |  | 0.3500 | 07/01/23 | 591400 |
|  |  |  |  |  | 1208966 |
|  | **STATE — 0.9%** |  |  |  |  |
| 200000 | State of Oregon |  | 0.6550 | 05/01/23 | 197773 |
| 300000 | State of Oregon |  | 0.7950 | 05/01/24 | 286101 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **39** |
| **E V E N T I D E** | **39** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 7.0% (Continued)** |  |  |  |  |
|  | **STATE — 0.9% (Continued)** |  |  |  |  |
| 500000 | State of Oregon |  | 0.8120 | 11/01/24 | $468116 |
| 300000 | State of Oregon |  | 0.8950 | 05/01/25 | 276156 |
|  |  |  |  |  | 1228146 |
|  | **WATER AND SEWER — 1.3%** |  |  |  |  |
| 2000000 | Boston Water & Sewer Commission |  | 0.9650 | 11/01/25 | 1807478 |
|  | **TOTAL MUNICIPAL BONDS (Cost $10,487,085)** |  |  |  | 9925538 |
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 24.7%** |  |  |  |  |
|  | **AGENCY FIXED RATE — 2.0%** |  |  |  |  |
| 1618089 | Freddie Mac Pool RD5050 |  | 2.0000 | 02/01/31 | 1494870 |
| 11 | Ginnie Mae I Pool 352081 |  | 7.0000 | 09/15/23 | 11 |
| 1416832 | Ginnie Mae II Pool MA7107 |  | 2.5000 | 01/20/36 | 1295861 |
|  |  |  |  |  | 2790742 |
|  | **AGENCY HYBRID ARMS — 0.0%<sup>2</sup>** |  |  |  |  |
| 7319 | Ginnie Mae II Pool 82903<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 08/20/41 | 7175 |
|  | **ARMS — 0.0%<sup>2</sup>** |  |  |  |  |
| 1835 | Fannie Mae Pool 791573<sup>3</sup> | H15T1Y + 2.170% | 4.1700 | 08/01/34 | 1815 |
| 204 | Freddie Mac Non Gold Pool 845965<sup>3</sup> | H15T1Y + 2.421% | 4.0750 | 01/01/24 | 203 |
| 327 | Freddie Mac Non Gold Pool 845590<sup>3</sup> | H15T1Y + 2.159% | 4.2500 | 01/01/24 | 323 |
| 190 | Ginnie Mae II Pool 8228<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 07/20/23 | 188 |
| 235 | Ginnie Mae II Pool 8259<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 08/20/23 | 233 |
| 332 | Ginnie Mae II Pool 8375<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 02/20/24 | 330 |
| 315 | Ginnie Mae II Pool 8395<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 03/20/24 | 313 |
| 151 | Ginnie Mae II Pool 8410<sup>3</sup> | H15T1Y + 1.500% | 2.8750 | 04/20/24 | 149 |
| 493 | Ginnie Mae II Pool 8421<sup>3</sup> | H15T1Y + 1.500% | 2.8750 | 05/20/24 | 492 |
| 804 | Ginnie Mae II Pool 8503<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 09/20/24 | 794 |
| 461 | Ginnie Mae II Pool 8502<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 09/20/24 | 455 |
| 582 | Ginnie Mae II Pool 8565<sup>3</sup> | H15T1Y + 1.500% | 2.0000 | 12/20/24 | 572 |
| 1431 | Ginnie Mae II Pool 8567<sup>3</sup> | H15T1Y + 1.500% | 2.5000 | 12/20/24 | 1408 |
| 3076 | Ginnie Mae II Pool 8595<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 02/20/25 | 3039 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **40** |
| **E V E N T I D E** | **40** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 24.7% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 24.7% (Continued)** | **U.S. GOVERNMENT & AGENCIES — 24.7% (Continued)** |  |
|  | **ARMS — 0.0%<sup>2</sup> (Continued)** |  |  |  |
| 768 Ginnie Mae II Pool 8660<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 07/20/25 | $757 |
| 13994 Ginnie Mae II Pool 80569<sup>3</sup> | H15T1Y + 1.500% | 2.6250 | 01/20/32 | 13725 |
| 1756 Ginnie Mae II Pool 80659<sup>3</sup> | H15T1Y + 1.500% | 1.7500 | 12/20/32 | 1700 |
|  |  |  |  | 26496 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 10.8%** | **GOVERNMENT OWNED, NO GUARANTEE — 10.8%** |  |  |
| 3000000 | Federal Home Loan Mortgage Corporation | 3.0500 | 05/12/25 | 2902024 |
| 3000000 | Federal Home Loan Mortgage Corporation | 0.7500 | 06/23/26 | 2648197 |
| 2000000 | Federal Home Loan Mortgage Corporation | 0.8000 | 10/27/26 | 1748761 |
| 2500000 | Federal National Mortgage Association | 0.7000 | 07/30/25 | 2268563 |
| 1000000 | Federal National Mortgage Association | 0.6500 | 08/25/25 | 904668 |
| 3000000 | Federal National Mortgage Association | 4.1250 | 08/28/25 | 2945627 |
| 2000000 | Federal National Mortgage Association | 0.8750 | 12/18/26 | 1752237 |
|  |  |  |  | 15170077 |
|  | **GOVERNMENT SPONSORED — 11.9%** |  |  |  |
| 3000000 | Federal Farm Credit Banks Funding Corporation | 3.6250 | 03/06/24 | 2959143 |
| 3000000 | Federal Farm Credit Banks Funding Corporation | 4.3400 | 09/19/24 | 2980718 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 0.9400 | 12/27/24 | 1626220 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 0.8750 | 02/03/25 | 1616213 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 1.4000 | 01/13/26 | 912294 |
| 3000000 | Federal Farm Credit Banks Funding Corporation | 2.9200 | 04/29/26 | 2832189 |
| 1500000 | Federal Farm Credit Banks Funding Corporation | 5.3000 | 10/19/26 | 1498746 |
| 1000000 | Federal Home Loan Mortgage Corporation | 5.2000 | 05/17/24 | 1000395 |
| 1500000 | Federal Home Loan Mortgage Corporation | 5.2500 | 12/09/24 | 1501178 |
|  |  |  |  | 16927096 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $36,288,310)** |  |  | 34921586 |
|  | **TOTAL INVESTMENTS - 96.5% (Cost $145,049,390)** | **TOTAL INVESTMENTS - 96.5% (Cost $145,049,390)** |  | $136121948 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.5%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.5%** |  | 4985658 |
|  | **NET ASSETS - 100.0%** |  |  | $141107606 |

---

LLC - Limited Liability Company

L.P. - Limited Partnership

LTD - Limited Company

REMICS - Real Estate Mortgage Investment Conduit

H15T1Y US Treasury Yield Curve Rate T Note Constant Maturity 1 Year

SOFRRATE United States SOFR Secured Overnight Financing Rate

US0003M ICE LIBOR USD 3 Month

*1.* *Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of December 31, 2022 the total market value of 144A securities is $12,036,652 or 8.5% of net assets.* 

*2.* *Percentage rounds to less than 0.1%.* 

*3.* *Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **41** |
| **E V E N T I D E** | **41** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 45.1%** |  |
|  | **BANKING - 1.8%** |  |
| 35700 | First Republic Bank | $4351473 |
| 50116 | Synovus Financial Corporation | 1881856 |
|  |  | 6233329 |
|  | **BIOTECH & PHARMA - 1.5%** |  |
| 25000 | Horizon Therapeutics plc<sup>1</sup> | 2845001 |
| 22272 | Royalty Pharma plc, Class A | 880189 |
| 11937 | Zoetis, Inc. | 1749367 |
|  |  | 5474557 |
|  | **CHEMICALS - 1.6%** |  |
| 311900 | Element Solutions, Inc. | 5673461 |
|  | **DIVERSIFIED INDUSTRIALS - 1.4%** |  |
| 111200 | Pentair PLC | 5001776 |
|  | **ELECTRIC UTILITIES - 4.6%** |  |
| 152900 | Clearway Energy, Inc. | 4872923 |
| 93900 | NextEra Energy Partners, L.P. | 6581451 |
| 51092 | WEC Energy Group, Inc. | 4790386 |
|  |  | 16244760 |
|  | **ELECTRICAL EQUIPMENT - 6.2%** |  |
| 264456 | nVent Electric plc | 10173622 |
| 12515 | Roper Technologies, Inc. | 5407606 |
| 36600 | Trane Technologies PLC | 6152094 |
|  |  | 21733322 |
|  | **HEALTH CARE FACILITIES & SERVICES - 1.0%** |  |
| 56495 | Encompass Health Corporation | 3378966 |
|  | **INDUSTRIAL REIT - 0.5%** |  |
| 15373 | Prologis, Inc. | 1732998 |
|  | **INFRASTRUCTURE REIT - 1.1%** |  |
| 28373 | Crown Castle, Inc. | 3848514 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **42** |
| **E V E N T I D E** | **42** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | |
|:---|:---|:---|
| *Shares* |  | *Fair Value* |
|  | **COMMON STOCKS — 45.1% (Continued)** |  |
|  | **INSTITUTIONAL FINANCIAL SERVICES - 2.1%** |  |
| 124280 | Nasdaq, Inc. | $7624577 |
|  | **INSURANCE - 1.3%** |  |
| 24446 | Arthur J Gallagher & Company | 4609049 |
|  | **MACHINERY - 1.2%** |  |
| 18800 | IDEX Corporation | 4292604 |
|  | **MEDICAL EQUIPMENT & DEVICES - 4.1%** |  |
| 54400 | Baxter International, Inc. | 2772768 |
| 56000 | Bruker Corporation | 3827600 |
| 1356 | Mettler-Toledo International, Inc.<sup>1</sup> | 1960030 |
| 33385 | STERIS plc | 6165876 |
|  |  | 14726274 |
|  | **OIL & GAS PRODUCERS - 5.1%** |  |
| 24746 | Cheniere Energy, Inc. | 3710910 |
| 37431 | Devon Energy Corporation | 2302381 |
| 57297 | EQT Corporation | 1938358 |
| 36463 | Targa Resources Corporation | 2680031 |
| 223547 | Williams Companies, Inc. (The) | 7354695 |
|  |  | 17986375 |
|  | **RESIDENTIAL REIT - 0.6%** |  |
| 33275 | Equity LifeStyle Properties, Inc. | 2149565 |
|  | **RETAIL - DISCRETIONARY - 1.5%** |  |
| 26448 | Lowe's Companies, Inc. | 5269500 |
|  | **SEMICONDUCTORS - 2.0%** |  |
| 41743 | Entegris, Inc. | 2737923 |
| 11284 | KLA Corporation | 4254407 |
|  |  | 6992330 |
|  | **SOFTWARE - 2.0%** |  |
| 28094 | Palo Alto Networks, Inc.<sup>1</sup> | 3920237 |
| 10000 | Synopsys, Inc.<sup>1</sup> | 3192900 |
|  |  | 7113137 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **43** |
| **E V E N T I D E** | **43** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Shares* |  |  |  | *Fair Value* |
|  | **COMMON STOCKS — 45.1% (Continued)** |  |  |  |
|  | **SPECIALTY FINANCE - 0.7%** |  |  |  |
| 32935 | Walker & Dunlop, Inc. |  |  | $2584739 |
|  | **SPECIALTY REITS - 0.4%** |  |  |  |
| 52813 | Hannon Armstrong Sustainable Infrastructure Capital, Inc. |  |  | 1530521 |
|  | **TECHNOLOGY SERVICES - 1.9%** |  |  |  |
| 38000 | CDW Corporation/DE |  |  | 6786040 |
|  | **TRANSPORTATION & LOGISTICS - 1.5%** |  |  |  |
| 18000 | Old Dominion Freight Line, Inc. |  |  | 5108040 |
|  | **WHOLESALE - CONSUMER STAPLES - 1.0%** |  |  |  |
| 46700 | Sysco Corporation |  |  | 3570215 |
|  | **TOTAL COMMON STOCKS (Cost $155,718,954)** |  |  | 159664649 |
| *Shares* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **PREFERRED STOCKS — 3.0%** |  |  |  |
|  | **AUTOMOTIVE — 0.5%** |  |  |  |
| 16000 | Aptiv plc | 5.5000 | 06/15/23 | 1721900 |
|  | **ELECTRIC UTILITIES — 2.5%** |  |  |  |
| 51600 | AES Corporation (The) | 6.8750 | 02/15/24 | 5263716 |
| 75000 | NextEra Energy, Inc. | 6.9260 | 09/01/25 | 3764250 |
|  |  |  |  | 9027966 |
|  | **TOTAL PREFERRED STOCKS (Cost $10,716,545)** |  |  | 10749866 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **44** |
| **E V E N T I D E** | **44** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **ASSET BACKED SECURITIES — 1.9%** |  |  |  |  |
|  | **AUTO LOAN — 1.4%** |  |  |  |  |
| 3150000 | CarMax Auto Owner Trust Series 2020-4 C | CarMax Auto Owner Trust Series 2020-4 C | 1.3000 | 08/17/26 | $2876437 |
| 750000 | CarMax Auto Owner Trust Series 2021-2 C | CarMax Auto Owner Trust Series 2021-2 C | 1.3400 | 02/16/27 | 678837 |
| 1500000 | World Omni Auto Receivables Trust Series 2019-B C | World Omni Auto Receivables Trust Series 2019-B C | 3.0300 | 01/15/26 | 1484101 |
|  |  |  |  |  | 5039375 |
|  | **OTHER ABS — 0.5%** |  |  |  |  |
| 1700000 | PFS Financing Corporation Series 2020-G A<sup>2</sup> | PFS Financing Corporation Series 2020-G A<sup>2</sup> | 0.9700 | 02/15/26 | 1604962 |
|  | **TOTAL ASSET BACKED SECURITIES (Cost $7,158,632)** | **TOTAL ASSET BACKED SECURITIES (Cost $7,158,632)** | **TOTAL ASSET BACKED SECURITIES (Cost $7,158,632)** |  | 6644337 |
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** | **COLLATERALIZED MORTGAGE OBLIGATIONS — 0.5%** |  |  |  |
|  | **CMBS — 0.5%** |  |  |  |  |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Certificates Series KG01 A10 | Freddie Mac Multifamily Structured Pass Through Certificates Series KG01 A10 | 2.9390 | 04/25/29 | 916150 |
| 1000000 | Freddie Mac Multifamily Structured Pass Through Certificates Series KG02 A2 | Freddie Mac Multifamily Structured Pass Through Certificates Series KG02 A2 | 2.4120 | 08/25/29 | 884771 |
|  |  |  |  |  | 1800921 |
|  | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,040,924)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,040,924)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,040,924)** | **TOTAL COLLATERALIZED MORTGAGE OBLIGATIONS (Cost $2,040,924)** | 1800921 |
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 25.8%** |  |  |  |  |
|  | **ASSET MANAGEMENT — 1.1%** |  |  |  |  |
| 3800000 | Vision Fund International<sup>3,4,5</sup> |  | 3.7250 | 02/24/25 | 3800000 |
|  | **AUTOMOTIVE — 0.5%** |  |  |  |  |
| 2025000 | Dana, Inc. |  | 4.2500 | 09/01/30 | 1634357 |
|  | **BANKING — 4.4%** |  |  |  |  |
| 3975000 | Bank of America Corporation<sup>6</sup> | US0003M + 0.870% | 2.4560 | 10/22/25 | 3760327 |
| 2400000 | First Horizon Corporation |  | 3.5500 | 05/26/23 | 2385043 |
| 3925000 | JPMorgan Chase & Company<sup>6</sup> | SOFRRATE + 0.600% | 0.6530 | 09/16/24 | 3786869 |
| 3300000 | National Bank of Canada<sup>6</sup> | H15T1Y + 0.400% | 0.5500 | 11/15/24 | 3160302 |
| 2365000 | Royal Bank of Canada |  | 1.1500 | 07/14/26 | 2088112 |
| 1000000 | Toronto-Dominion Bank (The) |  | 1.2500 | 12/13/24 | 931691 |
|  |  |  |  |  | 16112344 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **45** |
| **E V E N T I D E** | **45** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 25.8% (Continued)** |  |  |  |  |
|  | **CONSTRUCTION MATERIALS — 0.4%** |  |  |  |  |
| 1300000 | Advanced Drainage Systems, Inc.<sup>2</sup> |  | 5.0000 | 09/30/27 | $1214298 |
|  | **CONTAINERS & PACKAGING — 0.2%** |  |  |  |  |
| 1000000 | TriMas Corporation<sup>2</sup> |  | 4.1250 | 04/15/29 | 874610 |
|  | **ELEC & GAS MARKETING & TRADING — 0.6%** |  |  |  |  |
| 2250000 | Southern Power Company |  | 0.9000 | 01/15/26 | 1985275 |
|  | **ELECTRIC UTILITIES — 6.0%** |  |  |  |  |
| 1235000 | AES Corporation (The) |  | 1.3750 | 01/15/26 | 1099208 |
| 2350000 | Avangrid, Inc. |  | 3.1500 | 12/01/24 | 2248914 |
| 3266000 | CenterPoint Energy, Inc.<sup>6</sup> | SOFRRATE + 0.650% | 4.6090 | 05/13/24 | 3228611 |
| 3000000 | Dominion Energy, Inc. |  | 2.2500 | 08/15/31 | 2403235 |
| 600000 | Duke Energy Florida, LLC |  | 2.5000 | 12/01/29 | 516462 |
| 1225000 | MidAmerican Energy Company |  | 3.1000 | 05/01/27 | 1148817 |
| 3475000 | National Rural Utilities Cooperative Finance Corporation |  | 1.3500 | 03/15/31 | 2584666 |
| 315000 | NextEra Energy Capital Holdings, Inc.<sup>6</sup> | SOFRRATE + 0.540% | 4.5940 | 03/01/23 | 314868 |
| 3850000 | NextEra Energy Capital Holdings, Inc. |  | 1.9000 | 06/15/28 | 3300099 |
| 1250000 | Tucson Electric Power Company |  | 1.5000 | 08/01/30 | 962358 |
| 1000000 | WEC Energy Group, Inc. |  | 0.5500 | 09/15/23 | 969784 |
| 3303000 | Wisconsin Power and Light Company |  | 1.9500 | 09/16/31 | 2608911 |
|  |  |  |  |  | 21385933 |
|  | **ENGINEERING & CONSTRUCTION — 1.0%** |  |  |  |  |
| 1435000 | Installed Building Products, Inc.<sup>2</sup> |  | 5.7500 | 02/01/28 | 1292541 |
| 2000000 | MasTec, Inc.<sup>2</sup> |  | 4.5000 | 08/15/28 | 1798215 |
| 500000 | Quanta Services, Inc. |  | 0.9500 | 10/01/24 | 461001 |
|  |  |  |  |  | 3551757 |
|  | **FORESTRY, PAPER & WOOD PRODUCTS — 0.2%** | **FORESTRY, PAPER & WOOD PRODUCTS — 0.2%** | **FORESTRY, PAPER & WOOD PRODUCTS — 0.2%** |  |  |
| 1000000 | Louisiana-Pacific Corporation<sup>2</sup> |  | 3.6250 | 03/15/29 | 868041 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **46** |
| **E V E N T I D E** | **46** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 25.8% (Continued)** |  |  |  |  |
|  | **HOME & OFFICE PRODUCTS — 0.5%** |  |  |  |  |
| 1910000 | Tempur Sealy International, Inc.<sup>2</sup> |  | 4.0000 | 04/15/29 | $1607466 |
|  | **HOME CONSTRUCTION — 0.6%** |  |  |  |  |
| 1750000 | M/I Homes, Inc. |  | 3.9500 | 02/15/30 | 1415248 |
| 1000000 | Patrick Industries, Inc.<sup>2</sup> |  | 7.5000 | 10/15/27 | 974539 |
|  |  |  |  |  | 2389787 |
|  | **INDUSTRIAL SUPPORT SERVICES — 0.4%** |  |  |  |  |
| 1500000 | United Rentals North America, Inc. |  | 4.8750 | 01/15/28 | 1424783 |
|  | **INSTITUTIONAL FINANCIAL SERVICES — 1.0%** |  |  |  |  |
| 4125000 | Morgan Stanley<sup>6</sup> | SOFRRATE + 0.745% | 0.8640 | 10/21/25 | 3790196 |
|  | **INSURANCE — 0.8%** |  |  |  |  |
| 1015000 | Aflac, Inc. |  | 1.1250 | 03/15/26 | 901553 |
| 2000000 | Pacific Life Global Funding II<sup>2</sup> |  | 1.3750 | 04/14/26 | 1767982 |
|  |  |  |  |  | 2669535 |
|  | **MACHINERY — 1.0%** |  |  |  |  |
| 2000000 | Mueller Water Products, Inc.<sup>2</sup> |  | 4.0000 | 06/15/29 | 1760050 |
| 1875000 | Xylem, Inc. |  | 1.9500 | 01/30/28 | 1615882 |
|  |  |  |  |  | 3375932 |
|  | **OIL & GAS PRODUCERS — 0.3%** |  |  |  |  |
| 1000000 | Cheniere Energy Partners, L.P. |  | 4.5000 | 10/01/29 | 902038 |
|  | **REAL ESTATE INVESTMENT TRUSTS — 3.6%** | **REAL ESTATE INVESTMENT TRUSTS — 3.6%** | **REAL ESTATE INVESTMENT TRUSTS — 3.6%** |  |  |
| 2175000 | Alexandria Real Estate Equities, Inc. |  | 3.8000 | 04/15/26 | 2109342 |
| 1500000 | American Tower Corporation |  | 4.0500 | 03/15/32 | 1349087 |
| 2850000 | AvalonBay Communities, Inc. |  | 2.0500 | 01/15/32 | 2252946 |
| 1750000 | HAT Holdings I, LLC/HAT Holdings II, LLC<sup>2</sup> |  | 3.3750 | 06/15/26 | 1522833 |
| 1985000 | Prologis, L.P. |  | 1.2500 | 10/15/30 | 1514232 |
| 2210000 | Public Storage<sup>6</sup> | SOFRRATE + 0.470% | 4.2380 | 04/23/24 | 2194801 |
| 2000000 | Welltower, Inc. |  | 2.7000 | 02/15/27 | 1805947 |
|  |  |  |  |  | 12749188 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **47** |
| **E V E N T I D E** | **47** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Spread* | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **CORPORATE BONDS — 25.8% (Continued)** |  |  |  |  |
|  | **RETAIL - DISCRETIONARY — 0.6%** |  |  |  |  |
| 1000000 | Asbury Automotive Group, Inc. |  | 4.5000 | 03/01/28 | $881665 |
| 1000000 | Builders FirstSource, Inc.<sup>2</sup> |  | 4.2500 | 02/01/32 | 813366 |
| 500000 | Penske Automotive Group, Inc. |  | 3.5000 | 09/01/25 | 464817 |
|  |  |  |  |  | 2159848 |
|  | **SEMICONDUCTORS — 1.4%** |  |  |  |  |
| 1185000 | Amkor Technology, Inc.<sup>2</sup> |  | 6.6250 | 09/15/27 | 1174630 |
| 2800000 | NXP BV/NXP Funding, LLC/NXP USA, Inc. |  | 2.5000 | 05/11/31 | 2244475 |
| 1925000 | Synaptics, Inc.<sup>2</sup> |  | 4.0000 | 06/15/29 | 1624688 |
|  |  |  |  |  | 5043793 |
|  | **SOFTWARE — 0.3%** |  |  |  |  |
| 1000000 | Workday, Inc. |  | 3.8000 | 04/01/32 | 888897 |
|  | **TECHNOLOGY SERVICES — 0.2%** |  |  |  |  |
| 900000 | Visa, Inc. |  | 0.7500 | 08/15/27 | 768277 |
|  | **WHOLESALE - CONSUMER STAPLES — 0.7%** |  |  |  |  |
| 2775000 | Sysco Corporation |  | 2.4000 | 02/15/30 | 2319374 |
|  | **TOTAL CORPORATE BONDS (Cost $103,287,939)** | **TOTAL CORPORATE BONDS (Cost $103,287,939)** | **TOTAL CORPORATE BONDS (Cost $103,287,939)** |  | 91515729 |
| *Principal Amount ($)* |  |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 2.1%** |  |  |  |  |
|  | **COMBINED UTILITIES — 0.4%** |  |  |  |  |
| 1475000 | City of Tacoma, WA Electric System Revenue |  | 5.6410 | 01/01/27 | 1520901 |
|  | **COUNTY — 0.0%<sup>7</sup>** |  |  |  |  |
| 150000 | City & County of Honolulu, HI |  | 2.5180 | 10/01/26 | 140030 |
|  | **MISCELLANEOUS TAX — 0.6%** |  |  |  |  |
| 2050000 | Commonwealth of Massachusetts |  | 3.6390 | 07/15/24 | 2021492 |
|  | **MULTI-FAMILY HOUSING — 0.2%** |  |  |  |  |
| 500000 | New York City Housing Development Corporation |  | 1.3500 | 11/01/26 | 466167 |
| 100000 | New York State Housing Finance Agency |  | 0.6500 | 05/01/25 | 93606 |
|  |  |  |  |  | 559773 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **48** |
| **E V E N T I D E** | **48** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **MUNICIPAL BONDS — 2.1% (Continued)** |  |  |  |
|  | **RESOURCE RECOVERY — 0.0%<sup>7</sup>** |  |  |  |
| 100000 | City of Napa, CA Solid Waste Revenue | 2.3300 | 08/01/25 | $94105 |
|  | **SINGLE-FAMILY HOUSING — 0.2%** |  |  |  |
| 200000 | Pennsylvania Housing Finance Agency | 5.0000 | 04/01/23 | 200524 |
| 505000 | Texas Department of Housing & Community Affairs | 0.4500 | 01/01/24 | 490455 |
|  |  |  |  | 690979 |
|  | **STATE — 0.2%** |  |  |  |
| 200000 | State of Oregon | 0.8950 | 05/01/25 | 184104 |
| 250000 | State of Oregon | 1.1850 | 05/01/26 | 224524 |
| 500000 | State of Oregon | 1.3150 | 05/01/27 | 436698 |
|  |  |  |  | 845326 |
|  | **WATER AND SEWER — 0.5%** |  |  |  |
| 2000000 | City of Aurora, CO Water Revenue | 2.0980 | 08/01/34 | 1503428 |
| 200000 | City of Los Angeles, CA Wastewater System Revenue | 3.6940 | 06/01/32 | 180078 |
|  |  |  |  | 1683506 |
|  | **TOTAL MUNICIPAL BONDS (Cost $8,506,809)** |  |  | 7556112 |
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 18.6%** |  |  |  |
|  | **AGENCY FIXED RATE — 9.7%** |  |  |  |
| 330655 | Fannie Mae Pool MA2915 | 3.0000 | 02/01/27 | 320549 |
| 1008509 | Fannie Mae Pool MA4263 | 1.5000 | 02/01/31 | 916819 |
| 1069678 | Fannie Mae Pool MA4284 | 1.5000 | 03/01/31 | 972460 |
| 695672 | Fannie Mae Pool FM3333 | 2.0000 | 06/01/35 | 622220 |
| 525280 | Fannie Mae Pool MA4095 | 2.0000 | 08/01/35 | 469763 |
| 462796 | Fannie Mae Pool BM5466 | 2.5000 | 10/01/43 | 400220 |
| 451241 | Fannie Mae Pool BM5975 | 3.0000 | 12/01/45 | 411695 |
| 387323 | Fannie Mae Pool MA2806 | 3.0000 | 11/01/46 | 348708 |
| 409503 | Fannie Mae Pool BM5976 | 3.0000 | 02/01/47 | 372743 |
| 963902 | Fannie Mae Pool BP5878 | 2.5000 | 06/01/50 | 824251 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **49** |
| **E V E N T I D E** | **49** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 18.6% (Continued)** |  |  |  |
|  | **AGENCY FIXED RATE — 9.7% (Continued)** |  |  |  |
| 1389859 | Fannie Mae Pool MA4096 | 2.5000 | 08/01/50 | $1189166 |
| 1593633 | Fannie Mae Pool MA4306 | 2.5000 | 04/01/51 | 1357803 |
| 1602252 | Fannie Mae Pool MA4326 | 2.5000 | 05/01/51 | 1364971 |
| 1852074 | Fannie Mae Pool MA4327 | 3.0000 | 05/01/51 | 1632121 |
| 1917087 | Fannie Mae Pool MA4356 | 2.5000 | 06/01/51 | 1628980 |
| 2338543 | Fannie Mae Pool MA4379 | 2.5000 | 07/01/51 | 1991910 |
| 3725318 | Fannie Mae Pool CB2661 | 3.0000 | 01/01/52 | 3282131 |
| 3565508 | Fannie Mae Pool MA4600 | 3.5000 | 05/01/52 | 3247458 |
| 3029940 | Fannie Mae Pool MA4625 | 3.5000 | 06/01/52 | 2760481 |
| 2670004 | Fannie Mae Pool MA4655 | 4.0000 | 07/01/52 | 2511090 |
| 840125 | Freddie Mac Pool ZS9163 | 3.0000 | 09/01/33 | 791899 |
| 705493 | Freddie Mac Pool ZS9382 | 3.0000 | 09/01/43 | 643642 |
| 642498 | Freddie Mac Pool SD8089 | 2.5000 | 07/01/50 | 549372 |
| 1399439 | Freddie Mac Pool SD8122 | 2.5000 | 01/01/51 | 1193701 |
| 1917503 | Freddie Mac Pool RA5696 | 2.5000 | 08/01/51 | 1632727 |
| 3125460 | Freddie Mac Pool SD8214 | 3.5000 | 05/01/52 | 2849761 |
| 368786 | Ginnie Mae II Pool MA3375 | 3.0000 | 01/20/46 | 335841 |
|  |  |  |  | 34622482 |
|  | **GOVERNMENT OWNED, NO GUARANTEE — 3.6%** |  |  |  |
| 2125000 | Federal Home Loan Mortgage Corporation | 0.3000 | 11/16/23 | 2042300 |
| 1000000 | Federal Home Loan Mortgage Corporation | 0.6500 | 10/27/25 | 898307 |
| 1000000 | Federal Home Loan Mortgage Corporation | 0.7500 | 06/23/26 | 882732 |
| 1250000 | Federal Home Loan Mortgage Corporation | 0.8000 | 10/28/26 | 1091744 |
| 2500000 | Federal Home Loan Mortgage Corporation | 6.2500 | 07/15/32 | 2926535 |
| 1500000 | Federal National Mortgage Association | 0.8750 | 12/18/26 | 1314177 |
| 4350000 | Federal National Mortgage Association | 0.8750 | 08/05/30 | 3465346 |
|  |  |  |  | 12621141 |
|  | **GOVERNMENT SPONSORED — 5.3%** |  |  |  |
| 3500000 | Federal Farm Credit Banks Funding Corporation | 0.3500 | 06/08/23 | 3437860 |
| 2500000 | Federal Farm Credit Banks Funding Corporation | 0.4400 | 11/04/24 | 2314200 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 0.8750 | 02/03/25 | 923551 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 0.4800 | 03/03/25 | 912048 |
| 1000000 | Federal Farm Credit Banks Funding Corporation | 3.1250 | 04/26/30 | 921594 |
| 1250000 | Federal Farm Credit Banks Funding Corporation | 1.7300 | 09/22/31 | 1000910 |

---

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **50** |
| **E V E N T I D E** | **50** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **SCHEDULE OF INVESTMENTS (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Principal Amount ($)* |  | *Coupon Rate (%)* | *Maturity* | *Fair Value* |
|  | **U.S. GOVERNMENT & AGENCIES — 18.6% (Continued)** |  |  |  |
|  | **GOVERNMENT SPONSORED — 5.3% (Continued)** |  |  |  |
| 3250000 | Federal Farm Credit Banks Funding Corporation | 3.2500 | 07/28/32 | $2935019 |
| 1750000 | Federal Farm Credit Banks Funding Corporation | 1.4700 | 10/15/32 | 1313430 |
| 2500000 | Federal Home Loan Mortgage Corporation | 5.2000 | 05/17/24 | 2500987 |
| 1750000 | Federal Home Loan Mortgage Corporation | 5.2500 | 12/09/24 | 1751374 |
| 1000000 | Federal Home Loan Mortgage Corporation | 0.6000 | 10/15/25 | 892266 |
|  |  |  |  | 18903239 |
|  | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $72,914,452)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $72,914,452)** | **TOTAL U.S. GOVERNMENT & AGENCIES (Cost $72,914,452)** | 66146862 |
| *Shares* |  |  |  | *Fair Value* |
|  | **SHORT-TERM INVESTMENTS — 0.0%<sup>7</sup>** |  |  |  |
|  | **MONEY MARKET FUNDS - 0.0%<sup>7</sup>** |  |  |  |
| 103257 | Fidelity Government Portfolio, Class I, 4.06% (Cost $103,257) <sup>8</sup> | Fidelity Government Portfolio, Class I, 4.06% (Cost $103,257) <sup>8</sup> | Fidelity Government Portfolio, Class I, 4.06% (Cost $103,257) <sup>8</sup> | 103257 |
|  | **TOTAL INVESTMENTS - 97.0% (Cost $360,447,512)** | **TOTAL INVESTMENTS - 97.0% (Cost $360,447,512)** | **TOTAL INVESTMENTS - 97.0% (Cost $360,447,512)** | $344181733 |
|  | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.0%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.0%** | **OTHER ASSETS IN EXCESS OF LIABILITIES - 3.0%** | 10527889 |
|  | **NET ASSETS - 100.0%** |  |  | $354709622 |

---

LLC - Limited Liability Company

L.P. - Limited Partnership

PLC - Public Limited Company

REIT - Real Estate Investment Trust

H15T1Y US Treasury Yield Curve Rate T Note Constant Maturity 1 Year

SOFRRATE United States SOFR Secured Overnight Financing Rate

US0003M ICE LIBOR USD 3 Month

*1.* *Non-income producing security.* 

*2.* *Security exempt from registration under Rule 144A or Section 4(2) of the Securities Act of 1933. The security may be resold in transactions exempt from registration, normally to qualified institutional buyers. As of December 31, 2022 the total market value of 144A securities is $18,898,221 or 5.3% of net assets.* 

*3.* *Illiquid security. The total fair value of these securities as of December 31, 2022 was $3,800,000, representing 1.1% of net assets.* 

*4.* *The value of this security has been determined in good faith under policies of the Board of Trustees.* 

 

*5.* *Restricted security. See Note 6 for additional details.* 

*6.* *Variable or floating rate security, the interest rate of which adjusts periodically based on changes in current interest rates and prepayments on the underlying pool of assets.* 

*7.* *Percentage rounds to less than 0.1%.* 

*8.* *Rate disclosed is the seven day effective yield as of December 31, 2022.* 

*See accompanying notes to financial statements.*

---

| | |
|:---|:---|
| **E V E N T I D E** | **51** |
| **E V E N T I D E** | **51** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |  | *Eventide* |
|  | *Core Bond* | *Dividend* | *Exponential* | *Eventide* | *Healthcare &* |
|  | *Fund* | *Opportunities Fund* | *Technologies Fund* | *Gilead Fund* | *Life Sciences Fund* |
| **ASSETS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $61028564 | $510903662 | $93108281 | $2551417592 | $1148774750 |
| &nbsp;&nbsp;&nbsp;Affiliated investments at cost |  |  |  | 37399898 | 347855531 |
| &nbsp;&nbsp;&nbsp;Investments at cost | 61028564 | 510903662 | 93108281 | 2588817490 | 1496630281 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $52539961 | $485975938 | $83374374 | $3103038846 | $1325378950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments at value |  |  |  | 34392159 | 170228463 |
| &nbsp;&nbsp;&nbsp;Total investments at value | 52539961 | 485975938 | 83374374 | 3137431005 | 1495607413 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 371602 | 24052589 | 1459012 | 122275646 | 75298611 |
| &nbsp;&nbsp;&nbsp;Cash held at broker |  | 101325 | 12178 | 11830391 | 7070815 |
| &nbsp;&nbsp;&nbsp;Receivable for securities sold | 184340 |  |  |  | 30277629 |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 1380825 | 2209667 | 104635 | 3901545 | 4201429 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 362200 | 400867 | 29295 | 1324454 | 421797 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 11043 | 81514 | 34393 | 146591 | 110452 |
| &nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 54849971 | 512821900 | 85013887 | 3276909632 | 1612988146 |
| **LIABILITIES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares repurchased | 29281 | 526267 | 131443 | 10628761 | 3320678 |
| &nbsp;&nbsp;&nbsp;Management fees payable | 27387 | 296235 | 76974 | 2820800 | 1483385 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 949 | 68028 | 20833 | 90243 | 75801 |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 28599 | 43893 | 22871 | 398642 | 191639 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 56170 | 65189 | 26682 | 614385 | 536358 |
| &nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 142386 | 999612 | 278803 | 14552831 | 5607861 |
| **NET ASSETS** | $**54707585** | $**511822288** | $**84735084** | $**3262356801** | $**1607380285** |
| **Composition of Net Assets:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $73869614 | $540736744 | $139410313 | $2746006115 | $1650187804 |
| &nbsp;&nbsp;&nbsp;Accumulated earnings (losses) | (19162029) | (28914456) | (54675229) | 516350686 | (42807519) |
| **NET ASSETS** | $**54707585** | $**511822288** | $**84735084** | $**3262356801** | $**1607380285** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **52** |
| **E V E N T I D E** | **52** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |  | *Eventide* |
|  | *Core Bond* | *Dividend* | *Exponential* | *Eventide* | *Healthcare &* |
|  | *Fund* | *Opportunities Fund* | *Technologies Fund* | *Gilead Fund* | *Life Sciences Fund* |
| **Net Asset Value Per Share:** |  |  |  |  |  |
| Class N Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $27072673 | $90891068 | $11391217 | $474934389 | $123546233 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 3344248 | 6699324 | 1154756 | 11513155 | 3782262 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $8.10 | $13.57 | $9.86 <sup>2</sup> | $41.25 | $32.66 |
| Class A Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $200197 | $34941280 | $6762740 | $292563914 | $140709700 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 24619 | 2574088 | 685387 | 7138874 | 4338589 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share | $8.13 | $13.57 | $9.87<sup>2</sup> | $40.98 | $32.43 |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share (net asset value plus maximum sales charge of 5.75%) | $8.63 | $14.40 | $10.47 | $43.48 | $34.41 |
| Class C Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $232597 | $12340246 | $2162432 | $216100938 | $75914256 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 28877 | 915889 | 223318 | 5975040 | 2539345 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $8.05 | $13.47 | $9.68<sup>2</sup> | $36.17 | $29.90 |
| Class I Shares: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $27202118 | $373649694 | $64418695 | $2278757560 | $1267210096 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 3359947 | 27517328 | 6494767 | 53564975 | 38007286 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $8.10 | $13.58 | $9.92<sup>2</sup> | $42.54 | $33.34 |

---

*1.* *Unlimited number of shares of beneficial interest authorized, no par value.* 

*2.* *Redemptions made in the Eventide Exponential Technologies Fund less than 180 days of purchase may be assessed a redemption fee of 1.00%.* 

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **53** |
| **E V E N T I D E** | **53** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |
|  | *Large Cap* | *Limited-Term* | *Multi-Asset* |
|  | *Focus Fund* | *Bond Fund* | *Income Fund* |
| **ASSETS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Investment securities: |  |  |  |
| &nbsp;&nbsp;&nbsp;Unaffiliated investments at cost | $6183457 | $145049390 | $360447512 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments at value | $6000401 | $136121948 | $344181733 |
| &nbsp;&nbsp;&nbsp;Cash held at custodian | 294161 | 2695142 | 8121579 |
| &nbsp;&nbsp;&nbsp;Cash held at broker |  |  | 104958 |
| &nbsp;&nbsp;&nbsp;Receivable for securities sold |  | 141 | 1880237 |
| &nbsp;&nbsp;&nbsp;Receivable for Fund shares sold | 21000 | 1695007 | 700484 |
| &nbsp;&nbsp;&nbsp;Dividends and interest receivable | 3467 | 806457 | 1216637 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other assets |  | 43049 | 75861 |
| &nbsp;&nbsp;&nbsp;**TOTAL ASSETS** | 6319029 | 141361744 | 356281489 |
| **LIABILITIES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Payable for Fund shares repurchased |  | 143767 | 1223222 |
| &nbsp;&nbsp;&nbsp;Management fees payable | 1055 | 22124 | 176150 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees payable | 5 | 2749 | 79123 |
| &nbsp;&nbsp;&nbsp;Payable to related parties | 10694 | 31604 | 55757 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 22689 | 53894 | 37615 |
| &nbsp;&nbsp;&nbsp;**TOTAL LIABILITIES** | 34443 | 254138 | 1571867 |
| **NET ASSETS** | $**6284586** | $**141107606** | $**354709622** |
| **Composition of Net Assets:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Paid in capital | $6525653 | $156311747 | $373773865 |
| &nbsp;&nbsp;&nbsp;Accumulated losses | (241067) | (15204141) | (19064243) |
| **NET ASSETS** | $**6284586** | $**141107606** | $**354709622** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **54** |
| **E V E N T I D E** | **54** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Continued)** |
| **December 31, 2022** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |
|  | *Large Cap* | *Limited-Term* | *Multi-Asset* |
|  | *Focus Fund* | *Bond Fund* | *Income Fund* |
| **Net Asset Value Per Share:** |  |  |  |
| Class N Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $159817 | $19166769 | $49065359 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 16421 | 1991957 | 4107107 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $9.73 | $9.62 | $11.95 |
| Class A Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $63867 | $17542544 | $25392379 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 6565 | 1819057 | 2120799 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding) and redemption price per share | $9.73 | $9.64 | $11.97 |
| &nbsp;&nbsp;&nbsp;Maximum offering price per share (net asset value plus maximum sales charge of 5.75%) | $10.32 | $10.23 | $12.70 |
| Class C Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $10108 | $2114060 | $16955686 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 1042 | 220694 | 1426308 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $9.70 | $9.58 | $11.89 |
| Class I Shares: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Assets | $6050794 | $102284233 | $263296198 |
| &nbsp;&nbsp;&nbsp;Shares of beneficial interest outstanding <sup>1</sup> | 621608 | 10367066 | 22031212 |
| &nbsp;&nbsp;&nbsp;Net asset value (Net Assets ÷ Shares Outstanding), offering price, and redemption price per share | $9.73 | $9.87 | $11.95 |

---

*1.* *Unlimited number of shares of beneficial interest authorized, no par value.* 

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **55** |
| **E V E N T I D E** | **55** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF OPERATIONS (Unaudited)** |
| **For the Six Months Ended December 31, 2022** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |  | *Eventide* |
|  | *Core Bond* | *Dividend* | *Exponential* | *Eventide* | *Healthcare &* |
|  | *Fund* | *Opportunities Fund* | *Technologies Fund* | *Gilead Fund* | *Life Sciences Fund* |
| **INVESTMENT INCOME** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividend income | $— | $4420151 | $100064 | $10958991 | $1007074 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest | 906277 | 450669 | 83280 | 3821397 | 1897973 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes |  | (625) | (477) | (318487) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 906277 | 4870195 | 182867 | 14461901 | 2905047 |
| **EXPENSES** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Management fees | 123095 | 1749514 | 552583 | 17589012 | 8441927 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class N | 47972 | 86492 | 13652 | 547351 | 127373 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A | 254 | 39596 | 9648 | 398356 | 166779 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class C | 1184 | 56356 | 12648 | 1211812 | 370754 |
| &nbsp;&nbsp;&nbsp;&nbsp;Shareholder servicing fees | 75747 | 363204 | 74227 | 2198472 | 1096437 |
| &nbsp;&nbsp;&nbsp;&nbsp;Registration fees | 27600 | 55200 | 35144 | 92000 | 64400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Administrative fees | 12725 | 74553 | 18038 | 421362 | 180653 |
| &nbsp;&nbsp;&nbsp;&nbsp;Printing and postage expenses | 12072 | 63519 | 10334 | 181771 | 88219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Transfer agent fees | 8679 | 27736 | 15912 | 163559 | 87864 |
| &nbsp;&nbsp;&nbsp;&nbsp;Audit fees | 7435 | 6554 | 6427 | 16131 | 11089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Management services fees | 7267 | 51004 | 10669 | 385720 | 163244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trustees fees and expenses | 6856 | 6856 | 6856 | 6856 | 6856 |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal fees | 6127 | 6637 | 6127 | 7237 | 7919 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compliance officer fees | 5897 | 8924 | 4733 | 49122 | 22257 |
| &nbsp;&nbsp;&nbsp;&nbsp;Custodian fees | 3686 | 10289 | 4228 | 97709 | 36858 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance expense | 1840 | 6440 | 1288 | 73600 | 23000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Line of credit fees | 489 | 489 | 489 | 489 | 489 |
| &nbsp;&nbsp;&nbsp;&nbsp;Line of credit interest | 70 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other expenses | 1664 | 2320 | 2319 | 30327 | 14126 |
| &nbsp;&nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 350659 | 2615683 | 785322 | 23470886 | 10910244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Manager | (103404) | (130937) | (30941) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**NET EXPENSES** | 247255 | 2484746 | 754381 | 23470886 | 10910244 |
| **NET INVESTMENT INCOME (LOSS)** | 659022 | 2385449 | (571514) | (9008985) | (8005197) |
| &nbsp;&nbsp;&nbsp;&nbsp;**REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | (3359884) | (4391282) | (13295958) | (8356567) | 48006192 |
| &nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) |  |  |  | 1684920 | 61550946 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net realized gain (loss) | (3359884) | (4391282) | (13295958) | (6671647) | 109557138 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unaffiliated investments | 859851 | 8953668 | 3561273 | (59009016) | 81123464 |
| &nbsp;&nbsp;&nbsp;&nbsp;Affiliated investments (See Note 5) |  |  |  | 30413006 | 122878725 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) | 859851 | 8953668 | 3561273 | (28596010) | 204002189 |
| **NET REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** | (2500033) | 4562386 | (9734685) | (35267657) | 313559327 |
| **NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS** | $**(1841011)** | $**6947835** | $**(10306199)** | $**(44276642)** | $**305554130** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **56** |
| **E V E N T I D E** | **56** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Funds** |
| **STATEMENTS OF OPERATIONS (Unaudited) (Continued)** |
| **For the Six Months Ended December 31, 2022** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | *Eventide* | *Eventide* | *Eventide* |
|  | *Large Cap* | *Limited-Term* | *Multi-Asset* |
|  | *Focus Fund <sup>1</sup>* | *Bond Fund* | *Income Fund* |
| **INVESTMENT INCOME** |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend income | $11564 | $— | $1878732 |
| &nbsp;&nbsp;&nbsp;Interest | 5999 | 1747070 | 2333141 |
| &nbsp;&nbsp;&nbsp;Less: Foreign dividend withholding taxes | (509) |  | (160) |
| &nbsp;&nbsp;&nbsp;**TOTAL INVESTMENT INCOME** | 17054 | 1747070 | 4211713 |
| **EXPENSES** |  |  |  |
| &nbsp;&nbsp;&nbsp;Management fees | 11406 | 288745 | 1093614 |
| &nbsp;&nbsp;&nbsp;Distribution (12b-1) fees: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class N | 92 | 13434 | 48021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class A | 23 | 25055 | 32892 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Class C | 21 | 9096 | 88816 |
| &nbsp;&nbsp;&nbsp;Registration fees | 10981 | 33120 | 46000 |
| &nbsp;&nbsp;&nbsp;Transfer agent fees | 9160 | 13680 | 21633 |
| &nbsp;&nbsp;&nbsp;Printing and postage expenses | 8782 | 26238 | 61930 |
| &nbsp;&nbsp;&nbsp;Legal fees | 7461 | 6814 | 6431 |
| &nbsp;&nbsp;&nbsp;Audit fees | 6806 | 8571 | 8571 |
| &nbsp;&nbsp;&nbsp;Trustees fees and expenses | 6302 | 6856 | 6856 |
| &nbsp;&nbsp;&nbsp;Administrative fees | 5419 | 40831 | 59897 |
| &nbsp;&nbsp;&nbsp;Shareholder servicing fees | 4024 | 127089 | 245141 |
| &nbsp;&nbsp;&nbsp;Custodian fees | 3932 | 6311 | 11651 |
| &nbsp;&nbsp;&nbsp;Compliance officer fees | 3620 | 6593 | 9336 |
| &nbsp;&nbsp;&nbsp;Insurance expense | 916 | 2208 | 5520 |
| &nbsp;&nbsp;&nbsp;Line of credit fees | 489 | 489 | 489 |
| &nbsp;&nbsp;&nbsp;Management services fees | 334 | 18628 | 38786 |
| &nbsp;&nbsp;&nbsp;Line of credit interest |  | 3983 |  |
| &nbsp;&nbsp;&nbsp;Other expenses | 2521 | 2269 | 2255 |
| &nbsp;&nbsp;&nbsp;**TOTAL EXPENSES** | 82289 | 640010 | 1787839 |
| &nbsp;&nbsp;&nbsp;Less: Fees waived/reimbursed by the Manager | (66814) | (107306) | (104484) |
| &nbsp;&nbsp;&nbsp;**NET EXPENSES** | 15475 | 532704 | 1683355 |
| **NET INVESTMENT INCOME** | 1579 | 1214366 | 2528358 |
| **REALIZED AND UNREALIZED GAIN (LOSS) FROM INVESTMENTS** |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized loss from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Investments | (56379) | (4058878) | (2895707) |
| &nbsp;&nbsp;&nbsp;Net realized loss | (56379) | (4058878) | (2895707) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: |  |  |  |
| &nbsp;&nbsp;&nbsp;Investments | (183056) | 2164275 | 755813 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on: | (183056) | 2164275 | 755813 |
| **NET REALIZED AND UNREALIZED LOSS FROM INVESTMENTS** | (239435) | (1894603) | (2139894) |
| **NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS** | $**(237856)** | $**(680237)** | $**388464** |

---

*1.* *Eventide Large Cap Focus Fund commenced on June 30, 2022.* 

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **57** |
| **E V E N T I D E** | **57** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $659022 | $1073033 |
| &nbsp;&nbsp;&nbsp;Net realized loss from investments | (3359884) | (6461166) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments | 859851 | (8302256) |
| Net decrease in net assets resulting from operations | (1841011) | (13690389) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (401260) | (729933) |
| &nbsp;&nbsp;&nbsp;Class A | (2121) | (3145) |
| &nbsp;&nbsp;&nbsp;Class C | (1667) | (1363) |
| &nbsp;&nbsp;&nbsp;Class I | (283213) | (574609) |
| &nbsp;&nbsp;&nbsp;Return of Capital |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | (109235) |
| &nbsp;&nbsp;&nbsp;Class A |  | (366) |
| &nbsp;&nbsp;&nbsp;Class C |  | (219) |
| &nbsp;&nbsp;&nbsp;Class I |  | (42656) |
| Total distributions to shareholders | (688261) | (1461526) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 4055904 | 19899042 |
| &nbsp;&nbsp;&nbsp;Class A | 36778 | 135918 |
| &nbsp;&nbsp;&nbsp;Class C | 28361 | 211387 |
| &nbsp;&nbsp;&nbsp;Class I | 16742577 | 23817414 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 401104 | 838996 |
| &nbsp;&nbsp;&nbsp;Class A | 2122 | 3469 |
| &nbsp;&nbsp;&nbsp;Class C | 1667 | 1583 |
| &nbsp;&nbsp;&nbsp;Class I | 241855 | 590448 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (33945811) | (10625350) |
| &nbsp;&nbsp;&nbsp;Class A | (29482) | (294028) |
| &nbsp;&nbsp;&nbsp;Class C | (12386) | (131770) |
| &nbsp;&nbsp;&nbsp;Class I | (2750821) | (68398673) |
| Net decrease in net assets from shares of beneficial interest | (15228132) | (33951564) |
| **TOTAL DECREASE IN NET ASSETS** | (17757404) | (49103479) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 72464989 | 121568468 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**54707585** | $**72464989** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **58** |
| **E V E N T I D E** | **58** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 492405 | 2119735 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 49680 | 94241 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (4116379) | (1156503) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (3574294) | 1057473 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 4624 | 14231 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 262 | 382 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (3612) | (30806) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 1274 | (16193) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3388 | 23636 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 207 | 181 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (1539) | (13937) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 2056 | 9880 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2016883 | 2561464 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 29940 | 63677 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (337490) | (7637167) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 1709333 | (5012026) |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **59** |
| **E V E N T I D E** | **59** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $2385449 | $2168413 |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from investments | (4391282) | 13552049 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments | 8953668 | (89452647) |
| Net increase (decrease) in net assets resulting from operations | 6947835 | (73732185) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (975144) | (2519406) |
| &nbsp;&nbsp;&nbsp;Class A | (360422) | (839193) |
| &nbsp;&nbsp;&nbsp;Class C | (86749) | (227687) |
| &nbsp;&nbsp;&nbsp;Class I | (4294110) | (10661211) |
| Total distributions to shareholders | (5716425) | (14247497) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 28902426 | 56461865 |
| &nbsp;&nbsp;&nbsp;Class A | 9597999 | 27762830 |
| &nbsp;&nbsp;&nbsp;Class C | 3440943 | 9864580 |
| &nbsp;&nbsp;&nbsp;Class I | 125672856 | 344005015 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 951874 | 2359627 |
| &nbsp;&nbsp;&nbsp;Class A | 347117 | 792135 |
| &nbsp;&nbsp;&nbsp;Class C | 84188 | 221407 |
| &nbsp;&nbsp;&nbsp;Class I | 3886157 | 10078130 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (13707699) | (40190024) |
| &nbsp;&nbsp;&nbsp;Class A | (4448198) | (10920219) |
| &nbsp;&nbsp;&nbsp;Class C | (1220658) | (2404711) |
| &nbsp;&nbsp;&nbsp;Class I | (62874695) | (220287662) |
| Net increase in net assets from shares of beneficial interest | 90632310 | 177742973 |
| **TOTAL INCREASE IN NET ASSETS** | 91863720 | 89763291 |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 419958568 | 330195277 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**511822288** | $**419958568** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **60** |
| **E V E N T I D E** | **60** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2058244 | 3486424 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 69918 | 142270 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (1010396) | (2496966) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 1117766 | 1131728 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 686036 | 1707341 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 25432 | 47967 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (314583) | (705272) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 396885 | 1050036 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 251864 | 604239 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 6152 | 13203 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (89986) | (155395) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 168030 | 462047 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 8996119 | 21354456 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 285494 | 609287 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (4522703) | (14155468) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 4758910 | 7808275 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **61** |
| **E V E N T I D E** | **61** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(571514) | $(1843408) |
| &nbsp;&nbsp;&nbsp;Net realized loss from investments and securities sold short | (13295958) | (29183178) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments | 3561273 | (38234099) |
| Net decrease in net assets resulting from operations | (10306199) | (69260685) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | (255449) |
| &nbsp;&nbsp;&nbsp;Class A |  | (126950) |
| &nbsp;&nbsp;&nbsp;Class C |  | (41959) |
| &nbsp;&nbsp;&nbsp;Class I |  | (1482367) |
| Total distributions to shareholders |  | (1906725) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 2787593 | 12127019 |
| &nbsp;&nbsp;&nbsp;Class A | 988405 | 6263795 |
| &nbsp;&nbsp;&nbsp;Class C | 303850 | 2958436 |
| &nbsp;&nbsp;&nbsp;Class I | 25366175 | 71123517 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | 226434 |
| &nbsp;&nbsp;&nbsp;Class A |  | 119077 |
| &nbsp;&nbsp;&nbsp;Class C |  | 40806 |
| &nbsp;&nbsp;&nbsp;Class I |  | 1436229 |
| &nbsp;&nbsp;&nbsp;Redemption fee proceeds: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 11018 | 7981 |
| &nbsp;&nbsp;&nbsp;Class A | 6181 | 4019 |
| &nbsp;&nbsp;&nbsp;Class C | 2018 | 1370 |
| &nbsp;&nbsp;&nbsp;Class I | 61028 | 55043 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (2414850) | (6089688) |
| &nbsp;&nbsp;&nbsp;Class A | (858713) | (1682918) |
| &nbsp;&nbsp;&nbsp;Class C | (318901) | (953062) |
| &nbsp;&nbsp;&nbsp;Class I | (25737255) | (41904207) |
| Net increase in net assets from shares of beneficial interest | 196549 | 43733851 |
| **TOTAL DECREASE IN NET ASSETS** | (10109650) | (27433559) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 94844734 | 122278293 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**84735084** | $**94844734** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **62** |
| **E V E N T I D E** | **62** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 243039 | 721035 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 13359 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (230545) | (416618) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 12494 | 317776 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 89241 | 375322 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 7025 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (78768) | (109002) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 10473 | 273345 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 27852 | 172387 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 2433 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (29495) | (58818) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (1643) | 116002 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2190108 | 4328347 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 84434 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (2308129) | (2862825) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (118021) | 1549956 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **63** |
| **E V E N T I D E** | **63** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(9008985) | $(37833295) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from investments | (6671647) | 324733387 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized depreciation on investments | (28596010) | (2034275508) |
| Net decrease in net assets resulting from operations | (44276642) | (1747375416) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (26502428) | (50029637) |
| &nbsp;&nbsp;&nbsp;Class A | (15537719) | (28422072) |
| &nbsp;&nbsp;&nbsp;Class C | (13038729) | (26952726) |
| &nbsp;&nbsp;&nbsp;Class I | (117168110) | (222170791) |
| Total distributions to shareholders | (172246986) | (327575226) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 47803256 | 166322263 |
| &nbsp;&nbsp;&nbsp;Class A | 23709105 | 162435956 |
| &nbsp;&nbsp;&nbsp;Class C | 8202046 | 107364226 |
| &nbsp;&nbsp;&nbsp;Class I | 349210956 | 1036497941 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 25204656 | 46771045 |
| &nbsp;&nbsp;&nbsp;Class A | 14252437 | 25974652 |
| &nbsp;&nbsp;&nbsp;Class C | 12562355 | 25761719 |
| &nbsp;&nbsp;&nbsp;Class I | 103966492 | 193528454 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (95907451) | (198598681) |
| &nbsp;&nbsp;&nbsp;Class A | (27716776) | (167012421) |
| &nbsp;&nbsp;&nbsp;Class C | (23914698) | (149099850) |
| &nbsp;&nbsp;&nbsp;Class I | (435488830) | (911160701) |
| Net increase in net assets from shares of beneficial interest | 1883548 | 338784603 |
| **TOTAL DECREASE IN NET ASSETS** | (214640080) | (1736166039) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 3476996881 | 5213162920 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**3262356801** | $**3476996881** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **64** |
| **E V E N T I D E** | **64** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1044295 | 2800311 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 594029 | 741808 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (2141684) | (3366988) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (503360) | 175131 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 520887 | 2529402 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 338136 | 414401 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (614176) | (2647269) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 244847 | 296534 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 199647 | 1773495 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 337607 | 458834 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (598015) | (2616327) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (60761) | (383998) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 7440308 | 16796336 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 2376377 | 2986985 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (9361623) | (15837222) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 455062 | 3946099 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **65** |
| **E V E N T I D E** | **65** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss | $(8005197) | $(24994050) |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from investments | 109557138 | (42052079) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments | 204002189 | (677637461) |
| Net increase (decrease) in net assets resulting from operations | 305554130 | (744683590) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | (18248290) |
| &nbsp;&nbsp;&nbsp;Class A |  | (17603937) |
| &nbsp;&nbsp;&nbsp;Class C |  | (10868612) |
| &nbsp;&nbsp;&nbsp;Class I |  | (145913984) |
| Total distributions to shareholders |  | (192634823) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 12283273 | 57285702 |
| &nbsp;&nbsp;&nbsp;Class A | 11321751 | 57861212 |
| &nbsp;&nbsp;&nbsp;Class C | 4101805 | 34729716 |
| &nbsp;&nbsp;&nbsp;Class I | 231172845 | 793174870 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | 17652005 |
| &nbsp;&nbsp;&nbsp;Class A |  | 14878863 |
| &nbsp;&nbsp;&nbsp;Class C |  | 10395415 |
| &nbsp;&nbsp;&nbsp;Class I |  | 105640209 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (31102727) | (99392035) |
| &nbsp;&nbsp;&nbsp;Class A | (11884563) | (65373637) |
| &nbsp;&nbsp;&nbsp;Class C | (9431560) | (47488416) |
| &nbsp;&nbsp;&nbsp;Class I | (226200718) | (733072589) |
| Net increase (decrease) in net assets from shares of beneficial interest | (19739894) | 146291315 |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | 285814236 | (791027098) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 1321566049 | 2112593147 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**1607380285** | $**1321566049** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **66** |
| **E V E N T I D E** | **66** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 404169 | 1575629 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 464771 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (994368) | (2591532) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (590199) | (551132) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 378711 | 1538348 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 394351 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (392623) | (1756110) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (13912) | 176589 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 147239 | 993106 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 296588 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (338462) | (1372431) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (191223) | (82737) |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 7472079 | 22293426 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested |  | 2730427 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (7341617) | (20587267) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 130462 | 4436586 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **67** |
| **E V E N T I D E** | **67** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **STATEMENT OF CHANGES IN NET ASSETS** |

---

---

| | |
|:---|:---|
|  | *For the* |
|  | *Six Month Ended* |
|  | *December 31, 2022 <sup>1</sup>* |
|  | *(Unaudited)* |
| **FROM OPERATIONS** |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $1579 |
| &nbsp;&nbsp;&nbsp;Net realized loss from investments | (56379) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized depreciation on investments | (183056) |
| Net decrease in net assets resulting from operations | (237856) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |
| &nbsp;&nbsp;&nbsp;Class N | (12) |
| &nbsp;&nbsp;&nbsp;Class A | (14) |
| &nbsp;&nbsp;&nbsp;Class I | (3185) |
| Total distributions to shareholders | (3211) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |
| &nbsp;&nbsp;&nbsp;Class N | 207519 |
| &nbsp;&nbsp;&nbsp;Class A | 98825 |
| &nbsp;&nbsp;&nbsp;Class C | 10510 |
| &nbsp;&nbsp;&nbsp;Class I | 6897469 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |
| &nbsp;&nbsp;&nbsp;Class N | 7 |
| &nbsp;&nbsp;&nbsp;Class A | 14 |
| &nbsp;&nbsp;&nbsp;Class I | 3053 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |
| &nbsp;&nbsp;&nbsp;Class N | (44314) |
| &nbsp;&nbsp;&nbsp;Class A | (36439) |
| &nbsp;&nbsp;&nbsp;Class I | (610991) |
| Net increase in net assets from shares of beneficial interest | 6525653 |
| **TOTAL INCREASE IN NET ASSETS** | 6284586 |
| **NET ASSETS** |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period |  |
| &nbsp;&nbsp;&nbsp;End of Period | $**6284586** |

---

&nbsp;&nbsp;&nbsp;&nbsp;*1.* *Eventide Large Cap Focus Fund commenced on June 30, 2022.* 

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **68** |
| **E V E N T I D E** | **68** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **STATEMENT OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | |
|:---|:---|
|  | *For the* |
|  | *Six Month Ended* |
|  | *December 31, 2022 <sup>1</sup>* |
|  | *(Unaudited)* |
| **SHARE ACTIVITY** |  |
| Class N: |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 20933 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 1 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (4513) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 16421 |
| Class A: |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 10097 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 2 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (3534) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 6565 |
| Class C: |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 1042 |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 1042 |
| Class I: |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 684659 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 312 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (63363) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 621608 |

---

&nbsp;&nbsp;&nbsp;&nbsp;*1.* *Eventide Large Cap Focus Fund commenced on June 30, 2022.* 

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **69** |
| **E V E N T I D E** | **69** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $1214366 | $1123079 |
| &nbsp;&nbsp;&nbsp;Net realized loss from investments | (4058878) | (1842031) |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments | 2164275 | (11453973) |
| Net decrease in net assets resulting from operations | (680237) | (12172925) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (99970) | (45786) |
| &nbsp;&nbsp;&nbsp;Class A | (128359) | (167972) |
| &nbsp;&nbsp;&nbsp;Class C | (5914) | (2773) |
| &nbsp;&nbsp;&nbsp;Class I | (1056739) | (1134005) |
| &nbsp;&nbsp;&nbsp;Return of Capital |  |  |
| &nbsp;&nbsp;&nbsp;Class N |  | (31408) |
| &nbsp;&nbsp;&nbsp;Class A |  | (118494) |
| &nbsp;&nbsp;&nbsp;Class C |  | (3171) |
| &nbsp;&nbsp;&nbsp;Class I |  | (936564) |
| Total distributions to shareholders | (1290982) | (2440173) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 19970258 | 6269296 |
| &nbsp;&nbsp;&nbsp;Class A | 3620962 | 14052234 |
| &nbsp;&nbsp;&nbsp;Class C | 762016 | 1052949 |
| &nbsp;&nbsp;&nbsp;Class I | 46374480 | 113802147 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 99644 | 76046 |
| &nbsp;&nbsp;&nbsp;Class A | 127378 | 283529 |
| &nbsp;&nbsp;&nbsp;Class C | 5845 | 5863 |
| &nbsp;&nbsp;&nbsp;Class I | 916000 | 1812738 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (6593080) | (7137893) |
| &nbsp;&nbsp;&nbsp;Class A | (8149318) | (19743210) |
| &nbsp;&nbsp;&nbsp;Class C | (315740) | (801836) |
| &nbsp;&nbsp;&nbsp;Class I | (95794870) | (95139344) |
| Net increase (decrease) in net assets from shares of beneficial interest | (38976425) | 14532519 |
| **TOTAL DECREASE IN NET ASSETS** | (40947644) | (80579) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 182055250 | 182135829 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**141107606** | $**182055250** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **70** |
| **E V E N T I D E** | **70** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 2085963 | 604525 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 10377 | 7479 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (682647) | (692333) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | 1413693 | (80329) |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 374455 | 1367565 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 13192 | 27833 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (847586) | (1931999) |
| &nbsp;&nbsp;&nbsp;Net decrease in shares of beneficial interest outstanding | (459939) | (536601) |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 79835 | 103863 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 610 | 585 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (33017) | (79079) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 47428 | 25369 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 4679576 | 10908339 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 92761 | 174506 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (9708985) | (9184513) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (4936648) | 1898332 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **71** |
| **E V E N T I D E** | **71** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **FROM OPERATIONS** |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | $2528358 | $3259284 |
| &nbsp;&nbsp;&nbsp;Net realized gain (loss) from investments and foreign currency transactions | (2895707) | 12373588 |
| &nbsp;&nbsp;&nbsp;Net change in unrealized appreciation (depreciation) on investments and foreign currency translations | 755813 | (56988661) |
| Net increase (decrease) in net assets resulting from operations | 388464 | (41355789) |
| **DISTRIBUTIONS TO SHAREHOLDERS** |  |  |
| &nbsp;&nbsp;&nbsp;Total Distributions Paid |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (879155) | (2564067) |
| &nbsp;&nbsp;&nbsp;Class A | (454664) | (1586555) |
| &nbsp;&nbsp;&nbsp;Class C | (240439) | (1068493) |
| &nbsp;&nbsp;&nbsp;Class I | (5054320) | (19496798) |
| Total distributions to shareholders | (6628578) | (24715913) |
| **FROM SHARES OF BENEFICIAL INTEREST** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from shares sold: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 44726449 | 21618583 |
| &nbsp;&nbsp;&nbsp;Class A | 2138770 | 14677481 |
| &nbsp;&nbsp;&nbsp;Class C | 1204847 | 7579621 |
| &nbsp;&nbsp;&nbsp;Class I | 36994996 | 132340650 |
| &nbsp;&nbsp;&nbsp;Net asset value of shares issued in reinvestment of distributions: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | 848008 | 2432723 |
| &nbsp;&nbsp;&nbsp;Class A | 405614 | 1478839 |
| &nbsp;&nbsp;&nbsp;Class C | 225126 | 981945 |
| &nbsp;&nbsp;&nbsp;Class I | 4667332 | 18045148 |
| &nbsp;&nbsp;&nbsp;Payments for shares repurchased: |  |  |
| &nbsp;&nbsp;&nbsp;Class N | (29548905) | (22348326) |
| &nbsp;&nbsp;&nbsp;Class A | (2515320) | (8906607) |
| &nbsp;&nbsp;&nbsp;Class C | (2376294) | (5981374) |
| &nbsp;&nbsp;&nbsp;Class I | (43988238) | (108791176) |
| Net increase in net assets from shares of beneficial interest | 12782385 | 53127507 |
| **TOTAL INCREASE (DECREASE) IN NET ASSETS** | 6542271 | (12944195) |
| **NET ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Beginning of Period/Year | 348167351 | 361111546 |
| &nbsp;&nbsp;&nbsp;End of Period/Year | $**354709622** | $**348167351** |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **72** |
| **E V E N T I D E** | **72** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **STATEMENTS OF CHANGES IN NET ASSETS (Continued)** |

---

---

| | | |
|:---|:---|:---|
|  | *For the* |  |
|  | *Six Month Ended* | *For the* |
|  | *December 31, 2022* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* |
| **SHARE ACTIVITY** |  |  |
| Class N: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3670659 | 1536893 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 70020 | 171600 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (2510040) | (1642775) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 1230639 | 65718 |
| Class A: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 172630 | 1037604 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 33326 | 104231 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (205371) | (648352) |
| &nbsp;&nbsp;&nbsp;Net increase in shares of beneficial interest outstanding | 585 | 493483 |
| Class C: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 98854 | 537741 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 18645 | 69409 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (196173) | (436807) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (78674) | 170343 |
| Class I: |  |  |
| &nbsp;&nbsp;&nbsp;Shares Sold | 3029994 | 9464878 |
| &nbsp;&nbsp;&nbsp;Shares Reinvested | 384084 | 1274539 |
| &nbsp;&nbsp;&nbsp;Shares Repurchased | (3611132) | (8146723) |
| &nbsp;&nbsp;&nbsp;Net increase (decrease) in shares of beneficial interest outstanding | (197054) | 2592694 |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **73** |
| **E V E N T I D E** | **73** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | Class N | Class N | Class N |
|  | Six Months Ended<br>December 31, 2022<br>(Unaudited) |<br>Year Ended<br>June 30, 2022 |<br>Period Ended<br>June 30, 2021 \* |
| Net asset value, beginning of period | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.08 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.30) | (1.20) | (0.29) |
| Total from investment operations | (0.22) | (1.12) | (0.24) |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.09) | (0.11) | (0.05) |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.02) | (0.05) |
| Total distributions | (0.09) | (0.13) | (0.10) |
| Net asset value, end of period | $8.10 | $8.41 | $9.66 |
| Total return <sup>2</sup> | (2.64)%<sup>5,6</sup> | (11.69)% | (2.39)%<sup>6</sup> |
| Net assets, at end of period (000s) | $27073 | $58166 | $56644 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.07%<sup>7</sup> | 0.96% | 0.89%<sup>7</sup> |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 0.78%<sup>7</sup> | 0.78% | 0.78%<sup>7</sup> |
| Ratio of net investment income to average net assets <sup>4,8</sup> | 1.85%<sup>7</sup> | 0.88% | 0.53%<sup>7</sup> |
| Portfolio Turnover Rate | 21%<sup>6</sup> | 56% | 52%<sup>6</sup> |

---

*\** *Eventide Core Bond Fund commenced on July 31, 2020.*

*1.* *Per share amounts calculated using the average shares method.*

*2.* *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.*

*3.* *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.*

*4.* *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.*

*5.* *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.*

*6.* *Not annualized.*

*7.* *Annualized.*

*8.* *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.*

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **74** |
| **E V E N T I D E** | **74** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $8.44 | $9.71 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.07 | 0.05 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.30) | (1.22) | (0.27) |
| Total from investment operations | (0.22) | (1.15) | (0.22) |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.09) | (0.10) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.02) | (0.05) |
| Total distributions | (0.09) | (0.12) | (0.07) |
| Net asset value, end of period | $8.13 | $8.44 | $9.71 |
| Total return <sup>2</sup> | (2.63)%<sup>5</sup> | (11.91)% | (2.28)%<sup>5</sup> |
| Net assets, at end of period (000s) | $200 | $197 | $384 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.12%<sup>6</sup> | 1.01% | 0.94%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 0.83%<sup>6</sup> | 0.83% | 0.83%<sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,7</sup> | 1.85%<sup>6</sup> | 0.78% | 0.51%<sup>6</sup> |
| Portfolio Turnover Rate | 21%<sup>5</sup> | 56% | 52%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Core Bond Fund commenced on July 31, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **75** |
| **E V E N T I D E** | **75** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **FINANCIAL HIGHLIGHTS**  |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $8.37 | $9.63 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income (loss) <sup>1</sup> | 0.04 | 0.01 | (0.02) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.30) | (1.20) | (0.28) |
| Total from investment operations | (0.26) | (1.19) | (0.30) |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.06) | (0.06) | (0.02) |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.01) | (0.05) |
| Total distributions | (0.06) | (0.07) | (0.07) |
| Net asset value, end of period | $8.05 | $8.37 | $9.63 |
| Total return <sup>2</sup> | (3.13)%<sup>5</sup> | (12.37)% | (3.02)%<sup>5</sup> |
| Net assets, at end of period (000s) | $233 | $224 | $163 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.87%<sup>6</sup> | 1.76% | 1.69%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 1.58%<sup>6</sup> | 1.58% | 1.58%<sup>6</sup> |
| Ratio of net investment income (loss) to average net assets <sup>4,7</sup> | 1.09%<sup>6</sup> | 0.09% | (0.20)%<sup>6</sup> |
| Portfolio Turnover Rate | 21%<sup>5</sup> | 56% | 52%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Core Bond Fund commenced on July 31, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **76** |
| **E V E N T I D E** | **76** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Core Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $8.41 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.09 | 0.09 | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.30) | (1.19) | (0.29) |
| Total from investment operations | (0.21) | (1.10) | (0.22) |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.10) | (0.13) | (0.07) |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.02) | (0.05) |
| Total distributions | (0.10) | (0.15) | (0.12) |
| Net asset value, end of period | $8.10 | $8.41 | $9.66 |
| Total return <sup>2</sup> | (2.51)%<sup>5</sup> | (11.51)% | (2.24)%<sup>5</sup> |
| Net assets, at end of period (000s) | $27202 | $13877 | $64377 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 0.87%<sup>6</sup> | 0.76% | 0.69%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 0.58%<sup>6</sup> | 0.58% | 0.58%<sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,7</sup> | 2.13%<sup>6</sup> | 1.00% | 0.80%<sup>6</sup> |
| Portfolio Turnover Rate | 21%<sup>5</sup> | 56% | 52%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Core Bond Fund commenced on July 31, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **77** |
| **E V E N T I D E** | **77** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018 \** |
| Net asset value, beginning of period | $13.43 | $15.86 | $10.88 | $10.37 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.07 | 0.05 | 0.04 | 0.11 | 0.22 | 0.33 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | (2.01) | 5.08 | 0.57 | 0.66 | (0.52) |
| Total from investment operations | 0.29 | (1.96) | 5.12 | 0.68 | 0.88 | (0.19) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.06) | (0.18) | (0.14) | (0.10) | (0.16) | (0.14) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.09) | (0.29) |  |  |  | (0.01) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.07) | (0.01) |  |
| Total distributions | (0.15) | (0.47) | (0.14) | (0.17) | (0.17) | (0.15) |
| Net asset value, end of period | $13.57 | $13.43 | $15.86 | $10.88 | $10.37 | $9.66 |
| Total return <sup>2</sup> | 2.15%<sup>5</sup> | (12.90)% | 47.21% | 6.60% | 9.20% | (1.87)%<sup>5</sup> |
| Net assets, at end of period (000s) | $90891 | $74940 | $70566 | $18576 | $7254 | $4929 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.20%<sup>6</sup> | 1.14% | 1.19% | 1.50% | 2.00% | 3.30%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.15%<sup>6</sup> | 1.15% | 1.15% | 1.15% | 1.15% | 1.15%<sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,7</sup> | 0.88%<sup>6</sup> | 0.34% | 0.27% | 1.01% | 2.25% | 4.43%<sup>6</sup> |
| Portfolio Turnover Rate | 20%<sup>5</sup> | 50% | 35% | 90% | 50% | 13%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Dividend Opportunities Fund commenced on September 29, 2017.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **78** |
| **E V E N T I D E** | **78** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018 \** |
| Net asset value, beginning of period | $13.43 | $15.85 | $10.87 | $10.36 | $9.65 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.06 | 0.05 | 0.03 | 0.10 | 0.22 | 0.27 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.23 | (2.01) | 5.08 | 0.57 | 0.65 | (0.47) |
| Total from investment operations | 0.29 | (1.96) | 5.11 | 0.67 | 0.87 | (0.20) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.06) | (0.17) | (0.13) | (0.09) | (0.15) | (0.14) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.09) | (0.29) |  |  |  | (0.01) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.07) | (0.01) |  |
| Total distributions | (0.15) | (0.46) | (0.13) | (0.16) | (0.16) | (0.15) |
| Net asset value, end of period | $13.57 | $13.43 | $15.85 | $10.87 | $10.36 | $9.65 |
| Total return <sup>2</sup> | 2.12%<sup>5</sup> | (12.88)% | 47.22% | 6.55% | 9.15% | (2.01)%<sup>5</sup> |
| Net assets, at end of period (000s) | $34941 | $29243 | $17865 | $3184 | $957 | $511 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.25%<sup>6</sup> | 1.19% | 1.24% | 1.55% | 2.05% | 3.35%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.20%<sup>6</sup> | 1.20% | 1.20% | 1.20% | 1.20% | 1.20%<sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,7</sup> | 0.81%<sup>6</sup> | 0.31% | 0.22% | 0.89% | 2.28% | 3.58%<sup>6</sup> |
| Portfolio Turnover Rate | 20%<sup>5</sup> | 50% | 35% | 90% | 50% | 13%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Dividend Opportunities Fund commenced on September 29, 2017.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **79** |
| **E V E N T I D E** | **79** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018 \** |
| Net asset value, beginning of period | $13.34 | $15.77 | $10.86 | $10.35 | $9.66 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income (loss) <sup>1</sup> | 0.01 | (0.07) | (0.08) | 0.03 | 0.15 | 0.25 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | (2.00) | 5.06 | 0.56 | 0.65 | (0.49) |
| Total from investment operations | 0.23 | (2.07) | 4.98 | 0.59 | 0.80 | (0.24) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.01) | (0.07) | (0.07) | (0.05) | (0.10) | (0.09) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.09) | (0.29) |  |  |  | (0.01) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.03) | (0.01) |  |
| Total distributions | (0.10) | (0.36) | (0.07) | (0.08) | (0.11) | (0.10) |
| Net asset value, end of period | $13.47 | $13.34 | $15.77 | $10.86 | $10.35 | $9.66 |
| Total return <sup>2</sup> | 1.70%<sup>5</sup> | (13.57)% | 45.93% | 5.78% | 8.34% | (2.37)%<sup>5</sup> |
| Net assets, at end of period (000s) | $12340 | $9975 | $4508 | $824 | $541 | $299 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 2.00%<sup>6</sup> | 1.94% | 1.99% | 2.30% | 2.80% | 4.10%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.95%<sup>6</sup> | 1.95% | 1.95% | 1.95% | 1.95% | 1.95%<sup>6</sup> |
| Ratio of net investment income (loss) to average net assets <sup>4,7</sup> | 0.08%<sup>6</sup> | (0.42)% | (0.53)% | 0.25% | 1.53% | 3.39%<sup>6</sup> |
| Portfolio Turnover Rate | 20%<sup>5</sup> | 50% | 35% | 90% | 50% | 13%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Dividend Opportunities Fund commenced on September 29, 2017.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income/(loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **80** |
| **E V E N T I D E** | **80** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Dividend Opportunities Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018 \** |
| Net asset value, beginning of period | $13.44 | $15.87 | $10.88 | $10.37 | $9.67 | $10.00 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.09 | 0.07 | 0.12 | 0.24 | 0.26 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 0.22 | (2.02) | 5.07 | 0.57 | 0.66 | (0.43) |
| Total from investment operations | 0.30 | (1.93) | 5.14 | 0.69 | 0.90 | (0.17) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.07) | (0.21) | (0.15) | (0.10) | (0.19) | (0.15) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.09) | (0.29) |  |  |  | (0.01) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.08) | (0.01) |  |
| Total distributions | (0.16) | (0.50) | (0.15) | (0.18) | (0.20) | (0.16) |
| Net asset value, end of period | $13.58 | $13.44 | $15.87 | $10.88 | $10.37 | $9.67 |
| Total return <sup>2</sup> | 2.24%<sup>5</sup> | (12.72)% | 47.49% | 6.79% | 9.40% | (1.68)%<sup>5</sup> |
| Net assets, at end of period (000s) | $373650 | $305801 | $237256 | $45034 | $7892 | $5438 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.00%<sup>6</sup> | 0.94% | 0.99% | 1.30% | 1.80% | 3.10%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 0.95%<sup>6</sup> | 0.95% | 0.95% | 0.95% | 0.95% | 0.95%<sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,7</sup> | 1.08%<sup>6</sup> | 0.55% | 0.48% | 1.16% | 2.47% | 3.35%<sup>6</sup> |
| Portfolio Turnover Rate | 20%<sup>5</sup> | 50% | 35% | 90% | 50% | 13%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Dividend Opportunities Fund commenced on September 29, 2017.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived or recaptured a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **81** |
| **E V E N T I D E** | **81** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $10.92 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.08) | (0.25) | (0.25) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.99) | (7.69) | 9.33 |
| Total from investment operations | (1.07) | (7.94) | 9.08 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (0.23) | (0.02) |
| Total distributions |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees <sup>1</sup> | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period | $9.86 | $10.92 | $19.08 |
| Total return <sup>2</sup> | (9.71)%<sup>6,7</sup> | (42.00)% | 91.00% |
| Net assets, at end of period (000s) | $11391 | $12479 | $15730 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.69%<sup>8</sup> | 1.63% | 1.73% |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 1.63%<sup>8</sup> | 1.63% | 1.63% |
| Ratio of net investment loss to average net assets <sup>4,5</sup> | (1.26)%<sup>8</sup> | (1.54)% | (1.50)% |
| Portfolio Turnover Rate | 43%<sup>7</sup> | 69% | 60% |

---

---

| | |
|:---|:---|
| *\** | *Eventide Exponential Technologies Fund commenced on June 30, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.* |
| | |
| *7.* | *Not annualized.* |
| | |
| *8.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **82** |
| **E V E N T I D E** | **82** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $10.93 | $19.08 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.07) | (0.25) | (0.26) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (1.00) | (7.68) | 9.34 |
| Total from investment operations | (1.07) | (7.93) | 9.08 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (0.23) | (0.02) |
| Total distributions |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees <sup>1</sup> | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period | $9.87 | $10.93 | $19.08 |
| Total return <sup>2</sup> | (9.70)%<sup>6</sup> | (41.95)% | 91.00% |
| Net assets, at end of period (000s) | $6763 | $7377 | $7662 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.74%<sup>7</sup> | 1.68% | 1.78% |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 1.68%<sup>7</sup> | 1.68% | 1.68% |
| Ratio of net investment loss to average net assets <sup>4,5</sup> | (1.32)%<sup>7</sup> | (1.58)% | (1.55)% |
| Portfolio Turnover Rate | 43%<sup>6</sup> | 69% | 60% |

---

---

| | |
|:---|:---|
| *\** | *Eventide Exponential Technologies Fund commenced on June 30, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *Not annualized.* |
| | |
| *7.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **83** |
| **E V E N T I D E** | **83** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $10.77 | $18.96 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.12) | (0.37) | (0.38) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.98) | (7.60) | 9.35 |
| Total from investment operations | (1.10) | (7.97) | 8.97 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (0.23) | (0.02) |
| Total distributions |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees <sup>1</sup> | 0.01 | 0.01 | 0.01 |
| Net asset value, end of period | $9.68 | $10.77 | $18.96 |
| Total return <sup>2</sup> | (10.12)%<sup>6</sup> | (42.43)% | 89.80% |
| Net assets, at end of period (000s) | $2162 | $2422 | $2065 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 2.49%<sup>7</sup> | 2.43% | 2.53% |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 2.43%<sup>7</sup> | 2.43% | 2.43% |
| Ratio of net investment loss to average net assets <sup>4,5</sup> | (2.07)%<sup>7</sup> | (2.33)% | (2.30)% |
| Portfolio Turnover Rate | 43%<sup>6</sup> | 69% | 60% |

---

---

| | |
|:---|:---|
| *\** | *Eventide Exponential Technologies Fund commenced on June 30, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *Not annualized.* |
| | |
| *7.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **84** |
| **E V E N T I D E** | **84** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Exponential Technologies Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | |
|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021 \** |
| Net asset value, beginning of period | $10.97 | $19.12 | $10.00 |
| Activity from investment operations: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.06) | (0.22) | (0.22) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (1.00) | (7.71) | 9.34 |
| Total from investment operations | (1.06) | (7.93) | 9.12 |
| Less distributions from: |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (0.23) | (0.02) |
| Total distributions |  | (0.23) | (0.02) |
| Paid-in-capital from redemption fees <sup>1</sup> | 0.01 | 0.01 | 0.02 |
| Net asset value, end of period | $9.92 | $10.97 | $19.12 |
| Total return <sup>2</sup> | (9.57)%<sup>6</sup> | (41.86)% | 91.40% |
| Net assets, at end of period (000s) | $64419 | $72567 | $96821 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3,4</sup> | 1.49%<sup>7</sup> | 1.43% | 1.53% |
| Ratio of net expenses to average net assets after expense reimbursement <sup>4</sup> | 1.43%<sup>7</sup> | 1.43% | 1.43% |
| Ratio of net investment loss to average net assets <sup>4,5</sup> | (1.07)%<sup>7</sup> | (1.33)% | (1.30)% |
| Portfolio Turnover Rate | 43%<sup>6</sup> | 69% | 60% |

---

---

| | |
|:---|:---|
| *\** | *Eventide Exponential Technologies Fund commenced on June 30, 2020.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *Not annualized.* |
| | |
| *7.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **85** |
| **E V E N T I D E** | **85** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $44.10 | $69.91 | $47.16 | $41.75 | $37.80 | $29.99 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.14) | (0.53) | (0.51) | (0.25) | (0.14) | (0.06) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.43) | (21.01) | 23.77 | 6.98 | 5.80 | 7.87 |
| Total from investment operations | (0.57) | (21.54) | 23.26 | 6.73 | 5.66 | 7.81 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Total distributions | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Net asset value, end of period | $41.25 | $44.10 | $69.91 | $47.16 | $41.75 | $37.80 |
| Total return <sup>2</sup> | (1.43)%<sup>5</sup> | (32.65)% | 49.43% | 16.66% | 16.41% | 26.04% |
| Net assets, at end of period (000s) | $474934 | $529869 | $827811 | $549944 | $639372 | $435526 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.37%<sup>6</sup> | 1.31% | 1.31% | 1.38% | 1.39% | 1.39% |
| Ratio of net investment loss to average net assets <sup>3,4</sup> | (0.58)%<sup>6</sup> | (0.86)% | (0.85)% | (0.63)% | (0.37)% | (0.16)% |
| Portfolio Turnover Rate | 19%<sup>5</sup> | 27% | 19% | 35% | 38% | 24% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **86** |
| **E V E N T I D E** | **86** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $43.83 | $69.53 | $46.92 | $41.57 | $37.66 | $29.89 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.15) | (0.55) | (0.54) | (0.27) | (0.16) | (0.07) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.42) | (20.88) | 23.66 | 6.94 | 5.78 | 7.84 |
| Total from investment operations | (0.57) | (21.43) | 23.12 | 6.67 | 5.62 | 7.77 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Total distributions | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Net asset value, end of period | $40.98 | $43.83 | $69.53 | $46.92 | $41.57 | $37.66 |
| Total return <sup>2</sup> | (1.44)%<sup>5</sup> | (32.67)% | 49.39% | 16.58% | 16.36% | 26.00% |
| Net assets, at end of period (000s) | $292564 | $302171 | $458726 | $301013 | $274059 | $274257 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.42%<sup>6</sup> | 1.36% | 1.36% | 1.43% | 1.44% | 1.44% |
| Ratio of net investment loss to average net assets <sup>3,4</sup> | (0.63)%<sup>6</sup> | (0.91)% | (0.91)% | (0.69)% | (0.44)% | (0.21)% |
| Portfolio Turnover Rate | 19%<sup>5</sup> | 27% | 19% | 35% | 38% | 24% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any, and also does not reflect the impact of sales charges.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not Annualized.* |
| | |
| *6.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **87** |
| **E V E N T I D E** | **87** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $39.09 | $62.97 | $42.86 | $38.37 | $35.16 | $28.12 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.28) | (0.91) | (0.89) | (0.53) | (0.41) | (0.31) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.36) | (18.70) | 21.51 | 6.34 | 5.33 | 7.35 |
| Total from investment operations | (0.64) | (19.61) | 20.62 | 5.81 | 4.92 | 7.04 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Total distributions | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Net asset value, end of period | $36.17 | $39.09 | $62.97 | $42.86 | $38.37 | $35.16 |
| Total return <sup>2</sup> | (1.80)%<sup>5</sup> | (33.21)% | 48.23% | 15.71% | 15.51% | 25.04% |
| Net assets, at end of period (000s) | $216101 | $235967 | $404272 | $289242 | $266001 | $230290 |
| Ratio of net expenses to average net assets <sup>3</sup> | 2.17%<sup>6</sup> | 2.11% | 2.11% | 2.18% | 2.19% | 2.19% |
| Ratio of net investment loss to average net assets <sup>3,4</sup> | (1.38)%<sup>6</sup> | (1.67)% | (1.65)% | (1.43)% | (1.17)% | (0.96)% |
| Portfolio Turnover Rate | 19%<sup>5</sup> | 27% | 19% | 35% | 38% | 24% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **88** |
| **E V E N T I D E** | **88** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Gilead Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $45.36 | $71.65 | $48.22 | $42.59 | $38.44 | $30.43 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income (loss) <sup>1</sup> | (0.09) | (0.41) | (0.40) | (0.18) | (0.07) | 0.01 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.45) | (21.61) | 24.34 | 7.13 | 5.93 | 8.00 |
| Total from investment operations | (0.54) | (22.02) | 23.94 | 6.95 | 5.86 | 8.01 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Total distributions | (2.28) | (4.27) | (0.51) | (1.32) | (1.71) |  |
| Net asset value, end of period | $42.54 | $45.36 | $71.65 | $48.22 | $42.59 | $38.44 |
| Total return <sup>2</sup> | (1.33)%<sup>5</sup> | (32.52)% | 49.76% | 16.85% | 16.66% | 26.32% |
| Net assets, at end of period (000s) | $2278758 | $2408991 | $3522353 | $1997163 | $1475489 | $968578 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.17%<sup>6</sup> | 1.11% | 1.11% | 1.18% | 1.19% | 1.19% |
| Ratio of net investment income (loss) to average net assets <sup>3,4</sup> | (0.38)%<sup>6</sup> | (0.66)% | (0.65)% | (0.43)% | (0.17)% | 0.03% |
| Portfolio Turnover Rate | 19%<sup>5</sup> | 27% | 19% | 35% | 38% | 24% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment income (loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **89** |
| **E V E N T I D E** | **89** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $26.52 | $46.19 | $43.33 | $35.51 | $34.52 | $23.41 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.18) | (0.57) | (0.72) | (0.52) | (0.46) | (0.40) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.32 | (14.74) | 5.52 | 9.19 | 3.39 | 11.87 |
| Total from investment operations | 6.14 | (15.31) | 4.80 | 8.67 | 2.93 | 11.47 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  | (0.63) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (3.73) | (1.94) | (0.87) | (1.98) | (0.37) |
| Total distributions |  | (4.36) | (1.94) | (0.87) | (1.98) | (0.37) |
| Paid-in-capital from redemption fees <sup>1</sup> |  |  | 0.00<sup>4</sup> | 0.02 | 0.04 | 0.01 |
| Net asset value, end of period | $32.66 | $26.52 | $46.19 | $43.33 | $35.51 | $34.52 |
| Total return <sup>2</sup> | 22.87%<sup>5,8</sup> | (35.99)%<sup>5</sup> | 10.34% | 24.68% | 10.38%<sup>5</sup> | 49.45%<sup>5</sup> |
| Net assets, at end of period (000s) | $123546 | $115954 | $227441 | $231460 | $147468 | $93030 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.53%<sup>9</sup> | 1.50% | 1.48% | 1.50% | 1.49% | 1.50%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>3,7</sup> | (1.16)%<sup>9</sup> | (1.49)% | (1.47)% | (1.44)% | (1.38)% | (1.35)%<sup>6</sup> |
| Portfolio Turnover Rate | 44%<sup>8</sup> | 59% | 62% | 33% | 53% | 43% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *8.* | *Not annualized.* |
| | |
| *9.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **90** |
| **E V E N T I D E** | **90** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $26.34 | $45.91 | $43.10 | $35.33 | $34.40 | $23.33 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.18) | (0.58) | (0.74) | (0.53) | (0.48) | (0.40) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.27 | (14.64) | 5.49 | 9.15 | 3.35 | 11.83 |
| Total from investment operations | 6.09 | (15.22) | 4.75 | 8.62 | 2.87 | 11.43 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  | (0.62) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (3.73) | (1.94) | (0.87) | (1.98) | (0.37) |
| Total distributions |  | (4.35) | (1.94) | (0.87) | (1.98) | (0.37) |
| Paid-in-capital from redemption fees <sup>1</sup> |  |  | 0.00<sup>4</sup> | 0.02 | 0.04 | 0.01 |
| Net asset value, end of period | $32.43 | $26.34 | $45.91 | $43.10 | $35.33 | $34.40 |
| Total return <sup>2</sup> | 22.84%<sup>8</sup> | (36.02)%<sup>5</sup> | 10.28% | 24.67% | 10.24%<sup>5</sup> | 49.45%<sup>5</sup> |
| Net assets, at end of period (000s) | $140710 | $114642 | $191709 | $175151 | $143407 | $133329 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.58%<sup>9</sup> | 1.55% | 1.53% | 1.55% | 1.54% | 1.55%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>3,7</sup> | (1.20)%<sup>9</sup> | (1.54)% | (1.52)% | (1.49)% | (1.43)% | (1.40)%<sup>6</sup> |
| Portfolio Turnover Rate | 44%<sup>8</sup> | 59% | 62% | 33% | 53% | 43% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any, and also does not reflect the impact of sales charges.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *8.* | *Not annualized.* |
| | |
| *9.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **91** |
| **E V E N T I D E** | **91** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $24.37 | $42.78 | $40.56 | $33.54 | $33.00 | $22.57 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.28) | (0.80) | (1.04) | (0.76) | (0.69) | (0.60) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 5.81 | (13.60) | 5.20 | 8.63 | 3.17 | 11.39 |
| Total from investment operations | 5.53 | (14.40) | 4.16 | 7.87 | 2.48 | 10.79 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  | (0.28) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (3.73) | (1.94) | (0.87) | (1.98) | (0.37) |
| Total distributions |  | (4.01) | (1.94) | (0.87) | (1.98) | (0.37) |
| Paid-in-capital from redemption fees <sup>1</sup> |  |  | 0.00<sup>4</sup> | 0.02 | 0.04 | 0.01 |
| Net asset value, end of period | $29.90 | $24.37 | $42.78 | $40.56 | $33.54 | $33.00 |
| Total return <sup>2</sup> | 22.44%<sup>8</sup> | (36.51)%<sup>5</sup> | 9.45% | 23.73% | 9.50%<sup>5</sup> | 48.27%<sup>5</sup> |
| Net assets, at end of period (000s) | $75914 | $66540 | $120351 | $104202 | $87773 | $75025 |
| Ratio of net expenses to average net assets <sup>3</sup> | 2.33%<sup>9</sup> | 2.30% | 2.28% | 2.30% | 2.29% | 2.30%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>3,7</sup> | (1.95)%<sup>9</sup> | (2.29)% | (2.27)% | (2.23)% | (2.18)% | (2.15)%<sup>6</sup> |
| Portfolio Turnover Rate | 44%<sup>8</sup> | 59% | 62% | 33% | 53% | 43% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *8.* | *Not annualized.* |
| | |
| *9.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **92** |
| **E V E N T I D E** | **92** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Healthcare & Life Sciences Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $27.05 | $47.04 | $44.02 | $35.98 | $34.88 | $23.60 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.15) | (0.49) | (0.64) | (0.46) | (0.40) | (0.34) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | 6.44 | (15.03) | 5.60 | 9.35 | 3.44 | 11.98 |
| Total from investment operations | 6.29 | (15.52) | 4.96 | 8.89 | 3.04 | 11.64 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income |  | (0.74) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net realized gains |  | (3.73) | (1.94) | (0.87) | (1.98) | (0.37) |
| Total distributions |  | (4.47) | (1.94) | (0.87) | (1.98) | (0.37) |
| Paid-in-capital from redemption fees <sup>1</sup> |  |  | 0.00<sup>4</sup> | 0.02 | 0.04 | 0.01 |
| Net asset value, end of period | $33.34 | $27.05 | $47.04 | $44.02 | $35.98 | $34.88 |
| Total return <sup>2</sup> | 23.03%<sup>8</sup> | (35.85)%<sup>5</sup> | 10.54% | 24.97% | 10.60%<sup>5</sup> | 49.77%<sup>5</sup> |
| Net assets, at end of period (000s) | $1267210 | $1024430 | $1573091 | $1120862 | $705159 | $389458 |
| Ratio of net expenses to average net assets <sup>3</sup> | 1.33%<sup>9</sup> | 1.30% | 1.28% | 1.30% | 1.29% | 1.30%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>3,7</sup> | (0.96)%<sup>9</sup> | (1.29)% | (1.28)% | (1.24)% | (1.19)% | (1.15)%<sup>6</sup> |
| Portfolio Turnover Rate | 44%<sup>8</sup> | 59% | 62% | 33% | 53% | 43% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any.* |
| | |
| *3.* | *The ratios of expenses to average net assets and net investment loss to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Includes adjustments in accordance with accounting principles generally accepted in the United States of America and, consequently, the net asset value for financial reporting purposes and the returns based upon those net asset values may differ from the net asset values and returns for shareholder transactions.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *8.* | *Not annualized.* |
| | |
| *9.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **93** |
| **E V E N T I D E** | **93** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **FINANCIAL HIGHLIGHTS** |
| **Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented** |

---

---

| | |
|:---|:---|
|  | *Class N* |
|  | *Six Months Ended* |
|  | *December 31, 2022 \** |
|  | *(Unaudited)* |
| Net asset value, beginning of period | $10.00 |
| Activity from investment operations: |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.26) |
| Total from investment operations | (0.27) |
| Less distributions from: |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.00)<sup>4</sup> |
| Total distributions | (0.00)<sup>4</sup> |
| Net asset value, end of period | $9.73 |
| Total return <sup>2</sup> | (2.69)%<sup>5</sup> |
| Net assets, at end of period (000s) | $160 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 5.43%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 1.17%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>7</sup> | (0.07)%<sup>6</sup> |
| Portfolio Turnover Rate | 16%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Large Cap Focus Fund Class N commenced on June 30, 2022.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **94** |
| **E V E N T I D E** | **94** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented**

---

| | |
|:---|:---|
|  | *Class A* |
|  | *Six Months Ended* |
|  | *December 31, 2022 \** |
|  | *(Unaudited)* |
| Net asset value, beginning of period | $10.00 |
| Activity from investment operations: |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.26) |
| Total from investment operations | (0.27) |
| Less distributions from: |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.00)<sup>4</sup> |
| Total distributions | (0.00)<sup>4</sup> |
| Net asset value, end of period | $9.73 |
| Total return <sup>2</sup> | (2.68)%<sup>5</sup> |
| Net assets, at end of period (000s) | $64 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 5.48%<sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 1.22%<sup>6</sup> |
| Ratio of net investment loss to average net assets <sup>7</sup> | (0.08)%<sup>6</sup> |
| Portfolio Turnover Rate | 16%<sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Large Cap Focus Fund Class N commenced on June 30, 2022.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Amount represents less than $0.01 per share.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **95** |
| **E V E N T I D E** | **95** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented**

---

| | |
|:---|:---|
|  | *Class C* |
|  | *Six Months Ended* |
|  | *December 31, 2022 \** |
|  | *(Unaudited)* |
| Net asset value, beginning of period | $10.00 |
| Activity from investment operations: |  |
| &nbsp;&nbsp;&nbsp;Net investment loss <sup>1</sup> | (0.05) |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.25) |
| Total from investment operations | (0.30) |
| Net asset value, end of period | $9.70 |
| Total return <sup>2</sup> | (3.00)%<sup>4</sup> |
| Net assets, at end of period (000s) | $10 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 6.23%<sup>5</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 1.97%<sup>5</sup> |
| Ratio of net investment loss to average net assets <sup>6</sup> | (0.90)%<sup>5</sup> |
| Portfolio Turnover Rate | 16%<sup>4</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Large Cap Focus Fund Class N commenced on June 30, 2022.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *Not annualized.* |
| | |
| *5.* | *Annualized.* |
| | |
| *6.* | *Recognition of net investment loss is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **96** |
| **E V E N T I D E** | **96** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Large Cap Focus Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout the Period Presented**

---

| | |
|:---|:---|
|  | *Class I* |
|  | *Six Months Ended* |
|  | *December 31, 2022 \** |
|  | *(Unaudited)* |
| Net asset value, beginning of period | $10.00 |
| Activity from investment operations: |  |
| &nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.01 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized loss on investments | (0.27) |
| Total from investment operations | (0.26) |
| Less distributions from: |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.01) |
| Total distributions | (0.01) |
| Net asset value, end of period | $9.73 |
| Total return <sup>2</sup> | (2.65)%<sup>4</sup> |
| Net assets, at end of period (000s) | $6051 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 5.23%<sup>5</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 0.97%<sup>5</sup> |
| Ratio of net investment income to average net assets <sup>6</sup> | 0.11%<sup>5</sup> |
| Portfolio Turnover Rate | 16%<sup>4</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Large Cap Focus Fund Class N commenced on June 30, 2022.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Not annualized.* |
| | |
| *5.* | *Annualized.* |
| | |
| *6.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **97** |
| **E V E N T I D E** | **97** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019 \** |
| Net asset value, beginning of period | $9.72 | $10.49 | $10.62 | $10.38 | $10.03 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.07 | 0.04 | 0.06 | 0.15 | 0.12 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.10) | (0.69) | (0.01) | 0.30 | 0.34 |
| Total from investment operations | (0.03) | (0.65) | 0.05 | 0.45 | 0.46 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.07) | (0.07) | (0.07) | (0.19) | (0.11) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.07) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.05) | (0.04) | (0.02) |  |
| Total distributions | (0.07) | (0.12) | (0.18) | (0.21) | (0.11) |
| Net asset value, end of period | $9.62 | $9.72 | $10.49 | $10.62 | $10.38 |
| Total return <sup>2</sup> | (0.34) %<sup>4</sup> | (6.26)% | 0.48% | 4.37% | 4.64% <sup>4</sup> |
| Net assets, at end of period (000s) | $19167 | $5622 | $6906 | $37973 | $1680 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 0.88% <sup>5</sup> | 0.84% | 0.86% | 1.11% | 2.41% <sup>5</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 0.75% <sup>5</sup> | 0.75% | 0.75% | 0.75% | 0.98% <sup>5</sup> |
| Ratio of net investment income to average net assets <sup>6</sup> | 1.39% <sup>5</sup> | 0.42% | 0.54% | 1.44% | 2.20% <sup>5</sup> |
| Portfolio Turnover Rate | 18% <sup>4</sup> | 48% | 72% | 71% | 60% <sup>4</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Limited-Term Bond Fund Class N commenced on December 14, 2018.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Not annualized.* |
| | |
| *5.* | *Annualized.* |
| | |
| *6.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **98** |
| **E V E N T I D E** | **98** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* |
|  | *Six Months* | *Year* | *Year* | *Year* | *Period* | *Year* | *Year* |
|  | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* |
|  | *December 31, 2022* | *June 30,* | *June 30,* | *June 30,* | *June 30,* | *October 31,* | *October 31,* |
|  | *(Unaudited)* | 2022 | 2021 | 2020 | 2019\* | 2018 | 2017 |
| Net asset value, beginning of period | $9.75 | $10.51 | $10.65 | $10.41 | $10.06 | $10.44 | $10.48 |
| Activity from investment operations: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.05 | 0.04 | 0.03 | 0.17 | 0.14 | 0.19 | 0.19 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.10) | (0.69) | 0.01<sup>4</sup> | 0.27 | 0.37 | (0.35) | (0.04) |
| Total from investment operations | (0.05) | (0.65) | 0.04 | 0.44 | 0.51 | (0.16) | 0.15 |
| Less distributions from: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.06) | (0.06) | (0.07) | (0.18) | (0.16) | (0.20) | (0.19) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.07) |  |  | (0.02) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.05) | (0.04) | (0.02) |  |  |  |
| Total distributions | (0.06) | (0.11) | (0.18) | (0.20) | (0.16) | (0.22) | (0.19) |
| Paid-in-capital from redemption fees <sup>1</sup> |  |  |  |  |  | 0.00<sup>5</sup> | 0.00<sup>5</sup> |
| Net asset value, end of period | $9.64 | $9.75 | $10.51 | $10.65 | $10.41 | $10.06 | $10.44 |
| Total return <sup>2</sup> | (0.46) %<sup>6</sup> | (6.20)% | 0.45% | 4.30% | 5.08% <sup>6</sup> | (1.52)% | 1.49% |
| Net assets, at end of period(000s) | $17543 | $22210 | $29596 | $12873 | $13977 | $17191 | $25479 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 0.93% <sup>7</sup> | 0.89% | 0.91% | 1.16% | 2.09% <sup>7</sup> | 1.62% | 1.58% |
| Ratio of net expenses to average net assets after expense reimbursement | 0.80% <sup>7</sup> | 0.80% | 0.80% | 0.80% | 1.08% <sup>7</sup> | 1.25% | 1.25% |
| Ratio of net investment income to average net assets <sup>8</sup> | 1.17% <sup>7</sup> | 0.37% | 0.27% | 1.63% | 2.05% <sup>7</sup> | 1.89% | 1.84% |
| Portfolio Turnover Rate | 18% <sup>6</sup> | 48% | 72% | 71% | 60% <sup>6</sup> | 27% | 49% |

---

---

| | |
|:---|:---|
| *\** | *Represents the period November 1, 2018 through June 30, 2019. See Note 1.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.* |
| | |
| *5.* | *Amount represents less than $0.01 per share.* |
| | |
| *6.* | *Not annualized.* |
| | |
| *7.* | *Annualized.* |
| | |
| *8.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **99** |
| **E V E N T I D E** | **99** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Period Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019 \** |
| Net asset value, beginning of period | $9.68 | $10.44 | $10.60 | $10.37 | $10.03 |
| Activity from investment operations: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income (loss) <sup>1</sup> | 0.02 | (0.04) | (0.05) | (0.01) | 0.07 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.09) | (0.68) | 0.01<sup>4</sup> | 0.37 | 0.35 |
| Total from investment operations | (0.07) | (0.72) | (0.04) | 0.36 | 0.42 |
| Less distributions from: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.03) | (0.02) | (0.01) | (0.10) | (0.08) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.07) |  |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.02) | (0.04) | (0.03) |  |
| Total distributions | (0.03) | (0.04) | (0.12) | (0.13) | (0.08) |
| Net asset value, end of period | $9.58 | $9.68 | $10.44 | $10.60 | $10.37 |
| Total return <sup>2</sup> | (0.72) %<sup>5</sup> | (6.94)% | (0.38)% | 3.50% | 4.24% <sup>5</sup> |
| Net assets, at end of period (000s) | $2114 | $1678 | $1545 | $401 | $72 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 1.68% <sup>6</sup> | 1.64% | 1.66% | 1.91% | 3.21% <sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement | 1.55% <sup>6</sup> | 1.55% | 1.55% | 1.55% | 1.78% <sup>6</sup> |
| Ratio of net investment income (loss) to average net assets <sup>7</sup> | 0.47% <sup>6</sup> | (0.37)% | (0.50)% | (0.08)% | 1.45% <sup>6</sup> |
| Portfolio Turnover Rate | 18% <sup>5</sup> | 48% | 72% | 71% | 60% <sup>5</sup> |

---

---

| | |
|:---|:---|
| *\** | *Eventide Limited-Term Bond Fund Class C commenced on December 14, 2018.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.* |
| | |
| *5.* | *Not annualized.* |
| | |
| *6.* | *Annualized.* |
| | |
| *7.* | *Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **100** |
| **E V E N T I D E** | **100** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Limited-Term Bond Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* |
|  | *Six Months* | *Year* | *Year* | *Year* | *Period* | *Year* | *Year* |
|  | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* | *Ended* |
|  | *December 31, 2022* | *June 30,* | *June 30,* | *June 30,* | *June 30,* | *October 31,* | *October 31,* |
|  | *(Unaudited)* | 2022 | 2021 | 2020 | 2019\* | 2018 | 2017 |
| Net asset value, beginning of period | $9.97 | $10.75 | $10.89 | $10.64 | $10.27 | $10.63 | $10.51 |
| Activity from investment operations: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.07 | 0.05 | 0.17 | 0.16 | 0.22 | 0.15 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.10) | (0.71) | 0.01<sup>4</sup> | 0.31 | 0.38 | (0.36) | (0.02) |
| Total from investment operations | (0.02) | (0.64) | 0.06 | 0.48 | 0.54 | (0.14) | 0.13 |
| Less distributions from: |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.08) | (0.08) | (0.09) | (0.21) | (0.17) | (0.20) | (0.01) |
| &nbsp;&nbsp;&nbsp;Net realized gains |  |  | (0.07) |  |  | (0.02) |  |
| &nbsp;&nbsp;&nbsp;Return of capital |  | (0.06) | (0.04) | (0.02) |  |  |  |
| Total distributions | (0.08) | (0.14) | (0.20) | (0.23) | (0.17) | (0.22) | (0.01) |
| Paid-in-capital from redemption fees |  |  |  |  |  | (0.00)<sup>5</sup> | (0.00)<sup>5</sup> |
| Net asset value, end of period | $9.87 | $9.97 | $10.75 | $10.89 | $10.64 | $10.27 | $10.63 |
| Total return <sup>2</sup> | (0.23) %<sup>6</sup> | (6.02)% | 0.65% | 4.58% | 5.30% <sup>6</sup> | (1.31)% | 1.20% |
| Net assets, at end of period(000s) | $102284 | $152546 | $144089 | $28847 | $3230 | $1030 | $889 |
| Ratio of gross expenses to average net assets before expense reimbursement <sup>3</sup> | 0.68% <sup>7</sup> | 0.64% | 0.66% | 0.91% | 1.97% <sup>7</sup> | 1.38% | 1.97% |
| Ratio of net expenses to average net assets after expense reimbursement | 0.55% <sup>7</sup> | 0.55% | 0.55% | 0.55% | 0.81% <sup>7</sup> | 1.00% | 1.64% |
| Ratio of net investment income to average net assets <sup>8</sup> | 1.43% <sup>7</sup> | 0.64% | 0.49% | 1.58% | 2.30% <sup>7</sup> | 2.10% | 1.41% |
| Portfolio Turnover Rate | 18% <sup>6</sup> | 48% | 72% | 71% | 60% <sup>6</sup> | 27% | 49% |

---

---

| | |
|:---|:---|
| *\** | *Represents the period November 1, 2018 through June 30, 2019. See Note 1.* |
| | |
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements by the manager.* |
| | |
| *4.* | *Due to the timing of shareholder transactions, and allocations of expenses among share classes, the per unit amounts presented may not coincide with the aggregate presentation on the Statements of Operations.* |
| | |
| *5.* | *Amount represents less than $0.01 per share.* |
| | |
| *6.* | *Not annualized.* |
| | |
| *7.* | *Annualized.* |
| | |
| *8.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **101** |
| **E V E N T I D E** | **101** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* | *Class N* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $12.12 | $14.21 | $11.38 | $10.90 | $10.58 | $11.05 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.10 | 0.08 | 0.16 | 0.28 | 0.34 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.04) | (1.35) | 2.95 | 0.60 | 0.39 | (0.30) |
| Total from investment operations | 0.04 | (1.25) | 3.03 | 0.76 | 0.67 | 0.04 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.09) | (0.21) | (0.18) | (0.14) | (0.22) | (0.36) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.12) | (0.63) | (0.02) |  | (0.03) | (0.15) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.14) | (0.10) |  |
| Total distributions | (0.21) | (0.84) | (0.20) | (0.28) | (0.35) | (0.51) |
| Net asset value, end of period | $11.95 | $12.12 | $14.21 | $11.38 | $10.90 | $10.58 |
| Total return <sup>2</sup> | 0.38% <sup>7</sup> | (9.58)% | 26.81% | 7.03% | 6.61% | 0.29% |
| Net assets, at end of period (000s) | $49065 | $34856 | $39947 | $19454 | $17104 | $17028 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.08% <sup>8</sup> | 1.01% | 1.05% | 1.19% | 1.30% | 1.29% <sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.02% <sup>8</sup> | 1.02% | 1.02% | 1.10% | 1.15% | 1.16% <sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,5</sup> | 1.31% <sup>8</sup> | 0.69% | 0.59% | 1.44% | 2.71% | 3.05% <sup>6</sup> |
| Portfolio Turnover Rate | 19% <sup>7</sup> | 66% | 73% | 107% | 79% | 29% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Not annualized.* |
| | |
| *8.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **102** |
| **E V E N T I D E** | **102** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* | *Class A* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $12.14 | $14.22 | $11.38 | $10.89 | $10.57 | $11.05 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.08 | 0.09 | 0.07 | 0.15 | 0.28 | 0.30 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.03) | (1.33) | 2.96 | 0.61 | 0.39 | (0.28) |
| Total from investment operations | 0.05 | (1.24) | 3.03 | 0.76 | 0.67 | 0.02 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.10) | (0.21) | (0.17) | (0.13) | (0.22) | (0.35) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.12) | (0.63) | (0.02) |  | (0.03) | (0.15) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.14) | (0.10) |  |
| Total distributions | (0.22) | (0.84) | (0.19) | (0.27) | (0.35) | (0.50) |
| Net asset value, end of period | $11.97 | $12.14 | $14.22 | $11.38 | $10.89 | $10.57 |
| Total return <sup>2</sup> | 0.35% <sup>7</sup> | (9.55)% | 26.84% | 7.07% | 6.56% | 0.15% |
| Net assets, at end of period (000s) | $25392 | $25744 | $23139 | $10659 | $8817 | $11864 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.13% <sup>8</sup> | 1.06% | 1.10% | 1.24% | 1.35% | 1.34% <sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.07% <sup>8</sup> | 1.07% | 1.07% | 1.15% | 1.20% | 1.21% <sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,5</sup> | 1.24% <sup>8</sup> | 0.65% | 0.55% | 1.39% | 2.63% | 2.74% <sup>6</sup> |
| Portfolio Turnover Rate | 19% <sup>7</sup> | 66% | 73% | 107% | 79% | 29% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Not annualized.* |
| | |
| *8.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **103** |
| **E V E N T I D E** | **103** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* | *Class C* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $12.06 | $14.15 | $11.34 | $10.86 | $10.55 | $11.03 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income (loss) <sup>1</sup> | 0.03 | (0.01) | (0.03) | 0.07 | 0.20 | 0.24 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.03) | (1.35) | 2.95 | 0.60 | 0.38 | (0.29) |
| Total from investment operations | (0.00)<sup>7</sup> | (1.36) | 2.92 | 0.67 | 0.58 | (0.05) |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.05) | (0.10) | (0.09) | (0.09) | (0.16) | (0.28) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.12) | (0.63) | (0.02) |  | (0.03) | (0.15) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.10) | (0.08) |  |
| Total distributions | (0.17) | (0.73) | (0.11) | (0.19) | (0.27) | (0.43) |
| Net asset value, end of period | $11.89 | $12.06 | $14.15 | $11.34 | $10.86 | $10.55 |
| Total return <sup>2</sup> | (0.02) %<sup>8</sup> | (10.33)% | 25.85% | 6.23% | 5.73% | (0.49)% |
| Net assets, at end of period (000s) | $16956 | $18146 | $18883 | $8091 | $6194 | $6654 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 1.88% <sup>9</sup> | 1.81% | 1.85% | 1.99% | 2.10% | 2.09% <sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 1.82% <sup>9</sup> | 1.82% | 1.82% | 1.90% | 1.95% | 1.96% <sup>6</sup> |
| Ratio of net investment income (loss) to average net assets <sup>4,5</sup> | 0.48% <sup>9</sup> | (0.10)% | (0.21)% | 0.64% | 1.90% | 2.19% <sup>6</sup> |
| Portfolio Turnover Rate | 19% <sup>8</sup> | 66% | 73% | 107% | 79% | 29% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income (loss) to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment income (loss) is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Amount represents less than $0.01 per share.* |
| | |
| *8.* | *Not annualized.* |
| | |
| *9.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **104** |
| **E V E N T I D E** | **104** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **Eventide Multi-Asset Income Fund** |
| **FINANCIAL HIGHLIGHTS** |

---

**Per Share Data and Ratios for a Share of Beneficial Interest Outstanding Throughout Each of the Years or Periods Presented**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* | *Class I* |
|  | *Six Months Ended* |  |  |  |  |  |
|  | *December 31, 2022* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* | *Year Ended* |
|  | *(Unaudited)* | *June 30, 2022* | *June 30, 2021* | *June 30, 2020* | *June 30, 2019* | *June 30, 2018* |
| Net asset value, beginning of period | $12.12 | $14.22 | $11.38 | $10.90 | $10.58 | $11.05 |
| Activity from investment operations: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net investment income <sup>1</sup> | 0.09 | 0.12 | 0.11 | 0.18 | 0.31 | 0.36 |
| &nbsp;&nbsp;&nbsp;Net realized and unrealized gain (loss) on investments | (0.03) | (1.35) | 2.95 | 0.60 | 0.38 | (0.31) |
| Total from investment operations | 0.06 | (1.23) | 3.06 | 0.78 | 0.69 | 0.05 |
| Less distributions from: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net investment income | (0.11) | (0.24) | (0.20) | (0.15) | (0.23) | (0.37) |
| &nbsp;&nbsp;&nbsp;Net realized gains | (0.12) | (0.63) | (0.02) |  | (0.03) | (0.15) |
| &nbsp;&nbsp;&nbsp;Return of capital |  |  |  | (0.15) | (0.11) |  |
| Total distributions | (0.23) | (0.87) | (0.22) | (0.30) | (0.37) | (0.52) |
| Net asset value, end of period | $11.95 | $12.12 | $14.22 | $11.38 | $10.90 | $10.58 |
| Total return <sup>2</sup> | 0.48% <sup>7</sup> | (9.46)% | 27.12% | 7.23% | 6.81% | 0.47% |
| Net assets, at end of period (000s) | $263296 | $269421 | $279142 | $110295 | $79513 | $76764 |
| Ratio of gross expenses to average net assets before expense reimbursement/recapture <sup>3,4</sup> | 0.88% <sup>8</sup> | 0.81% | 0.85% | 0.99% | 1.10% | 1.09% <sup>6</sup> |
| Ratio of net expenses to average net assets after expense reimbursement/recapture <sup>4</sup> | 0.82% <sup>8</sup> | 0.82% | 0.82% | 0.90% | 0.95% | 0.96% <sup>6</sup> |
| Ratio of net investment income to average net assets <sup>4,5</sup> | 1.49% <sup>8</sup> | 0.90% | 0.81% | 1.65% | 2.92% | 3.32% <sup>6</sup> |
| Portfolio Turnover Rate | 19% <sup>7</sup> | 66% | 73% | 107% | 79% | 29% |

---

---

| | |
|:---|:---|
| *1.* | *Per share amounts calculated using the average shares method.* |
| | |
| *2.* | *Total return in the above table is historical in nature and represents the rate that the investor would have earned or lost on an investment in the Fund assuming reinvestment of dividends and capital gain distributions, if any and does not reflect the impact of sales charges. Had the manager not waived a portion of the Fund's expenses in certain periods, total returns would have been lower.* |
| | |
| *3.* | *Represents the ratio of expenses to average net assets absent fee waivers and/or expense reimbursements/recapture by the manager.* |
| | |
| *4.* | *The ratios of expenses to average net assets and net investment income to average net assets do not reflect the expenses of the underlying investment companies in which the Fund invests.* |
| | |
| *5.* | *Recognition of net investment income is affected by the timing and declaration of dividends by the underlying investment companies in which the Fund invests.* |
| | |
| *6.* | *The ratios include 0.01% for the year ended June 30, 2018 attributed to interest expense.* |
| | |
| *7.* | *Not annualized.* |
| | |
| *8.* | *Annualized.* |

---

*See accompanying notes to financial statements.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **105** |
| **E V E N T I D E** | **105** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | |
|:---|:---|
| **Eventide Funds** |  |
| **Notes to Financial Statements** | **December 31, 2022** |

---

**1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES**

Mutual Fund Series Trust (the *"**Trust**"*), was organized as an Ohio business trust on February 27, 2006. The Trust is registered as an open-end management investment company under the Investment Company Act of 1940, as amended (*"**1940 Act**"*). The Trust currently consists of thirty-six series. These financial statements include the following series: Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, Eventide Limited-Term Bond Fund and the Eventide Multi-Asset Income Fund (each a *"**Fund**"* or collectively the *"**Funds**"*). Each Fund except Eventide Exponential Technologies Fund and Eventide Large Cap Focus Fund is a diversified series of the Trust. Eventide Exponential Technologies Fund and Eventide Large Cap Focus Fund are non-diversified series of the Trust. The Funds' investment manager is Eventide Asset Management, LLC (the *"**Manager**"*).

Eventide Core Bond Fund commenced operations on July 31, 2020. The Fund's investment objective is total return consistent with income generation.

Eventide Dividend Opportunities Fund commenced operations on September 29, 2017. The Fund's investment objectives are dividend income and long-term capital appreciation. The Fund's secondary objective is dividend growth.

Eventide Exponential Technologies Fund commenced operations on June 30, 2020. The Fund's investment objective is long-term capital appreciation.

Eventide Gilead Fund commenced operations on July 8, 2008. The Fund's investment objective is long-term capital appreciation.

Eventide Healthcare & Life Sciences Fund commenced operations on December 27, 2012. The Fund's investment objective is long-term capital appreciation.

Eventide Large Cap Focus Fund commenced operations on June 30, 2022. The Fund's investment objective is long-term capital appreciation.

Eventide Limited-Term Bond Fund (formerly Epiphany FFV Strategic Income Fund) Class A and Class I shares commenced operations on July 28, 2010. On March 29, 2017, the Board of Trustees of Epiphany Funds voted to reclassify (the *"**Conversion**"*) all outstanding Class C Shares of the Epiphany FFV Strategic Income Fund to Class I shares to be effective on May 30, 2017 (the *"**Conversion Date**"*). On the Conversion Date, each Class C share was reclassified as a Class I shares equal in value to the Class C shares owned by that shareholder. The Eventide Limited-Term Bond Fund's Class N and Class C shares commenced operations December 14, 2018. The Fund changed its fiscal year end from October 31 to June 30. The Fund's investment objective is income.

Eventide Multi-Asset Income Fund commenced operations on July 15, 2015. The Fund's investment objective is current income while maintaining the potential for capital appreciation.

---

| | |
|:---|:---|
| **E V E N T I D E** | **106** |
| **E V E N T I D E** | **106** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

Each Fund offers four classes of shares, Class N, Class A, Class C and Class I. Each class differs as to sales and redemption charges and ongoing fees.

The following is a summary of significant accounting policies consistently followed by the Funds and are in accordance with accounting principles generally accepted in the United States of America (*"**GAAP**"*). The Funds are investment companies and accordingly follow the investment company accounting and reporting guidance of the Financial Accounting Standards Board (FASB) Accounting Standards Codification Topic 946 "Financial Services – Investment Companies" including Accounting Standards Update 2013-08.

**a) Securities Valuation** – Securities listed on an exchange are valued at the last reported sale price at the close of the regular trading session of the exchange on the business day the value is being determined, or in the case of securities listed on NASDAQ, at the NASDAQ Official Closing Price (*"**NOCP**"*). In the absence of a sale, such securities shall be valued at the last bid price on the day of valuation. Debt securities (other than short-term obligations) are valued each day by an independent pricing service approved by the Board of Trustees (the *"**Board**"*) using methods which include current market quotations from a major market maker in the securities and based on methods which include the consideration of yields or prices of securities of comparable quality, coupon, maturity and type. The Funds may invest in portfolios of open-end or closed-end investment companies (the *"**underlying funds**"*). Open-end investment companies are valued at their respective net asset values as reported by such investment companies. The underlying funds value securities in their portfolios for which market quotations are readily available at their market values (generally the last reported sale price) and all other securities and assets at their fair value by the methods established by the boards of trustees of the underlying funds. The shares of many closed-end investment companies, after their initial public offering, frequently trade at a price per share, which is different than the net asset value per share. The difference represents a market premium or market discount of such shares. There can be no assurances that the market discount or market premium on shares of any closed-end investment company purchased by the Funds will not change. The independent pricing service does not distinguish between smaller-sized bond positions known as "odd lots" and larger institutional-sized bond positions known as "round lots". The Funds may fair value a particular bond if the manager does not believe that the round lot value provided by the independent pricing service reflects fair value of the Fund's holding. Short term debt obligations having 60 days or less remaining until maturity, at time of purchase, may be valued at amortized cost, provided each such valuations represent fair value. Options are valued at their closing price on the exchange they are traded on. When no closing price is available, options are valued at their mean price.

The Fund may hold securities, such as private investments, interests in commodity pools, other non-traded securities or temporarily illiquid securities, for which market quotations are not readily available or are determined to be unreliable. These securities are valued using the "fair value" procedures approved by the Board. The Board has designated the adviser as its valuation designee (the "Valuation Designee") to execute these procedures. The Board may also enlist third party consultants such a valuation specialist at a public accounting firm, valuation consultant or financial officer of a security issuer on an as-needed basis to assist the Valuation Designee in determining a security-specific fair value. The Board is responsible for reviewing and approving fair value methodologies utilized by the Valuation Designee, approval of which shall be based upon whether the Valuation Designee followed the valuation procedures established by the Board.

---

| | |
|:---|:---|
| **E V E N T I D E** | **107** |
| **E V E N T I D E** | **107** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

The Funds utilize various methods to measure the fair value of most of their investments on a recurring basis. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of input are:

■ Level
1 – Unadjusted quoted prices in active markets for identical assets and liabilities that the Funds have the ability to access.

■ Level
2 – Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly
or indirectly. These inputs may include quoted prices for the identical instrument in an inactive market, prices for similar instruments,
interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

■ Level
3 – Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the
Funds' own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based
on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. The following tables summarize the inputs used as of December 31, 2022 for the Funds' assets measured at fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Core Bond Fund Assets** | **Eventide Core Bond Fund Assets** | **Eventide Core Bond Fund Assets** | **Eventide Core Bond Fund Assets** | **Eventide Core Bond Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Asset Backed Securities <sup>1</sup> | $— | $4573043 | $— | $4573043 |
| Corporate Bonds <sup>1</sup> |  | 28218108 |  | 28218108 |
| Municipal Bonds <sup>1</sup> |  | 5585068 |  | 5585068 |
| U.S. Government & Agencies <sup>1</sup> |  | 14163742 |  | 14163742 |
| **Total** | $— | $52539961 | $— | $52539961 |
| **Eventide Dividend Opportunities Fund Assets** | **Eventide Dividend Opportunities Fund Assets** | **Eventide Dividend Opportunities Fund Assets** | **Eventide Dividend Opportunities Fund Assets** | **Eventide Dividend Opportunities Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $461640575 | $— | $— | $461640575 |
| Preferred Stocks <sup>1</sup> | 18926566 |  |  | 18926566 |
| Corporate Bonds <sup>1</sup> |  | 2000300 | 2000000 | 4000300 |
| Short-Term Investments | 1408497 |  |  | 1408497 |
| **Total** | $481975638 | $2000300 | $2000000 | $485975938 |
| **Eventide Exponential Technologies Fund Assets** | **Eventide Exponential Technologies Fund Assets** | **Eventide Exponential Technologies Fund Assets** | **Eventide Exponential Technologies Fund Assets** | **Eventide Exponential Technologies Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $82462612 | $— | $— | $82462612 |
| Corporate Bond <sup>1</sup> |  | 900135 |  | 900135 |
| Short-Term Investments | 11627 |  |  | 11627 |
| **Total** | $82474239 | $900135 | $— | $83374374 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **108** |
| **E V E N T I D E** | **108** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Eventide Gilead Fund Assets** | **Eventide Gilead Fund Assets** | **Eventide Gilead Fund Assets** | **Eventide Gilead Fund Assets** | **Eventide Gilead Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $3015756138 | $— | $— | $3015756138 |
| Contingent Value Rights <sup>1</sup> |  |  | 2906351 | 2906351 |
| Private Investments <sup>1</sup> |  |  | 32492360 | 32492360 |
| Corporate Bonds <sup>1</sup> |  | 24001800 | 27000000 | 51001800 |
| Warrant <sup>1</sup> |  |  | 1899799 | 1899799 |
| Short-Term Investment | 33374557 |  |  | 33374557 |
| **Total** | $3049130695 | $24001800 | $64298510 | $3137431005 |
| **Eventide Healthcare & Life Sciences Fund Assets** | **Eventide Healthcare & Life Sciences Fund Assets** | **Eventide Healthcare & Life Sciences Fund Assets** | **Eventide Healthcare & Life Sciences Fund Assets** | **Eventide Healthcare & Life Sciences Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $1319309929 | $— | $— | $1319309929 |
| Contingent Value Rights <sup>1</sup> |  |  | 1115617 | 1115617 |
| Private Investments <sup>1</sup> |  | 580994 | 95637849 | 96218843 |
| Warrant <sup>1</sup> |  |  | 949847 | 949847 |
| Short-Term Investment | 78013177 |  |  | 78013177 |
| **Total** | $1397323106 | $580994 | $97703313 | $1495607413 |
| **Eventide Large Cap Focus Fund Assets** | **Eventide Large Cap Focus Fund Assets** | **Eventide Large Cap Focus Fund Assets** | **Eventide Large Cap Focus Fund Assets** | **Eventide Large Cap Focus Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $5722829 | $— | $— | $5722829 |
| Short-Term Investment | 277572 |  |  | 277572 |
| **Total** | $6000401 | $— | $— | $6000401 |
| **Eventide Limited-Term Bond Fund Assets** | **Eventide Limited-Term Bond Fund Assets** | **Eventide Limited-Term Bond Fund Assets** | **Eventide Limited-Term Bond Fund Assets** | **Eventide Limited-Term Bond Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Asset Backed Securities <sup>1</sup> | $— | $10834057 | $— | $10834057 |
| Collateralized Mortgage Obligations <sup>1</sup> |  | 57660 |  | 57660 |
| Corporate Bonds <sup>1</sup> |  | 80383107 |  | 80383107 |
| Municipal Bonds <sup>1</sup> |  | 9925538 |  | 9925538 |
| U.S. Government & Agencies <sup>1</sup> |  | 34921586 |  | 34921586 |
| **Total** | $— | $136121948 | $— | $136121948 |
| **Eventide Multi-Asset Income Fund Assets** | **Eventide Multi-Asset Income Fund Assets** | **Eventide Multi-Asset Income Fund Assets** | **Eventide Multi-Asset Income Fund Assets** | **Eventide Multi-Asset Income Fund Assets** |
| *Security Classifications* | *Level 1* | *Level 2* | *Level 3* | *Totals* |
| Common Stocks <sup>1</sup> | $159664649 | $— | $— | $159664649 |
| Preferred Stocks <sup>1</sup> | 10749866 |  |  | 10749866 |
| Asset Backed Securities <sup>1</sup> |  | 6644337 |  | 6644337 |
| Collateralized Mortgage Obligations <sup>1</sup> |  | 1800921 |  | 1800921 |
| Corporate Bonds <sup>1</sup> |  | 87715729 | 3800000 | 91515729 |
| Municipal Bonds <sup>1</sup> |  | 7556112 |  | 7556112 |
| U.S. Government & Agencies <sup>1</sup> |  | 66146862 |  | 66146862 |
| Short-Term Investments | 103257 |  |  | 103257 |
| **Total** | $170517772 | $169863961 | $3800000 | $344181733 |

---

*1.* *For a detailed break-out of investments by industry, please refer to the Schedule of Investments.* 

---

| | |
|:---|:---|
| **E V E N T I D E** | **109** |
| **E V E N T I D E** | **109** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

The following is a reconciliation of assets in which level 3 inputs were used in determining value:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** |  |  |  |
|  | *Corporate Bonds* | *Total* |  |  |  |
| Beginning balance 6/30/2022 | $2000000 | $2000000 |  |  |  |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) |  |  |  |  |  |
| Cost of purchases |  |  |  |  |  |
| Proceeds from sales |  |  |  |  |  |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2022 | $2000000 | $2000000 |  |  |  |
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |  |  |  |
|  | *Contingent Value* |  |  |  |  |
|  | *Rights* | *Private Investments* | *Corporate Bonds* | *Warrant* | *Total* |
| Beginning balance 6/30/2022 | $3068855 | $32492360 | $22000000 | $1899799 | $59461014 |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) | (162504) |  |  |  | (162504) |
| Cost of purchases |  |  | 5000000 |  | 5000000 |
| Proceeds from sales |  |  |  |  |  |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2022 | $2906351 | $32492360 | $27000000 | $1899799 | $64298510 |
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |  |  |  |
|  | *Contingent Value* |  |  |  |  |
|  | *Rights* | *Private Investments* | *Convertible Bonds* | *Warrant* | *Total* |
| Beginning balance 6/30/2022 | $1177995 | $126990296 | $795520 | $949847 | $129913658 |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) | (62378) | (33580781) | 41870 |  | (33601289) |
| Cost of purchases |  | 2228334 |  |  | 2228334 |
| Proceeds from sales |  |  |  |  |  |
| Corporate Action |  |  | (837390) |  | (837390) |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2022 | $1115617 | $95637849 | $— | $949847 | $97703313 |
| **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** |  |  |  |
|  | *Corporate Bonds* | *Total* |  |  |  |
| Beginning balance 6/30/2022 | $3800000 | $3800000 |  |  |  |
| Total realized gain (loss) |  |  |  |  |  |
| Change in unrealized appreciation (depreciation) |  |  |  |  |  |
| Cost of purchases |  |  |  |  |  |
| Proceeds from sales |  |  |  |  |  |
| Net transfers in/out of level 3 |  |  |  |  |  |
| Ending balance 12/31/2022 | $3800000 | $3800000 |  |  |  |

---

------

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Arch Oncology, Inc. Series C1 are as follows: (1) recent investor transactions in the company (2) updates from the company including new clinical trials data and (3) a ninety-percent discount to cost based on termination of trial and estimated remaining cash and wind-down expenses.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Beta Bionic Series B, Beta Bionic Series B2, Beta Bionic Series C, Beta Bionics Series C Warrant, are as follows: (1) recent investor transactions in the companies (2) updates from the companies including new clinical trials data and (3) a five-percent discount off of the Series C cost, adjusted valuation to reflect the Series C financing

---

| | |
|:---|:---|
| **E V E N T I D E** | **110** |
| **E V E N T I D E** | **110** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

valuation, including the impact of dilution shares and warrants that came with Series C. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in BioSplice Therapeutics were as follows: (1) recent investor transactions in the company (2) updates from the company including new clinical trials data and (3) a sixty-percent discount to cost based on lower probability of success. A significant increase or decrease in the estimated probability of success could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Casma Therapeutics, Inc. Series B1, Casma Therapeutics, Inc. Series B2, Casma Therapeutics, Inc. Series C1, Flare Therapeutics, Inc. Series A, Flare Therapeutics, Inc. Series A2, Kojin Therapeutics, Inc. Series A-1, Kojin Therapeutics, Inc. Series A-2, Korro Bio, Inc. Series B1, LEXEO Therapeutics Series B, Metagenomi, LLC Series B, Metagenomi, LLC Series B-1, Prometheus Laboratories, Inc., and Shoreline Biosciences Series B private investments are as follows: (1) recent investor transactions in the companies (2) updates from the companies including new clinical trials data and (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Freenome Holdings, Inc. Series D are as follows: (1) recent investor transactions in the company (2) updates from the company including new clinical trials data and (3) a 5% discount to an approximate 44% write-down to Series E Strategic Investment price. Valuation is supported by update to model which included lowering peak sales and adjusting weighted probabilities. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Goldfinch Biopharma, Inc. Series A, Goldfinch Biopharma, Inc. Series B, Goldfinch Biopharma, Inc. Series B2 are as follows: (1) recent investor transactions in the companies (2) updates from the companies and (3) a 100% write-down. Lead investor is walking away from Series C Funding. The current investor syndicate is unable to fill funding gap. Goldfinch management has immediately transitioned to wind down the company.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Turnstone Biologics, Inc. Series D, are as follows: (1) recent investor transactions in the company (2) updates from the company including new clinical trials data and (3) a five-percent discount to an approximate 58.9% write-down to Series D price based on relevant public comps. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private note in Vision Fund International are as follows: (1) credit quality of the issuer, and (2) underlying business conditions for the issuer. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

---

| | |
|:---|:---|
| **E V E N T I D E** | **111** |
| **E V E N T I D E** | **111** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | |
|:---|:---|:---|:---|
| *Fair Value at December 31, 2022* | *Valuation Techniques* | *Unobservable Input* | *Impact to Valuation* |
| 100% | The Manager plans to hold these securities to maturity and monitor's the issuer's ability to pay interest and principal and additional financial risk metrics and views par as the appropriate valuation. The initial interest rate was set with a spread to the relevant benchmark to compensate for liquidity and interest rate risks. | There is no active market for these securities however there is significant credit coverage for the loans, the Manager believes the issuer will be current with interest payments and pay principal in full at maturity. | A decline credit quality of the issuer could decrease the value of the security. |

---

The significant unobservable inputs used in the fair value measurement of the Funds' Level 3 private investment in Peloton Therapeutics, Inc. contingent value rights are as follows: (1) updated valuations to reflect recent milestone payments, (2) DCF model reflecting the Manager's probability of success for achieving the remaining milestone payments and (3) a five-percent discount based on liquidity of the securities held. A significant increase or decrease in the liquidity discount could result in a significantly lower or higher fair value, respectively.

---

| | | | |
|:---|:---|:---|:---|
| *Fair Value at December 31, 2022* | *Valuation Techniques* | *Unobservable Input* | *Impact to Valuation* |
| $0.73 | Anticipated sale price less discounts plus discounted cash flow of contingent future payments. | 2.5 - 75% range NPV of the milestone payments using POS (probability of success) based on our diligence for each milestone. 5% Liquidity Risk | Increase (Decrease) in Rate of Success Ratio equals increases (decreases) value |

---

The total change in unrealized depreciation included in the Statements of Operations attributable to Level 3 investments still held at December 31, 2022 was $0, $162,504, $33,601,289 and $0 for the Eventide Dividend Opportunities Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund and Eventide Multi-Asset Income Fund, respectively.

**b) Accounting for Options** – When the Funds write an option, an amount equal to the premium received by the Funds is recorded as a liability and is subsequently adjusted to the current fair value of the option written. Premiums received from writing options that expire unexercised are treated by the Funds on the expiration date as realized gains from investments. The difference between the premium and the amount paid on effecting a closing purchase transaction, including brokerage commissions, is also treated as a realized gain, or, if the premium is less than the amount paid for the closing purchase transaction, as a realized loss. If a call option is exercised, the premium is added to the proceeds from the sale of the underlying security or currency in determining whether the Funds have realized gains or losses. If a put option is exercised, the premium reduces the cost basis of the securities purchased by the Funds.

The Manager may use options strategies, such as puts and covered calls on individual securities, as well as options on securities indices, to generate income, to reduce portfolio volatility, or to reduce downside risk when the manager believes adverse market, political or other conditions are likely. The Manager may also utilize a combination of puts and/or calls regarding the same security (sometimes referred to as "straddles," "collars" or "spreads") or utilize puts and calls on related securities. The Funds may purchase a call option on a stock (including securities of exchange traded funds (*"**ETFs**"*)) it may purchase at some point in the future. When the Funds purchase an option, the premium paid is recorded as an asset. Each day the option contract is valued in accordance with the procedures for security valuation discussed above. When an offsetting option is written (a closing transaction) or the option contract expires, the Funds realize a gain or loss and the asset representing

---

| | |
|:---|:---|
| **E V E N T I D E** | **112** |
| **E V E N T I D E** | **112** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

such option contract is eliminated. When a put option is exercised, the Funds realize a gain or loss from the sale of the underlying security and the proceeds of the sale are decreased by the premiums originally paid. When a call option is exercised, the Funds purchase the underlying security and the cost basis of such purchase is increased by the premium originally paid.

**c) Short Sales** – The Funds may sell securities short. A short sale is a transaction in which the Funds sell securities they do not own in anticipation of a decline in the market price of the securities. To deliver the securities to the buyer, the Funds must arrange through a broker to borrow the securities and, in so doing, the Funds become obligated to replace the securities borrowed at their market price at the time of replacement, whatever that price may be. The Funds will make a profit or incur a loss as a result of a short sale depending on whether the price of the securities decrease or increase between the date of the short sale and the date on which the Funds purchased the securities to replace the borrowed securities that have been sold.

**d) Federal Income Tax** – The Funds have qualified and intend to continue to qualify as regulated investment companies and to comply with the applicable provisions of the Internal Revenue Code of 1986, as amended, and to distribute substantially all of their taxable income to their shareholders. Therefore, no federal income or excise tax provisions are required.

As of and during the six months ended December 31, 2022, the Funds did not have a liability for any unrecognized tax expense. The Funds recognize interest and penalties, if any, related to unrecognized tax expense as income tax expense in the Statements of Operations. As of December 31, 2022, the Funds did not incur any interest or penalties. Management has analyzed the Funds' tax positions and has concluded that no liability for unrecognized tax benefits should be recorded related to uncertain tax positions taken on returns filed for open tax years ended June 30, 2020 to June 30, 2022 or expected to be taken in the Funds' June 30, 2023 year-end tax return.

**e) Distributions to Shareholders** – Distributions to shareholders, which are determined in accordance with income tax regulations and may differ from GAAP, are recorded on the ex-dividend date. Each Fund typically distributes substantially all of its net investment income in the form of dividends, interest and taxable capital gains to its shareholders. These distributions are automatically reinvested in the Fund unless you request cash distributions on your application or through a written request to the Fund. Each Fund expects that its distributions will consist of both capital gains and net investment income. Each Fund may make distributions of its net realized capital gains (after any reductions for capital loss carry forwards) annually. The Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, Eventide Limited-Term Bond Fund and the Eventide Multi-Asset Income Fund intend to make annual capital gains distributions if applicable. The Eventide Core Bond Fund, Eventide Dividend Opportunities Fund and Eventide Large Cap Focus Fund intend to make quarterly income distributions if applicable. The Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund intend to make monthly income distributions if applicable.

**f) Multiple Class Allocations** – Income, non-class specific expenses and realized/unrealized gains or losses are allocated to each class based on relative net assets. Distribution fees are charged to each respective share class in accordance with the distribution plan. Expenses of the Trust that are directly identifiable to a specific fund are charged to that fund. Expenses, which are not readily identifiable to a specific fund, are allocated in such a manner as deemed equitable, taking into consideration the nature and type of expense and the relative sizes of the funds in the Trust.

---

| | |
|:---|:---|
| **E V E N T I D E** | **113** |
| **E V E N T I D E** | **113** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**g) Security Transactions and Investment Income** – Investment and shareholder transactions are recorded on the trade date. The Funds determine the gain or loss realized from the investment transactions by comparing the specific identified cost of the security lot sold with the net sales proceeds. Dividend income is recognized on the ex-dividend date or as soon as information is available to the Funds and interest income is recognized on an accrual basis. Discounts and premiums on debt securities are amortized over their respective lives using the effective interest method, except certain callable debt securities that are held at premium and will be amortized to the earliest call date. Withholding taxes on foreign dividends have been provided for in accordance with the Funds' understanding of the applicable country's tax rules and rates. Distributions received from a Fund's investments in MLPs generally are comprised of income and return of capital. The Funds record these distributions as investment income and subsequently adjusts these distributions within the components of net assets based upon their tax treatment when the information becomes available. Distribution from REITs are initially recorded as dividend income and, to the extent such represent a return of capital or capital gain for tax purposes, are reclassified when such information becomes available.

**h) Use of Estimates** – The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**i) Indemnification** – The Trust indemnifies its offers and Trustees for certain liabilities that may arise from the performance of their duties to the Trust. In the normal course of business, the Trust may enter into contracts that contain a variety of representations and warranties and provide general indemnifications. The Funds' maximum exposure under these arrangements is dependent on future claims that may be made against the Funds and, therefore, cannot be estimated; however, management considers the risk of loss from such claims to be remote.

**j) Redemption Fees and Sales Charges (loads)** – A $15 fee may be charged for redemptions made by wire. Redemptions of Eventide Exponential Technologies Fund within 180 days of purchase are subject to a redemption fee of 1.00%. A maximum sales charge of 5.75% is imposed on Class A shares of the Funds. The maximum deferred sales charge on Class A shares applies only to purchases of $1 million or more made without an initial sales charge and applies to shares sold within 18 months of purchase. The maximum deferred sales charge on Class C shares applies to shares sold within 12 months of purchase. Class A shares purchased where the sales charge was waived, are subject to a CDSC of 1.00% on redemptions within 180 days of purchase. The respective shareholders pay such CDSC charges, which are not an expense of the Funds. For the six months ended December 31, 2022, Eventide Core Bond Fund and Eventide Large Cap Focus Fund had $0 redemption fees paid to the fund and $0 CDSC fees paid to the distributor. For the six months ended December 31, 2022, there were the following redemption fees paid to the fund and CDSC fees paid to the distributor:

---

| | | | |
|:---|:---|:---|:---|
|  |  | *CDSC Fees* | *CDSC Fees* |
| *Fund* | *Redemption Fees* | *Class A* | *Class C* |
| Eventide Dividend Opportunities Fund | $— | $82 | $677 |
| Eventide Exponential Technologies Fund | 80245 |  | 372 |
| Eventide Gilead Fund |  | 22 | 1793 |
| Eventide Healthcare & Life Sciences Fund |  | 128 | 1698 |
| Eventide Limited-Term Bond Fund |  |  | 176 |
| Eventide Multi-Asset Income Fund |  | 37 | 251 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **114** |
| **E V E N T I D E** | **114** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**k) Cash and cash equivalents** – Cash and cash equivalents are held with a financial institution. The asset of the Funds may be placed in deposit accounts at U.S. banks and such deposits generally exceed Federal Deposit Insurance Corporation (*"**FDIC**"*) insurance limits. The FDIC insures deposit accounts up to $250,000 for each accountholder. The counterparty is generally a single bank rather than a group of financial institutions; thus there may be a greater counterparty credit risk. The Funds place deposits only with those counterparties which are believed to be creditworthy and there has been no history of loss.

**2. INVESTMENT TRANSACTIONS**

For the six months ended December 31, 2022, aggregate purchases and proceeds from sales of investment securities (excluding short-term investments) for the Funds were as follows:

---

| | | |
|:---|:---|:---|
| *Fund* | *Purchases* | *Sales* |
| Eventide Core Bond Fund | $13189585 | $28706440 |
| Eventide Dividend Opportunities Fund | 176181083 | 88804846 |
| Eventide Exponential Technologies Fund | 51989875 | 39105916 |
| Eventide Gilead Fund | 630701814 | 677995934 |
| Eventide Healthcare & Life Sciences Fund | 592255682 | 590948733 |
| Eventide Large Cap Focus Fund | 6487758 | 525495 |
| Eventide Limited-Term Bond Fund | 30509584 | 70122998 |
| Eventide Multi-Asset Income Fund | 81899842 | 70260392 |

---

**3. INVESTMENT ADVISORY AGREEMENT AND TRANSACTIONS WITH RELATED PARTIES**

Eventide Asset Management, LLC acts as investment manager to the Funds pursuant to the terms of a management agreement between the Manager and the Trust (the *"**Management Agreement**"*). Since December 14, 2018, Eventide Asset Management, LLC serves as investment adviser to the Eventide Limited-Term Bond Fund. Prior to December 14, 2018, Trinity Fiduciary Partners, LLC (*"**Trinity**"*) served as the investment adviser to Epiphany FFV Strategic Income Fund (*"**Epiphany FFV Fund**"*), the predecessor to Eventide Limited-Term Bond Fund. Boyd Watterson Asset Management, LLC serves as sub-adviser to the Eventide Limited-Term Bond Fund, the Eventide Core Bond Fund, and a portion of the Eventide Multi-Asset Income Fund's portfolio. Under the terms of the Management Agreement, the Manager manages the investment operations of the Funds in accordance with the Funds' investment policies and restrictions. The Manager provides the Funds with investment advice and supervision and furnishes an investment program for the Funds. The fees paid by the Funds to the Manager are described in greater detail below. Prior to March 2, 2020, Eventide Multi-Asset Income Fund paid to the manager, as of the last day of each month, an annualized fee equal to 0.73% of its average net assets. Prior to December 14, 2018, the Epiphany FFV Fund paid to Trinity, as of the last day of each month, an annualized fee equal to 0.45% of its average net assets. The Manager pays expenses incurred by it in connection with acting as investment manager to the Funds other than costs (including taxes and brokerage commissions, borrowing costs, costs of investing in underlying funds and extraordinary expenses, if any) of securities purchased for the Funds and certain other expenses paid by the Funds (as detailed in the Management Agreement). The Manager pays for all employees, office space and facilities required by it to provide services under the Management Agreement, with the exception of specific items of expense (as detailed in the Management Agreement). For the six months ended December 31, 2022, management fees of $123,095, $1,749,514, $552,583, $17,589,012, $8,441,927, $11,406, $288,745 and $1,093,614 were incurred by the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, Eventide Limited-

---

| | |
|:---|:---|
| **E V E N T I D E** | **115** |
| **E V E N T I D E** | **115** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

Term Bond Fund and Eventide Multi-Asset Income Fund, respectively, before the waivers and reimbursements described below.

Each Fund is authorized to pay the Manager an annual fee based on its average daily net assets. The management fee is paid monthly. The Manager has contractually agreed to waive fees and/or reimburse expenses, but only to the extent necessary to maintain each Fund's total annual operating expenses (excluding front-end or contingent deferred loads, taxes, leverage interest, brokerage commissions, expenses incurred in connection with any merger or reorganization, dividend expense on securities sold short, underlying fund fees and expenses or extraordinary expenses such as litigation) at a certain level through October 31, 2023. This agreement may be terminated by the Board only on 60 days' written notice to the Manager and upon the termination of the Management Agreement between the Trust and the Manager. Fee waivers and expense reimbursements are subject to possible recoupment by the Manager from the Funds in future years on a rolling three-year basis (within the three years after the fees have been waived or reimbursed) if, after the recoupment is taken into account, such recoupment can be achieved within the lesser of the expense limitation in place at the time of waiver/reimbursement and the expense limitation in place at the time of recapture. Prior to December 14, 2018, Trinity had contractually agreed to waive fees and/or reimburse expenses but only to the extent necessary to maintain total annual operating expenses at 1.25% and 1.00% of the average daily net assets of Epiphany FFV Fund's Class A and Class I. Each waiver or reimbursement by the Manager is subject to repayment by the Fund within the three years following the year in which that particular expense is incurred, if the Fund is able to make the repayment without exceeding the expense limitation in effect at that time and the repayment is approved by the Board.

---

| | |
|:---|:---|
| **E V E N T I D E** | **116** |
| **E V E N T I D E** | **116** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

The following table lists the contractual management fee and the expense limitation for each Fund.

---

| | | | |
|:---|:---|:---|:---|
| *Fund* | *Contractual Advisory Fee* | *Expense Limitation* | *Expense Limitation* |
| Eventide Core Bond Fund | 0.36% | Class N: | 0.78% |
|  |  | Class A: | 0.83% |
|  |  | Class C: | 1.58% |
|  |  | Class I: | 0.58% |
| Eventide Dividend Opportunities Fund | 0.73% | Class N: | 1.15% |
|  |  | Class A: | 1.20% |
|  |  | Class C: | 1.95% |
|  |  | Class I: | 0.95% |
| Eventide Exponential Technologies Fund | 1.10% | Class N: | 1.63% |
|  |  | Class A: | 1.68% |
|  |  | Class C: | 2.43% |
|  |  | Class I: | 1.43% |
| Eventide Gilead Fund | 1.00% of the first $2 billion; | Class N: | 1.62% |
|  | 0.95% on the next $1 billion; | Class A: | 1.67% |
|  | 0.90% on the next $1 billion; | Class C: | 2.42% |
|  | and 0.85% thereafter | Class I: | 1.42% |
| Eventide Healthcare & Life Sciences Fund | 1.10% | Class N: | 1.63% |
|  |  | Class A: | 1.68% |
|  |  | Class C: | 2.43% |
|  |  | Class I: | 1.43% |
| Eventide Large Cap Focus Fund | 0.73% | Class N: | 1.14% |
|  |  | Class A: | 1.19% |
|  |  | Class C: | 1.94% |
|  |  | Class I: | 0.94% |
| Eventide Limited-Term Bond Fund | 0.33% | Class N: | 0.75% |
|  |  | Class A: | 0.80% |
|  |  | Class C: | 1.55% |
|  |  | Class I: | 0.55% |
| Eventide Multi-Asset Income Fund | 0.60% | Class N: | 1.02% |
|  |  | Class A: | 1.07% |
|  |  | Class C: | 1.82% |
|  |  | Class I: | 0.82% |

---

For the six months ended December 31, 2022, the Manager waived no management fees from Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund and waived fees of $103,404, $130,937, $30,941, $66,814, $107,306 and $104,484 from the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Exponential Technologies Fund, Eventide Large Cap Focus Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund, respectively. As of December 31, 2022, the Manager has waived/reimbursed expenses that may be recovered no later than June 30 of the years indicated below:

---

| | | | |
|:---|:---|:---|:---|
|  | *2023* | *2024* | *2025* |
| Eventide Core Bond Fund | $— | $99512 | $201020 |
| Eventide Dividend Opportunities Fund | 113677 | 64772 |  |
| Eventide Exponential Technologies Fund |  | 53115 |  |
| Eventide Limited-Term Bond Fund | 148648 | 133760 | 165476 |
| Eventide Multi-Asset Income Fund | 103007 | 65335 |  |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **117** |
| **E V E N T I D E** | **117** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund do not have any expenses previously waived by the Manager that are subject to recapture and did not waive any further expenses during the six months ended December 31, 2022.

The Trust has entered into a Management Services Agreement with MFund Services, LLC (*"**MFund**"*). Pursuant to the Management Services Agreement, MFund provides management and legal administrative services. For these services, the Fund pays MFund an annualized asset based fee which scales downward based upon net assets. In addition, the Funds reimburse MFund for any reasonable out- of- pocket expenses incurred in the performance of its duties under the Management Services Agreement. The amounts due to MFund for the Management Services Agreement are listed in the Statements of Assets and Liabilities under "Payable to related parties" and the amounts accrued for the year are shown in the Statements of Operations under "Management service fees." A Trustee of the Trust is also the controlling member of MFund and the investment advisers to other series of the Trust.

Pursuant to the Compliance Services Agreement, MFund provides chief compliance officer services to the Funds. For these services, the Funds pay MFund as of the last day of each month an annualized base fee plus an annualized asset-based fee based upon net assets. In addition, the Funds reimburse MFund for any reasonable out-of-pocket expenses incurred in the performance of its duties under the Compliance Services Agreement.

The amounts due to MFund for chief compliance officer services are listed in the Statements of Assets and Liabilities under "Compliance officer fees payable" and the amounts accrued for the year are shown in the Statements of Operations under "Compliance officer fees."

Trustees who are not "interested persons" as that term is defined in the 1940 Act, are paid a quarterly retainer and receive compensation for each special in-person meeting attended. The fees paid to the Independent Trustees for their attendance at a meeting will be shared equally by the funds of the Trust in which the meeting relates. The Lead Independent Trustee of the Trust, the Chairman of the Trust's Audit Committee and the Chairman of the Risk and Compliance Committee receive an additional quarterly retainer. The "interested persons" of the Trust receive no compensation from the Funds. The "interested persons" of the Trust receive no compensation from the Fund. The Trust reimburses each Trustee and Officer for his or her travel and other expenses related to attendance at such meetings.

Ultimus Fund Solutions, LLC (*"**UFS**"*), an affiliate of the distributor, provides administrative, fund accounting, and transfer agency services to the Funds pursuant to agreements with the Trust, for which it receives from each Fund: (i) basis points in decreasing amounts as assets reach certain breakpoints; and (ii) any related out-of-pocket expenses.

Blu Giant, LLC (*"**Blu Giant**"*), an affiliate of UFS and the distributor, provides EDGAR conversion and filing services as well as print management services for the Funds on an ad-hoc basis. For the provision of these services, Blu Giant receives customary fees from the Funds.

The Trust's officers are not paid any fees directly by the Trust for serving in such capacity except for the chief compliance officer.

The Trust has adopted a distribution plan pursuant to rule 12b-1 under the 1940 Act for each class of shares except Class I, that allows the Funds to pay distribution and shareholder servicing expenses of up to 0.25% per

---

| | |
|:---|:---|
| **E V E N T I D E** | **118** |
| **E V E N T I D E** | **118** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

annum for the Class N shares, up to 0.50% per annum for the Class A shares and up to 1.00% for the Class C shares based on average daily net assets of each class. The Class N shares are currently paying 0.20% per annum of 12b-1 fees, Class A shares are currently paying 0.25% per annum of 12b-1 fees and Class C shares are currently paying 1.00% per annum of 12b-1 fees.

The 12b-1 fees may be used for a variety of purposes, including compensating dealers and other financial service organizations for eligible services provided by those parties to the Funds and their shareholders and to reimburse Northern Lights Distributors, LLC. (the *"**Distributor**"*) and the Manager for distribution related expenses.

For the six months ended December 31, 2022, the Distributor received $210, $22,716, $3,354, $76,298, $30,911, $394, $527 and $10,114 in underwriter commissions from the sale of Class A shares of the Fund from the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund, respectively.

**4. DISTRIBUTIONS TO SHAREHOLDERS AND TAX COMPONENTS OF CAPITAL**

The following table represents aggregate cost for federal tax purposes, including options written, for the Funds as of December 31, 2022 and differs from market value by net unrealized appreciation/depreciation which consisted of:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | *Gross Unrealized* | *Gross Unrealized* | *Total Unrealized Appreciation* |
| *Fund* | *Aggregate Cost* | *Appreciation* | *Depreciation* | *(Depreciation)* |
| Eventide Core Bond Fund | $61106923 | $8467 | $(8575429) | $(8566962) |
| Eventide Dividend Opportunities Fund | 510169532 | 22707315 | (46900909) | (24193594) |
| Eventide Exponential Technologies Fund | 95282513 | 6545890 | (18454029) | (11908139) |
| Eventide Gilead Fund | 2582874547 | 952740632 | (398184174) | 554556458 |
| Eventide Healthcare & Life Sciences Fund | 1523076322 | 404915954 | (432384863) | (27468909) |
| Eventide Large Cap Focus Fund | 6183457 | 103923 | (286979) | (183056) |
| Eventide Limited-Term Bond Fund | 145049390 | 11909 | (8939351) | (8927442) |
| Eventide Multi-Asset Income Fund | 359823095 | 15459276 | (31100638) | (15641362) |

---

The tax character of fund distributions for the years ended June 30, 2022 and June 30, 2021 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *For the year ended June 30, 2022:* | *For the year ended June 30, 2022:* | *For the year ended June 30, 2022:* | *For the year ended June 30, 2022:* |
|  | *Ordinary* | *Long-Term* | *Return of* |  |
| *Fund* | *Income* | *Capital Gains* | *Capital* | *Total* |
| Eventide Core Bond Fund | $1309050 | $— | $152476 | $1461526 |
| Eventide Dividend Opportunities Fund | 5984302 | 8263195 |  | 14247497 |
| Eventide Exponential Technologies Fund | 1906725 |  |  | 1906725 |
| Eventide Gilead Fund |  | 327575226 |  | 327575226 |
| Eventide Healthcare & Life Sciences Fund | 34043234 | 158591589 |  | 192634823 |
| Eventide Limited-Term Bond Fund | 1300163 | 50373 | 1089637 | 2440173 |
| Eventide Multi-Asset Income Fund | 11154838 | 13561075 |  | 24715913 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **119** |
| **E V E N T I D E** | **119** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *For the year en<u>de</u>d June 30, 2021:* | *For the year en<u>de</u>d June 30, 2021:* | *For the year en<u>de</u>d June 30, 2021:* | *For the year en<u>de</u>d June 30, 2021:* |
|  | *Ordinary* | *Long-Term* | *Return of* |  |
| *Fund* | *Income* | *Capital Gains* | *Capital* | *Total* |
| Eventide Core Bond Fund | $662544 | $— | $372081 | $1034625 |
| Eventide Dividend Opportunities Fund | 2119397 | 442713 |  | 2562110 |
| Eventide Exponential Technologies Fund | 119830 |  |  | 119830 |
| Eventide Gilead Fund |  | 46777382 |  | 46777382 |
| Eventide Healthcare & Life Sciences Fund | 2584287 | 84024399 |  | 86608686 |
| Eventide Limited-Term Bond Fund | 1241376 | 265225 | 435931 | 1942532 |
| Eventide Multi-Asset Income Fund | 3474637 | 1599165 |  | 5073802 |

---

As of June 30, 2022, the components of accumulated earnings/ (deficit) on a tax basis were as follows:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | *Undistributed* | *Undistributed* | *Post October Loss* | *Capital Loss* | *Other* | *Unrealized* | *Total* |
|  | *Ordinary* | *Long-Term* | *and* | *Carry* | *Book/Tax* | *Appreciation/* | *Accumulated* |
| *Portfolio* | *Income* | *Capital Gains* | *Late Year Loss* | *Forwards* | *Differences* | *(Depreciation)* | *Earnings/(Deficits)* |
| Eventide Core Bond Fund | $— | $— | $(6486403) | $(719541) | $— | $(9426813) | $(16632757) |
| Eventide Dividend Opportunities Fund |  | 3227726 | (226330) |  |  | (33147262) | (30145866) |
| Eventide Exponential Technologies Fund |  |  | (26412440) | (2487178) |  | (15469412) | (44369030) |
| Eventide Gilead Fund |  | 172237611 | (22515765) |  |  | 583152468 | 732874314 |
| Eventide Healthcare & Life Sciences Fund |  |  | (116890551) |  |  | (231471098) | (348361649) |
| Eventide Limited-Term Bond Fund |  |  | (2141205) |  |  | (11091717) | (13232922) |
| Eventide Multi-Asset Income Fund |  | 3573046 |  |  |  | (16397175) | (12824129) |

---

The difference between book basis and tax basis undistributed net investment income/(loss), accumulated net realized gain/(loss), and unrealized appreciation/(depreciation) from investments is primarily attributable to the tax deferral of losses on wash sales, passive foreign investment companies<u>,</u> and adjustments for partnerships, real estate investment trusts, C-Corporation return of capital, paydowns and deemed distributions.

Late year losses incurred after December 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such late year losses as follows:

---

| | |
|:---|:---|
|  | *Late Year* |
| *Fund* | *Losses* |
| Eventide Exponential Technologies Fund | $833342 |
| Eventide Gilead Fund | 22515765 |
| Eventide Healthcare & Life Sciences Fund | 16016085 |

---

Capital losses incurred after October 31 within the fiscal year are deemed to arise on the first business day of the following fiscal year for tax purposes. The Funds incurred and elected to defer such capital losses as follows:

---

| | |
|:---|:---|
|  | *Post October* |
| *Portfolio* | *Losses* |
| Eventide Core Bond Fund | $6486403 |
| Eventide Dividend Opportunities Fund | 226330 |
| Eventide Exponential Technologies Fund | 25579098 |
| Eventide Healthcare & Life Sciences Fund | 100874466 |
| Eventide Limited-Term Bond Fund | 2141205 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **120** |
| **E V E N T I D E** | **120** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

<sub></sub>At June 30, 2022, the Funds had capital loss carry forwards for federal income tax purposes available to offset future capital gains, and utilized capital loss carryforwards as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Non-Expiring* | *Non-Expiring* |  |  |
| *Portfolio* | *Short-Term* | *Long-Term* | *Total* | *CLCF Utilized* |
| Eventide Core Bond Fund | $708473 | $11068 | $719541 | $— |
| Eventide Exponential Technologies Fund | 2355821 | 131357 | 2487178 |  |

---

During the fiscal period ended June 30, 2022, certain of the Funds utilized tax equalization which is the use of earnings and profits distributions to shareholders on redemption of shares as part of the dividends paid deduction for income tax purposes. Permanent book and tax differences, primarily attributable to the book/tax basis treatment of net operating losses, distribution reclasses, and use of tax equalization credits, resulted in reclassifications for the Funds for the fiscal year ended June 30, 2022 as follows:

---

| | | |
|:---|:---|:---|
|  | *Paid* |  |
|  | *In* | *Accumulated* |
| *Portfolio* | *Capital* | *Earnings (Losses)* |
| Eventide Core Bond Fund | $— | $— |
| Eventide Dividend Opportunities Fund | 1301507 | (1301507) |
| Eventide Exponential Technologies Fund | (1010828) | 1010828 |
| Eventide Gilead Fund | (17961736) | 17961736 |
| Eventide Healthcare & Life Sciences Fund | (3871416) | 3871416 |
| Eventide Limited-Term Bond Fund |  |  |
| Eventide Multi-Asset Income Fund | 1668708 | (1668708) |

---

**5. INVESTMENTS IN AFFILIATED COMPANIES**

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities. Companies which are affiliates of the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund at December 31, 2022 are noted in the Funds' Schedule of Investments. Transactions during the year with companies which are affiliates are as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
|  |  |  |  |  |  |  | *Net Increase/* |  |  |  |
|  |  |  |  |  |  | *Dividends* | *Decrease in* |  | *Market Value at* | *Share Balance at* |
|  | *Market Value at* | *Share Balance at* |  |  | *Corporate* | *Credited to* | *Appreciation* | *Realized Gains* | *December 31,* | *December 31,* |
| *Description* | *June 30, 2022* | *June 30, 2022* | *Purchases* | *Sales Proceeds* | *Actions* | *Income* | *(Depreciation)* | *(Losses)* | *2022* | *2022* |
| KnowBe4, Inc. | $61042694 | 3907983 | $— | $(93140620) | $— | $— | $30413006 | $1684920 | $— |  |
| Beta Bionics Series B | 18435172 | 139527 |  |  |  |  |  |  | 18435172 | 139527 |
| Beta Bionics Series B2 | 6457272 | 48872 |  |  |  |  |  |  | 6457272 | 48872 |
| Beta Bionics Series C | 7599916 | 71900 |  |  |  |  |  |  | 7599916 | 71900 |
| Beta Bionics Series C Warrants | 1899799 | 17975 |  |  |  |  |  |  | 1899799 | 17975 |
| Total | $95434853 | 4186257 | $— | $(93140620) | $— | $— | $30413006 | $1684920 | $34392159 | 278274 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **121** |
| **E V E N T I D E** | **121** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
|  |  |  |  |  |  |  | *Net Increase/* |  |  |  |
|  |  |  |  |  |  | *Dividends* | *Decrease in* |  | *Market Value at* | *Share Balance at* |
|  | *Market Value at* | *Share Balance at* |  |  | *Corporate* | *Credited to* | *Appreciation* | *Realized Gains* | *December 31,* | *December 31,* |
| *Description* | *June 30, 2022* | *June 30, 2022* | *Purchases* | *Sales Proceeds* | *Actions* | *Income* | *(Depreciation)* | *(Losses)* | *2022* | *2022* |
| 908 Devices, Inc. <sup>1</sup> | $30845900 | 1498101 | $9612056 | $— | $— | $— | $(23460289) | $— | $16997667 | 2230665 |
| Annexon, Inc. | 13671935 | 3626508 |  |  |  |  | 5077111 |  | 18749046 | 3626508 |
| Aura Biosciences, Inc. |  |  | 27266590 |  |  |  | (3627226) |  | 23639364 | 2251368 |
| Casma Therapeutics, Inc.Series B1 | 2185000 | 5000000 |  |  |  |  |  |  | 2185000 | 5000000 |
| Casma Therapeutics, Inc.Series B2 | 2185000 | 5000000 |  |  |  |  |  |  | 2185000 | 5000000 |
| Casma Therapeutics, Inc.Series C1 <sup>2</sup> |  |  |  |  | 837390 |  | (41870) |  | 795520 | 1820413 |
| Casma Therapeutics, Inc.Series C Tranche 1 ,5.0000% 4/28/23 <sup>2</sup> | 795520 | 830000 |  |  | (837390) |  | 41870 |  |  |  |
| Essa Pharma, Inc. | 9143220 | 2902609 |  | (9390280) |  |  | 14877478 | (14630418) |  |  |
| Freeline Therapeutics Ltd. | 4144233 | 4721696 |  | (14842) |  |  | (1281571) | (511444) | 2336376 | 4692461 |
| Freeline Therapeutics Ltd.Series C | 1024178 | 1228304 |  |  |  |  | (443184) |  | 580994 | 1228304 |
| Goldfinch Biopharma, Inc.Series A | 5605000 | 5000000 |  |  |  |  | (5605000) |  |  | 5000000 |
| Goldfinch Biopharma, Inc.Series B | 9500000 | 8474576 |  |  |  |  | (9500000) |  |  | 8474576 |
| Goldfinch Biopharma, Inc.Series B2 | 4750000 | 4237288 |  |  |  |  | (4750000) |  |  | 4237288 |
| LEXEO Therapeutics Series B | 14250300 | 8718446 |  |  |  |  |  |  | 14250300 | 8718446 |
| Marinus Pharmaceuticals,Inc. |  |  | 14962500 |  |  |  | (2425500) |  | 12537000 | 3150000 |
| Mirum Pharmaceuticals,Inc. |  |  | 43799054 |  |  |  | (3687554) |  | 40111500 | 2057000 |
| Praxis Precision Medicines,Inc. | 6043628 | 2466787 |  |  |  |  | (172675) |  | 5870953 | 2466787 |
| Prometheus Laboratories,Inc. | 667148 | 1017770 |  |  |  |  |  |  | 667148 | 1017770 |
| Sutro Biopharma, Inc. | 14113760 | 2708975 |  | (20153320) |  |  | 20274321 | (14234761) |  |  |
| VectivBio Holdings A.G. | 12630838 | 2339044 | 7999500 |  |  |  | 8692257 |  | 29322595 | 3405644 |
| Zymeworks, Inc. | 28515060 | 5380200 |  | (37063954) |  |  | 83486125 | (74937231) |  |  |
| TOTAL | $160070720 | 65150304 | $103639700 | $(66622396) | $— | $— | $77454293 | (104313854) | $170228463 | 64377230 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **122** |
| **E V E N T I D E** | **122** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**Eventide Healthcare & Life Sciences Fund**

*Investments no longer affiliated as of December 31, 2022*

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  |  | *Net Increase/* |  |  |  |
|  |  |  |  |  |  | *Dividends* | *Decrease in* |  | *Market Value at* | *Share Balance at* |
|  | *Market Value at* | *Share Balance at* |  |  | *Corporate* | *Credited to* | *Appreciation* | *Realized Gains* | *December 31,* | *December 31,* |
| *Description* | *June 30, 2022* | *June 30, 2022* | *Purchases* | *Sales Proceeds* | *Actions* | *Income* | *(Depreciation)* | *(Losses)* | *2022* | *2022* |
| Cogent Biosciences, Inc. | $45956900 | 5095000 | $— | $(40585147) | $— | $— | $7969290 | $16596791 | $29937834 | 2589778 |
| Prometheus Biosciences,Inc. | 91259120 | 3232700 |  | (186359092) |  |  | 37455142 | 149268009 | 91623179 | 832938 |
| Total | $137216020 | 8327700 | $— | $(226944239) | $— | $— | $45424432 | $165864800 | $121561013 | 3422716 |
|  | $297286740 | 73478004 | $103639700 | $(293566635) | $— | $— | $122878725 | $61550946 | $291789476 | 67799946 |

---

*1.* *Not affiliated June 30, 2022.* 

 

*2.* *Conversion of convertible note to private investment.* 

**6. INVESTMENT IN RESTRICTED SECURITIES**

Restricted securities include securities that have not been registered under the Securities Act of 1933, as amended, and securities that are subject to restrictions on resale. Each Fund may invest in restricted securities that are consistent with the Fund's investment objectives and investment strategies. A Fund will not invest in a restricted security if, immediately after and as a result of the investment in such security, more than 15% of the Fund's net assets would be invested in illiquid securities. In some cases, the issuer of restricted securities has agreed to register such securities for resale, at the issuer's expense either upon demand by the Funds or in connection with another registered offering of the securities. Investments in restricted securities are valued at fair value as determined in good faith in accordance with procedures adopted by the Board. It is possible that the estimated value may differ significantly from the amount that might ultimately be realized in the near term, and the difference could be material.

As of December 31, 2022, the Eventide Dividend Opportunities Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund and Eventide Multi-Asset Income Fund were invested in the following restricted securities:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** | **Eventide Dividend Opportunities Fund** |
|  | *Initial Acquisition* |  |  |  |  |
| *Security* | *Date* | *Shares* | *Cost* | *Value* | *% of Net Assets* |
| Vision Fund International, 2.6110%, 11/30/23 | 12/1/21 | 2000000 | $2000000 | $2000000 | 0.4% |
| **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** | **Eventide Gilead Fund** |
|  | *Initial Acquisition* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;*Security* | *Date* | *Shares* | *Cost* | *Value* | *% of Net Assets* |
| Beta Bionic Series B | 8/31/18 | 139527 | $20000031 | $18435172 | 0.6% |
| Beta Bionic Series B2 | 6/27/19 | 48872 | 7400000 | 6457272 | 0.2% |
| Beta Bionic Series C | 2/16/22 | 71900 | 9999867 | 7599916 | 0.2% |
| Beta Bionic Series C Warrant | 2/16/22 | 17975 |  | 1899799 | 0.1% |
| Peloton Therapeutics, Inc. - CVR | 2/14/19 | 3982940 |  | 2906351 | 0.1% |
| Vision Fund International, 2.6110%, 11/30/23 | 12/1/21 | 7000000 | 7000000 | 7000000 | 0.2% |
| Vision Fund International, 3.1500%, 12/15/25 | 12/16/21 | 5000000 | 5000000 | 5000000 | 0.2% |
| Vision Fund International, 3.2230%, 12/15/26 | 12/16/21 | 5000000 | 5000000 | 5000000 | 0.2% |
| Vision Fund International, 4.7400%, 06/16/25 | 5/18/22 | 5000000 | 5000000 | 5000000 | 0.2% |
| Vision Fund International, 5.9030%, 09/19/25 | 9/21/22 | 5000000 | 5000000 | 5000000 | 0.2% |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **123** |
| **E V E N T I D E** | **123** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** | **Eventide Healthcare & Life Sciences Fund** |
|  | *Initial Acquisition* |  |  |  |  |
| *Security* | *Date* | *Shares* | *Cost* | *Value* | *% of Net Assets* |
| Arch Oncology, Inc. Series C1 | 4/26/21 | 4643043 | 5952381 | 565523 | 0.0% |
| Beta Bionic Series B | 8/31/18 | 69763 | 10000016 | 9217520 | 0.6% |
| Beta Bionic Series B2 | 6/27/19 | 59439 | 9000000 | 7853449 | 0.5% |
| Beta Bionic Series C | 2/16/22 | 35950 | 4999933 | 3799958 | 0.2% |
| Beta Bionic Series C Warrant | 2/16/22 | 8987 |  | 949847 | 0.1% |
| BioSplice Therapeutics | 3/5/21 | 295276 | 15000021 | 5435470 | 0.3% |
| Casma Therapeutics, Inc. Series B1 | 8/26/20 | 5000000 | 3750000 | 2185000 | 0.1% |
| Casma Therapeutics, Inc. Series B2 | 6/7/21 | 5000000 | 3750000 | 2185000 | 0.1% |
| Casma Therapeutics, Inc. Series C1 | 7/6/22 | 1820413 | 837390 | 795520 | 0.0% |
| Flare Therapeutics, Inc. Series A | 4/22/21 | 1097561 | 1097561 | 1042683 | 0.1% |
| Flare Therapeutics, Inc. Series A2 | 5/31/22 | 902439 | 902439 | 857317 | 0.1% |
| Freeline Therapeutics Ltd. Series C | 6/29/20 | 1228304 | 15750000 | 580994 | 0.0% |
| Freenome Holdings, Inc. Series D | 11/22/21 | 928098 | 6999994 | 5760519 | 0.4% |
| Goldfinch Biopharma, Inc. Series A | 3/15/19 | 5000000 | 5000000 |  | 0.0% |
| Goldfinch Biopharma, Inc. Series B | 6/29/20 | 8474576 | 10000000 |  | 0.0% |
| Goldfinch Biopharma, Inc. Series B2 | 3/21/22 | 4237288 | 5000000 |  | 0.0% |
| Kojin Therapeutics, Inc. Series A-1 | 6/2/21 | 763319 | 1499998 | 1424998 | 0.1% |
| Kojin Therapeutics, Inc. Series A-2 | 1/28/22 | 763319 | 1499998 | 1424998 | 0.1% |
| Korro Bio, Inc. Series B1 | 11/8/21 | 3831418 | 10000001 | 9500001 | 0.6% |
| LEXEO Therapeutics Series B | 8/10/21 | 8718446 | 14999999 | 14250300 | 0.9% |
| Metagenomi, LLC Series B | 1/21/22 | 686724 | 7999998 | 9177586 | 0.6% |
| Metagenomi, LLC Series B-1 | 12/20/22 | 98875 | 1390944 | 1321395 | 0.1% |
| Peloton Therapeutics, Inc. - CVR | 2/14/19 | 1528871 |  | 1115617 | 0.1% |
| Prometheus Laboratories, Inc. | 12/31/20 | 1017770 | 702262 | 667148 | 0.0% |
| Shoreline Biosciences Series B | 10/28/21 | 1489958 | 15000003 | 14249958 | 0.9% |
| Turnstone Biologics Inc. Series D | 6/29/21 | 3660670 | 9999999 | 3923506 | 0.2% |
| **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** | **Eventide Multi-Asset Income Fund** |
|  | *Initial Acquisition* |  |  |  |  |
| *Security* | *Date* | *Shares* | *Cost* | *Value* | *% of Net Assets* |
| Vision Fund International, 3.7250%, 2/24/25 | 2/25/22 | 3800000 | $3800000 | $3800000 | 1.1% |

---

**7. PORTFOLIO CONCENTRATION RISK**

The Eventide Exponential Technologies Fund invests primarily in equity and equity-related securities of companies in the technology sectors that derive or are expected to derive 50% or more of their revenue from technology products and services including, but not limited to, information technology, communications companies, internet and direct marketing retail services and healthcare technology and devices companies. Because of its focus on technology companies, the Eventide Exponential Technologies Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Exponential Technologies Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

The Eventide Healthcare & Life Sciences Fund invests primarily in equity and equity-related securities of companies in the healthcare and life sciences sectors that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. Because of its focus on healthcare and life science companies, the Eventide Healthcare &

---

| | |
|:---|:---|
| **E V E N T I D E** | **124** |
| **E V E N T I D E** | **124** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

Life Sciences Fund's investment performance will be closely tied to many factors which affect those companies. As a result, the Eventide Healthcare & Life Sciences Fund's net asset value is more likely to have greater fluctuations than that of a fund which invests in other industries.

**8. OPTIONS RISK**

There are risks associated with the sale and purchase of call and put options. The seller (writer) of a call option which is covered (e.g., the writer holds the underlying security) assumes the risk of a decline in the market price of an underlying security below the purchase price of an underlying security less the premium received, and gives up the opportunity for gain on the underlying security above the exercise price of the option. The seller of an uncovered call option assumes the risk of a theoretical unlimited increase in the market price of an underlying security above the exercise price of the option. The securities necessary to satisfy the exercise of the call option may be unavailable for purchase except at much higher prices. Purchasing securities to satisfy the exercise of the call option can itself cause the price of securities to rise further, sometimes by a significant amount, thereby exacerbating the loss. The buyer of a call option assumes the risk of losing its entire premium invested in the call option. The seller (writer) of a put option which is covered (e.g., the writer has a short position in the underlying security) assumes the risk of an increase in the market price of the underlying security above the sales price (in establishing the short position) of the underlying security plus the premium received, and gives up the opportunity for gain on the underlying security below the exercise price of the option. The seller of an uncovered put option assumes the risk of a decline in the market price of the underlying security below the exercise price of the option. The buyer of a put option assumes the risk of losing his entire premium invested in the put option.

**9. MARKET RISK**

Overall market risks may also affect the value of the Funds. The market values of securities or other investments owned by the Funds will go up or down, sometimes rapidly or unpredictably. Factors such as economic growth and market conditions, interest rate levels, exchange rates and political events affect the securities markets. Changes in market conditions and interest rates generally do not have the same impact on all types of securities and instruments. Unexpected local, regional or global events and their aftermath, such as war; acts of terrorism; financial, political or social disruptions; natural, environmental or man-made disasters; climate-change and climate-related events; the spread of infectious illnesses or other public health issues; recessions and depressions; or other tragedies, catastrophes and events could have a significant impact on the Funds and their investments and could result in increased premiums or discounts to a Fund's net asset value, and may impair market liquidity, thereby increasing liquidity risk. Such events can cause investor fear and panic, which can adversely affect the economies of many companies, sectors, nations, regions and the market in general, in ways that cannot necessarily be foreseen. The Funds could lose money over short periods due to short-term market movements and over longer periods during more prolonged market downturns. During a general market downturn, multiple asset classes may be negatively affected. In times of severe market disruptions you could lose your entire investment.

The impact of the COVID-19 pandemic adversely affected, and other infectious illness outbreaks that may arise in the future could adversely affect, the economies of many nations and the entire global economy, individual issuers and capital markets in ways that cannot necessarily be foreseen. In addition, the impact of infectious illnesses in emerging market countries may be greater due to generally less established healthcare systems. Public health crises may exacerbate other pre-existing political, social and economic risks in certain countries or globally. The duration of the effects cannot be determined with certainty.

---

| | |
|:---|:---|
| **E V E N T I D E** | **125** |
| **E V E N T I D E** | **125** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

**10. LINE OF CREDIT**

Currently, the Eventide Funds have a $150,000,000 uncommitted line of credit provided by U.S. Bank National Association (the *"**Bank**"*) under an agreement (the *"**Uncommitted Line**"*). Any advance under the Uncommitted Line is contemplated primarily for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. Interest on borrowings is payable on an annualized basis. The Uncommitted Line is not a "committed" line of credit, which is to say that the Bank is not obligated to lend money to the Funds. Accordingly, it is possible that Funds may wish to borrow money for a temporary or emergency purpose but may not be able to do so. During the six months ended December 31, 2022, the Eventide Core Bond Fund and the Eventide Limited-Term Bond Fund accessed the line of credit. Based only on the days borrowed, the average amount of borrowings outstanding was $459,000 and $7,339,500, respectively. As of December 31, 2022, the line of credit was used a total of one day for the Eventide Core Bond Fund and two days for the Eventide Limited-Term Bond Fund. As of December 31, 2022, the interest expense for the Eventide Core Bond Fund and the Eventide Limited-Term Bond Fund is $70 and $3,983, respectively. The average interest rate for the Eventide Core Bond Fund and the Eventide Limited-Term Bond Fund during the six months ended December 31, 2022 was 5.50% and 5.50%, respectively. As of December 31, 2022, the Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Large Cap Focus Fund, Eventide Limited-Term Bond Fund and the Eventide Multi-Asset Income Fund each paid $489 in line of credit fees. As of December 31, 2022, the Eventide Core Bond Fund and the Eventide Limited-Term Bond Fund had $0 and $0 in outstanding borrowings on the Uncommitted Line, respectively.

**11. BENEFICIAL OWNERSHIP**

The beneficial ownership, either directly or indirectly, of more than 25% of the voting securities of a fund creates a presumption of control of the fund, under Section 2(a)(9) of the 1940 Act. As of December 31, 2022, Charles Schwab & Co, Inc. Special Custody Account for the Exclusive Benefit of Customers held 70.61% and 32.91% of the Eventide Core Bond Fund and Eventide Limited-Term Bond Fund, respectively. As of December 31, 2022, TD Ameritrade, Inc. for the Exclusive Benefit of Customers held 37.40% of the Eventide Large Cap Focus Fund.

**12. SUBSEQUENT EVENTS**

Subsequent events after the date of the Statements of Assets and Liabilities have been evaluated through the date the financial statements were issued. Management has determined that no events or transactions occurred requiring adjustment or disclosure in the financial statements.

---

| | |
|:---|:---|
| **E V E N T I D E** | **126** |
| **E V E N T I D E** | **126** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

<br> **Eventide Large Cap Focus Fund**

**Consideration and Approval of Management Agreement between Mutual Fund Series Trust and Eventide Asset Management, LLC with respect to Eventide Large Cap Focus Fund**

In connection with a meeting held on April 28, May 17 & 26, 2022 the Board of Trustees (the *"**Board**"*) of Mutual Fund Series Trust (the *"**Trust**"*), including a majority of the Trustees who are not "interested persons" as that term is defined in the Investment Company Act of 1940, as amended, considered the advisory agreement (the *"**Management Agreement**"*) between the Trust and Eventide Asset Management, LLC (*"**Eventide**"*) with respect to Eventide Large Cap Focus Fund (*"**Eventide LC**"*).

The Board examined Eventide's responses to a series of questions regarding, among other things, the management services it would provide to Eventide LC, comparative fee and expense information, and profitability from managing Eventide LC. The Board was assisted by legal counsel throughout the review process and relied upon the advice of legal counsel and its own business judgment in determining the material factors to be considered in evaluating the Management Agreement and the weight to be given to each factor considered. The conclusions reached by the Board were based on a comprehensive evaluation of all of the information provided and were not the result of any one factor. Moreover, each Trustee may have afforded different weight to various factors in reaching his conclusions with respect to the approval of the Management Agreement.

***Nature, Extent and Quality of Services.*** The Board considered its significant experience with Eventide as the advisor to several other series of the Trust, and its strong working relationship with Eventide and its personnel. The Board remarked that Eventide's portfolio management team would combine its investment experience with proprietary research provided by research partners and industry experts to identify investment opportunities. It noted that Eventide would review Eventide LC's portfolio on a regular basis and would monitor Eventide LC's investment limitations daily through an automated compliance script. The Board noted that Eventide would review Eventide LC's holdings for consistency with Eventide LC's values-based screens through Eventide's Edify system. The Board observed that Eventide directed trades to broker-dealers with an eye toward obtaining best execution in terms of share price, quality of service and commissions. The Board discussed that Eventide recently rolled out a mobile device management solution and implemented vendor management software to manage third-party risk. The Board observed that a third-party cybersecurity review of Eventide's infrastructure and processes was currently underway. The Board remarked that Eventide did not report any material litigation or administrative actions involving Eventide or any Eventide affiliate and had no pending regulatory examinations or investigations. After discussion, the Board concluded that Eventide had the potential to provide high quality services to Eventide LC and its shareholders.

***Performance.*** The Board noted that Eventide had demonstrated, as evidenced by the other series of the Trust it managed, that it had the ability to successfully manage Eventide LC and ensure compliance with portfolio restrictions and limitations. The Board reviewed the performance of mutual funds managed by Eventide LC's proposed portfolio managers, each of which had outperformed all benchmarks since their inception. The Board determined that Eventide's track record of managing mutual funds gave the Board confidence that Eventide would provide value to shareholders as advisor to Eventide LC.

***Fees and Expenses.*** The Board noted that the 0.73% advisory fee for Eventide LC was slightly higher than the average of the peer group but lower than the peer group high of 1.00% and the Morningstar category high of 1.25%.

---

| | |
|:---|:---|
| **E V E N T I D E** | **127** |
| **E V E N T I D E** | **127** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

The Board discussed that the 1.19% estimated net expense ratio for Eventide LC was equal to the average of its peer group and well below the Morningstar category high of 2.15%. The Board acknowledged Eventide's robust discussion of the reasonableness of its fee, including the level of expertise and skill required to manage a fund like Eventide LC and Eventide's highly differentiated values-based screening process. The Board concluded that the proposed advisory fee for Eventide LC was not unreasonable.

***Profitability.*** The Board reviewed a profitability analysis provided by Eventide and noted that it anticipated a loss in connection with its relationship with Eventide LC during the first year of the Management Agreement and at a slim profit during the second year of the Management Agreement. After discussion, the Board agreed that excessive profitability was not an issue for Eventide LC at this time.

***Economies of Scale.*** The Board considered whether there would be economies of scale with respect to the management of Eventide LC and noted that Eventide was not inclined to offer fee concessions at this time due in part to the high (and continuously increasing) costs of sponsoring mutual funds as well as the business and financial risks assumed by Eventide when managing a mutual fund, particularly a new fund. The Board noted material economies were not anticipated to be reached during the initial period of the Management Agreement and agreed that the matter of economies of scale would be revisited as Eventide LC's size materially increased.

***Conclusion.*** Having requested and received such information from Eventide as the Board believed to be reasonably necessary to evaluate the terms of the Management Agreement, and as assisted by the advice of counsel, the Board concluded that the fee structure for Eventide LC was reasonable, and that approval of the Management Agreement was in the best interests of Eventide LC and its future shareholders.

---

| | |
|:---|:---|
| **E V E N T I D E** | **128** |
| **E V E N T I D E** | **128** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | |
|:---|:---|
| <br> **Eventide Funds** |  |
| **Expense Examples (Unaudited)** | **December 31, 2022** |

---

As a shareholder of a Fund, you incur two types of costs: (1) transaction costs, including sales charges (loads) on purchases of Class A shares; and (2) ongoing costs, including management fees, distribution and/or service (12b-1) fees, and other Fund expenses. This example is intended to help you understand your ongoing costs (in dollars) of investing in a Fund and to compare these costs with the ongoing costs of investing in other mutual funds.

The example for Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund is based on an investment of $1,000 invested at the beginning of the period and held for the entire period from July 1, 2022 through December 31, 2022.

**Actual Expenses**

The "Actual" columns in the table below provide information about actual account values and actual expenses. You may use the information below, together with the amount you invested, to estimate the expenses that you paid over the period. Simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the table under the heading entitled "Expenses Paid During Period" to estimate the expenses you paid on your account during this period.

**Hypothetical Example for Comparison Purposes**

The "Hypothetical" columns in the table below provide information about hypothetical account values and hypothetical expenses based on the actual expense ratio of each of Eventide Core Bond Fund, Eventide Dividend Opportunities Fund, Eventide Exponential Technologies Fund, Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, Eventide Limited-Term Bond Fund and Eventide Multi-Asset Income Fund and an assumed rate of return of 5% per year before expenses, which is not the Funds' actual returns. The hypothetical account values and expenses may not be used to estimate the actual ending account balances or expenses you paid for the period. You may use this information to compare this 5% hypothetical example with the 5% hypothetical examples that appear in the shareholder reports of other funds.

Please note that the expenses shown in the table are meant to highlight your ongoing costs only and do not reflect any transactional costs, such as sales charges (loads), or redemption fees. Therefore, the table is useful in comparing ongoing costs only, and will not help you determine the relative total costs of owning different funds. In addition, if these transactional costs were included, your costs would have been higher.

---

| | |
|:---|:---|
| **E V E N T I D E** | **129** |
| **E V E N T I D E** | **129** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | ***Hypothetical*** | ***Hypothetical*** |
|  |  |  | Actual | Actual | *(5% return before expenses)* | *(5% return before expenses)* |
|  |  | *Beginning* | *Ending* |  | *Ending* | *Expenses* |
|  | *Funds' Annualized* | *Account Value* | *Account Value* | *Expenses* | *Account Value* | *Paid During* |
|  | *Expense Ratio* | *7/1/22* | *12/31/22* | *Paid During Period\** | *12/31/22* | *Period* |
| Eventide Core Bond Fund - Class N | 0.78% | $1000.00 | $972.40 | $3.88 | $1021.27 | $3.97 |
| Eventide Core Bond Fund – Class A | 0.83% | 1000.00 | 973.70 | 4.13 | 1021.02 | 4.23 |
| Eventide Core Bond Fund – Class C | 1.58% | 1000.00 | 968.70 | 7.84 | 1017.24 | 8.04 |
| Eventide Core Bond Fund – Class I | 0.58% | 1000.00 | 974.90 | 2.89 | 1022.28 | 2.96 |
| Eventide Dividend Opportunities Fund - Class N | 1.15% | 1000.00 | 1021.50 | 5.86 | 1019.41 | 5.85 |
| Eventide Dividend Opportunities Fund – Class A | 1.20% | 1000.00 | 1021.20 | 6.11 | 1019.16 | 6.11 |
| Eventide Dividend Opportunities Fund – Class C | 1.95% | 1000.00 | 1017.00 | 9.91 | 1015.38 | 9.91 |
| Eventide Dividend Opportunities Fund – Class I | 0.95% | 1000.00 | 1022.40 | 4.84 | 1020.42 | 4.84 |
| Eventide Exponential Technologies Fund - Class N | 1.63% | 1000.00 | 903.80 | 7.83 | 1016.98 | 8.29 |
| Eventide Exponential Technologies Fund – Class A | 1.68% | 1000.00 | 903.00 | 8.06 | 1016.73 | 8.54 |
| Eventide Exponential Technologies Fund – Class C | 2.43% | 1000.00 | 898.80 | 11.63 | 1012.95 | 12.33 |
| Eventide Exponential Technologies Fund – Class I | 1.43% | 1000.00 | 904.30 | 6.87 | 1017.99 | 7.28 |
| Eventide Gilead Fund – Class N | 1.37% | 1000.00 | 985.70 | 6.86 | 1018.30 | 6.97 |
| Eventide Gilead Fund – Class A | 1.42% | 1000.00 | 985.60 | 7.11 | 1018.05 | 7.22 |
| Eventide Gilead Fund – Class C | 2.17% | 1000.00 | 982.00 | 10.84 | 1014.27 | 11.02 |
| Eventide Gilead Fund – Class I | 1.17% | 1000.00 | 986.70 | 5.88 | 1019.28 | 5.98 |
| Eventide Healthcare & Life Sciences Fund – Class N | 1.53% | 1000.00 | 1229.10 | 8.62 | 1017.47 | 7.80 |
| Eventide Healthcare & Life Sciences Fund – Class A | 1.58% | 1000.00 | 1228.40 | 8.89 | 1017.22 | 8.05 |
| Eventide Healthcare & Life Sciences Fund – Class C | 2.33% | 1000.00 | 1224.40 | 13.08 | 1013.44 | 11.84 |
| Eventide Healthcare & Life Sciences Fund – Class I | 1.33% | 1000.00 | 1230.30 | 7.50 | 1018.48 | 6.78 |
| Eventide Large Cap Focus Fund – Class N | 1.17% | 1000.00 | 973.10 | 5.82 | 1019.31 | 5.96 |
| Eventide Large Cap Focus Fund – Class A | 1.22% | 1000.00 | 973.20 | 6.07 | 1019.06 | 6.21 |
| Eventide Large Cap Focus Fund – Class C | 1.97% | 1000.00 | 970.00 | 9.78 | 1015.27 | 10.01 |
| Eventide Large Cap Focus Fund – Class I | 0.97% | 1000.00 | 973.50 | 4.83 | 1020.31 | 4.94 |
| Eventide Limited-Term Bond Fund – Class N | 0.75% | 1000.00 | 996.60 | 3.77 | 1021.42 | 3.82 |
| Eventide Limited-Term Bond Fund – Class A | 0.80% | 1000.00 | 995.40 | 4.05 | 1021.15 | 4.10 |
| Eventide Limited-Term Bond Fund – Class C | 1.55% | 1000.00 | 992.80 | 7.81 | 1017.37 | 7.91 |
| Eventide Limited-Term Bond Fund – Class I | 0.55% | 1000.00 | 997.70 | 2.77 | 1022.43 | 2.80 |
| Eventide Multi-Asset Income Fund – Class N | 1.02% | 1000.00 | 1003.80 | 5.15 | 1020.06 | 5.15 |
| Eventide Multi-Asset Income Fund – Class A | 1.07% | 1000.00 | 1003.50 | 5.40 | 1019.81 | 5.45 |
| Eventide Multi-Asset Income Fund – Class C | 1.82% | 1000.00 | 999.80 | 9.17 | 1016.03 | 9.25 |
| Eventide Multi-Asset Income Fund – Class I | 0.82% | 1000.00 | 1004.80 | 4.14 | 1021.07 | 4.18 |

---

\* *Expenses are equal to the average account value over the period, multiplied by the Funds' annualized expense ratio, multiplied by the number of days in the period (184) divided by the number of days in the fiscal year (365).*

---

| | |
|:---|:---|
| **E V E N T I D E** | **130** |
| **E V E N T I D E** | **130** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | |
|:---|:---|
| **Eventide Funds** |  |
| **Additional Information (Unaudited)** | **December 31, 2022** |

---

Reference is made to the Prospectus and the Statement of Additional Information for more detailed descriptions of the Management Agreement, Services Agreement and Distribution and/or Service (12b-1) Plan, tax aspects of each Fund and the calculation of the net asset value of shares of each Fund.

The Funds file a complete schedule of portfolio holdings with the Securities and Exchange Commission (the *"**SEC**"*) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT, within sixty days after the end of the period. Form N-PORT reports are available at the SEC's website at http://www.sec.gov. The information on Form N-PORT is available without charge, upon request, by calling 1-877-771-3836.

Information regarding how each Fund voted proxies relating to portfolio securities during the twelve month period ended June 30 as well as a description of the policies and procedures that each Fund uses to determine how to vote proxies relating to portfolio securities is available without charge, upon request, by calling 1-877-771-3836; and on the SEC's website at http://www.sec.gov.

---

| | |
|:---|:---|
| **E V E N T I D E** | **131** |
| **E V E N T I D E** | **131** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | |
|:---|:---|
| **Privacy Notice** | **Privacy Notice** |
| **Mutual Fund Series Trust** Revised July 2017 | 1 of 2 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**FACTS** | &nbsp;&nbsp;**WHAT DOES MUTUAL FUND SERIES TRUST DO WITH YOUR PERSONAL INFORMATION?** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Why?** | &nbsp;&nbsp;Financial companies choose how they share your personal information. Federal law gives consumers the right to limit some, but not all sharing. Federal law also requires us to tell you how we collect, share, and protect your personal information. Please read this notice carefully to understand what we do. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**What?** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The types of personal information we collect and share depends on the product or service that you have with us. This information can include:<br>■ Social Security number and wire transfer instructions<br>■ account transactions and transaction history<br>■ investment experience and purchase history<br>When you are no longer our customer, we continue to share your information as described in this notice. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**How?** | &nbsp;&nbsp;All financial companies need to share customers' personal information to run their everyday business. In the section below, we list the reasons financial companies can share their customers' personal information; the reasons Mutual Fund Series Trust chooses to share; and whether you can limit this sharing. |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Reasons we can share your personal<br> information:** | &nbsp;&nbsp;**Does Mutual Fund Series<br> Trust share information?** | &nbsp;&nbsp;**Can you limit this sharing?** |
| &nbsp;&nbsp;For our everyday business purposes such as to process your transactions, maintain your account(s), respond to court orders and legal investigations, or report to credit bureaus. | &nbsp;&nbsp;**YES** | &nbsp;&nbsp;**NO** |
| &nbsp;&nbsp;For our marketing purposes to offer our products and services to you. | **NO** | **We don't share** |
| &nbsp;&nbsp;For joint marketing with other financial companies. | **NO** | **We don't share** |
| &nbsp;&nbsp;For our affiliates' everyday business purposes - information about your transactions and records. | **NO** | **We don't share** |
| &nbsp;&nbsp;For our affiliates' everyday business purposes - information about your credit worthiness. | **NO** | **We don't share** |
| &nbsp;&nbsp;For our affiliates to market to you | **NO** | **We don't share** |
| &nbsp;&nbsp;For non-affiliates to market to you | **NO** | **We don't share** |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **132** |
| **E V E N T I D E** | **132** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| | |
|:---|:---|
| **Privacy Notice** | **Privacy Notice** |
| **Mutual Fund Series Trust** Revised July 2017 | 2 of 2 |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**What we do:** | &nbsp;&nbsp;**What we do:** |
| &nbsp;&nbsp; **How does Mutual Fund Series Trust protect my personal information?** | &nbsp;&nbsp;To protect your personal information from unauthorized access and use, we use security measures that comply with federal law. These measures include computer safeguards and secured files and buildings.<br>Our service providers are held accountable for adhering to strict policies and procedures to prevent any misuse of your nonpublic personal information. |
| &nbsp;&nbsp; **How does Mutual Fund Series Trust collect my personal information?** | &nbsp;&nbsp;&nbsp;&nbsp;We collect your personal information, for example, when you:<br> ■ open an account or deposit money<br>■ direct us to buy securities or direct us to sell your securities<br>■ seek advice about your investments<br>We also collect your personal information from others, such as credit bureaus, affiliates, or other companies. |
| &nbsp;&nbsp; **Why can't I limit all sharing?** | &nbsp;&nbsp;&nbsp;&nbsp;Federal law gives you the right to limit only:<br> ■ sharing for affiliates' everyday business purposes – information about your creditworthiness.<br>■ affiliates from using your information to market to you.<br>■ sharing for non-affiliates to market to you. <br>State laws and individual companies may give you additional rights to limit sharing. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Definitions** | &nbsp;&nbsp;**Definitions** |
| &nbsp;&nbsp;**Affiliates** | &nbsp;&nbsp;&nbsp;&nbsp;Companies related by common ownership or control. They can be financial and non-financial companies.<br>■ Mutual Fund Series Trust does not share with affiliates. |
| &nbsp;&nbsp;**Non-affiliates** | &nbsp;&nbsp;&nbsp;&nbsp;Companies not related by common ownership or control. They can be financial and non-financial companies.<br>■ Mutual Fund Series Trust doesn't share with non-affiliates so they can market to you. |
| &nbsp;&nbsp;**Joint marketing** | &nbsp;&nbsp;&nbsp;&nbsp;A formal agreement between nonaffiliated financial companies that together market financial products or services to you.<br>■ Mutual Fund Series Trust doesn't jointly market. |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**QUESTIONS?** | &nbsp;&nbsp;**Call 1-866-447-4228** |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **133** |
| **E V E N T I D E** | **133** |

---

---

| | |
|:---|:---|
| **S E M I - A N N U A L R E P O R T** | December 31, 2022 |

---

---

| |
|:---|
| **MUTUAL FUND SERIES TRUST** |
| 4221 North 203rd Street, Suite 100 |
| Elkhorn, NE 68022 |
| **MANAGER** |
| Eventide Asset Management, LLC |
| One International Place |
| Suite 4210 |
| Boston, MA 02110 |
| **ADMINISTRATOR** |
| Ultimus Fund Solutions, LLC |
| 225 Pictoria Drive, Suite 450 |
| Cincinnati, OH 45246 |
| **TRANSFER AGENT** |
| Ultimus Fund Solutions, LLC |
| 225 Pictoria Drive, Suite 450 |
| Cincinnati, OH 45246 |
| **INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** |
| BBD, LLP |
| 1835 Market Street |
| 3rd Floor |
| Philadelphia, PA 19103 |
| **LEGAL COUNSEL** |
| Thompson Hine LLP |
| 41 South High Street |
| Suite 1700 |
| Columbus, OH 43215 |
| **CUSTODIAN BANK** |
| U.S. Bank |
| 1555 N. Rivercenter Drive. |
| Suite 302 |
| Milwaukee, WI 53212 |
| ETF-SAR22 |

---

---

| | |
|:---|:---|
| **E V E N T I D E** | **134** |
| **E V E N T I D E** | **134** |

---

(b) Not applicable

Item 2. Code of Ethics.

Not applicable for semi-annual reports.

Item 3. Audit Committee Financial Expert.

Not applicable for semi-annual reports.

Item 4. Principal Accountant Fees and Services.

Not applicable for semi-annual reports.

Item 5. Audit Committee of Listed Companies. Not applicable to open-end investment companies.

Item 6. Schedule of Investments. See Item 1.

Item 7. Disclosure of Proxy Voting Policies and Procedures for Closed-End Funds. Not applicable to open-end investment companies.

Item 8. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers. Not applicable to open-end investment companies.

Item 9. Submission of Matters to a Vote of Security Holder. None.

Item 10. Submission of Matters to a Vote of Security Holder. None.

Item 11. Controls and Procedures.

&nbsp;&nbsp;&nbsp;&nbsp;(a) The registrant's principal executive and principal financial officers, or persons performing similar
functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the 1940 Act, are
effective, as of a date within 90 days of the filing date of this report, based on the evaluation of these controls and procedures required
by Rule 30a-3(b) under the 1940 Act and Rule 15d-15(b) under the Securities Exchange Act of 1934, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;(b) There were no significant changes in the Registrant's internal control over financial reporting
that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the
Registrant's internal control over financial reporting.

Item 12. Disclosure of Securities Lending Activities For Closed-End Management Investment Companies. Not applicable to open-end investment companies.

Item 13. Exhibits

Code of Ethics for Principal Executive and Senior Financial Officers is attached hereto.

[Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 are filed herewith.](cert1.htm)

[Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are filed herewith.](cert2.htm)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Mutual Fund Series Trust

---

| | |
|:---|:---|
| By Michael Schoonover | <u>/s/ Michael Schoonover</u> |
| President, | President, |
| Date: 3/8/2023 |  |

---

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following person on behalf of the registrant and in the capacities and on the date indicated.

---

| | |
|:---|:---|
| By Michael Schoonover | <u>/s/ Michael Schoonover ___________</u> |
| President | President |

---

Date: 3/8/2023

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following person on behalf of the registrant and in the capacities and on the date indicated.

---

| | |
|:---|:---|
| By Erik Naviloff | <u>/s/ Erik Naviloff_____________</u> |
| Treasurer | Treasurer |
| Date: 3/8/2023 |  |

---

## Ex-99.Cert

**Certification Pursuant to Section 302 of the Sarbanes-Oxley Act**

I, Michael Schoonoveri, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form N-CSR of the Eventide Funds, a series of the Mutual Fund Series
Trust (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the schedules of investments included in this report fairly present in all material
respects the investments of the registrant as of the end of the fiscal period for which the report is filed;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3 (d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the
filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's
internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the
audit committee of the registrant's board of Trustees (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report
financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 3/8/2023 | <u>/s/ Michael Schoonover_____</u> |
|  | Michael Schoonover |
|  | President |

---

------

**Certification Pursuant to Section 302 of the Sarbanes-Oxley Act**

I, Erik Naviloff, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this report on Form N-CSR of the Eventide Funds, a series of the Mutual Fund Series
Trust (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the schedules of investments included in this report fairly present in all material
respects the investments of the registrant as of the end of the fiscal period for which the report is filed;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3 (d) under the Investment Company Act of 1940) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in
this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the
filing date of this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that
occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's
internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the
audit committee of the registrant's board of Trustees (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize,
and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: 3/8/2023 | <u>/s/ Erik Naviloff________</u> |
|  | Erik Naviloff |
|  | Treasurer |

---

## Exhibit 99.906

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

I, Michael Schoonoveri, President of the Mutual Fund Series Trust, (the "Funds"), certify that:

1. The N-CSR of the Funds for the period ended December 31, 2022 (the "Report") fully complies with the requirements of Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | |
|:---|:---|
| By: | <u>/s/ Michael Schoonover__________</u> |
|  | Michael Schoonover |
|  | President |
| Date: | 3/8/2023 |

---

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, OR OTHER DOCUMENT AUTHENTICATING, ACKNOWLEDGING, OR OTHERWISE ADOPTING THE SIGNATURE THAT APPEARS IN TYPED FORM WITHIN THE ELECTRONIC VERSION OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, HAS BEEN PROVIDED TO GEMINI FUND SERVICES, LLC AND WILL BE RETAINED BY GEMINI FUND SERVICES, LLC AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.

------

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

I, Erik Naviloff, Treasurer of the Mutual Fund Series Trust, (the "Funds"), certify that:

1. The N-CSR of the Funds for the period ended December 31, 2022 (the "Report") fully complies with the requirements of Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

---

| | |
|:---|:---|
| By: | <u>/s/ Erik Naviloff_______</u> |
|  | Erik Naviloff |
|  | Treasurer |
| Date: | 3/8/2023 |

---

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, OR OTHER DOCUMENT AUTHENTICATING, ACKNOWLEDGING, OR OTHERWISE ADOPTING THE SIGNATURE THAT APPEARS IN TYPED FORM WITHIN THE ELECTRONIC VERSION OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906, HAS BEEN PROVIDED TO GEMINI FUND SERVICES, LLC AND WILL BE RETAINED BY GEMINI FUND SERVICES, LLC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.